PART 1. FINANCIAL INFORMATION

Item 1.

Financial Statements

VASCULAR SOLUTIONS, INC.

Consolidated Balance Sheets

	September 30, 2014			December 31, 2013
	(unaudited)			(see note)
Assets
Current assets:
Cash and cash equivalents	$	41,649,000		$	30,785,000
Accounts receivable, net of reserves of $285,000 and $200,000 in 2014 and 2013, respectively		16,091,000			14,481,000
Inventories		15,732,000			14,002,000
Prepaid expenses and other		4,478,000			2,472,000
Current portion of deferred tax assets		6,000,000			6,000,000
Total current assets		83,950,000			67,740,000

Property, plant and equipment, net		17,616,000			16,187,000
Goodwill		10,346,000			10,532,000
Intangible assets, net		10,614,000			11,943,000
Deferred tax assets, net of current portion		594,000			1,739,000
Total assets	$	123,120,000		$	108,141,000

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	4,847,000		$	3,762,000
Accrued compensation		5,074,000			4,365,000
Accrued expenses		3,683,000			2,467,000
Accrued royalties		229,000			235,000
Current portion of deferred revenue		425,000			556,000
Total current liabilities		14,258,000			11,385,000

Long-term deferred revenue, net of current portion		253,000			406,000
Long-term deferred tax liabilities		723,000			–
Total long-term liabilities		976,000			406,000

Shareholders’ equity:
Common stock, $0.01 par value: Authorized shares – 40,000,000 Issued and outstanding shares – 17,176,172 – 2014; 16,964,953 – 2013		172,000			170,000
Additional paid-in capital		95,853,000			92,346,000
Accumulated other comprehensive earnings		(548,000	)		(1,000	)
Retained earnings		12,409,000			3,835,000
Total shareholders’ equity		107,886,000			96,350,000
Total liabilities and shareholders’ equity	$	123,120,000		$	108,141,000

See accompanying notes.

Note: The balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

Page 2

VASCULAR SOLUTIONS, INC.

Consolidated Statements of Earnings

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
	(unaudited)						(unaudited)

Net revenue:
Product revenue	$	31,766,000		$	27,926,000		$	92,216,000		$	81,197,000
License, royalty and collaboration revenue		163,000			83,000			297,000			230,000
Total revenue		31,929,000			28,009,000			92,513,000			81,427,000

Product costs and operating expenses:
Cost of goods sold		10,291,000			9,197,000			30,158,000			26,432,000
Collaboration expenses		93,000			32,000			125,000			41,000
Research and development		3,322,000			3,140,000			9,839,000			10,027,000
Clinical and regulatory		1,196,000			997,000			3,771,000			3,259,000
Sales and marketing		7,327,000			6,706,000			22,406,000			20,462,000
General and administrative		3,692,000			2,362,000			9,282,000			6,871,000
Litigation		–			812,000			–			812,000
Medical device excise taxes		385,000			339,000			1,083,000			995,000
Amortization of purchased technology and intangibles		410,000			404,000			1,234,000			1,162,000
Total product costs and operating expenses		26,716,000			23,989,000			77,898,000			70,061,000

Operating earnings		5,213,000			4,020,000			14,615,000			11,366,000

Other earnings (expenses):
Interest expense		–			(3,000	)		–			(9,000	)
Foreign exchange gain (loss)		(9,000	)		7,000			(8,000	)		(2,000	)

Earnings before income taxes		5,204,000			4,024,000			14,607,000			11,355,000

Income tax expense		(2,634,000	)		(1,352,000	)		(6,033,000	)		(3,750,000	)
Net earnings	$	2,570,000		$	2,672,000		$	8,574,000		$	7,605,000

Net earnings per share – basic	$	0.15		$	0.16		$	0.51		$	0.47
Net earnings per share – diluted	$	0.15		$	0.16		$	0.49		$	0.45

See accompanying notes.

Page 3

VASCULAR SOLUTIONS, INC.

Consolidated Statements of Comprehensive Earnings

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2014			2013		2014			2013
	(unaudited)					(unaudited)

Net earnings	$	2,570,000		$	2,672,000	$	8,574,000		$	7,605,000
Other comprehensive earnings (losses), net of $0 tax: Foreign currency translation adjustments		(346,000	)		192,000		(547,000	)		61,000
Comprehensive earnings	$	2,224,000		$	2,864,000	$	8,027,000		$	7,666,000

See accompanying notes.

Page 4

VASCULAR SOLUTIONS, INC.

Consolidated Statements of Cash Flows

	Nine Months Ended
	September 30,
	2014			2013
	(unaudited)
Operating activities
Net earnings	$	8,574,000		$	7,605,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation		2,381,000			2,109,000
Amortization		1,234,000			1,162,000
Stock-based compensation		3,030,000			2,567,000
Deferred taxes, net		1,868,000			2,275,000
Excess tax benefit from stock-based compensation		–			(1,331,000	)
Change in fair value of contingent consideration		–			(79,000	)
Gain on disposal of equipment		(24,000	)		(22,000	)
Change in accounts receivable allowance		85,000			15,000
Changes in operating assets and liabilities:
Accounts receivable		(1,708,000	)		(691,000	)
Inventories		(1,738,000	)		(685,000	)
Prepaid expenses and other		(2,038,000	)		(176,000	)
Accounts payable		1,099,000			127,000
Accrued expenses and compensation		1,776,000			659,000
Amortization of deferred license fees and other deferred revenue		(285,000	)		101,000
Net cash provided by operating activities		14,254,000			13,636,000

Investing activities
Purchase of property and equipment		(3,829,000	)		(3,486,000	)
Cash paid for acquisition of license		–			(500,000	)
Proceeds from the sale of equipment		28,000			22,000
Net cash used in investing activities		(3,801,000	)		(3,964,000	)

Financing activities
Repurchase of common shares		(2,312,000	)		(1,211,000	)
Excess tax benefit from stock-based compensation		1,182,000			1,331,000
Proceeds from the exercise of stock options and sale of stock, net of expenses		1,609,000			2,759,000
Net cash provided by financing activities		479,000			2,879,000
Increase in cash and cash equivalents		10,932,000			12,551,000
Effect of exchange rate changes on cash and cash equivalents		(68,000	)		(3,000	)
Cash and cash equivalents at beginning of period		30,785,000			11,554,000
Cash and cash equivalents at end of period	$	41,649,000		$	24,102,000

Supplemental disclosure of cash flow
Cash paid for interest	$	3,000		$	9,000
Cash paid for taxes	$	3,844,000		$	1,499,000

See accompanying notes.

Page 5

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements

(1)	Basis of Presentation

The accompanying unaudited consolidated financial statements of Vascular Solutions, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal, recurring adjustments considered necessary for a fair presentation have been included. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission. Interim results of operations are not necessarily indicative of the results to be expected for the full year or any other interim periods.

(2)	Net Earnings per Share

In accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share, basic net earnings per share for the three and nine months ended September 30, 2014 and 2013 is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented. Diluted net earnings per weighted average common share is computed by dividing net earnings by the weighted average common shares outstanding during the period, increased to include dilutive potential common shares issuable upon the exercise of stock options and restricted stock awards that were outstanding during the period.

Weighted average common shares outstanding for the three and nine months ended September 30, 2014 and 2013 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
	(unaudited)				(unaudited)
Weighted average shares outstanding – basic		16,871,000		16,451,000		16,827,000		16,299,000
Weighted average shares outstanding – diluted		17,691,000		17,067,000		17,642,000		16,894,000

(3)	Revenue Recognition

In the United States, the Company sells its products and services directly to hospitals and clinics. Revenue is recognized in accordance with generally accepted accounting principles as outlined in ASC 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. The Company recognizes revenue as products are shipped and title passes to customers based on FOB shipping point terms. The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price. All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.

Page 6

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics. The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor. The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor. Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order. Allowances are provided for estimated returns and costs at the time of shipment. Sales and use taxes are reported on a net basis, excluding them from revenue.

The Company’s revenues from license agreements and research collaborations are recognized when earned. In accordance with ASC 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller. Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit. Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.

The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-Pad^®, Thrombi-Gel^® and Thrombi-Paste^TM products to King in exchange for a license fee. The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products. The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry. In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement. This agreement was fully amortized during 2013.

Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST^® radiofrequency catheters. In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of goods sold.

In addition, the Company has reviewed the provisions of ASC 808, Collaborative Arrangements, and the adoption of this ASC has had no impact on the amounts recorded under these agreements. In accordance with ASC 605-45-45, the Company includes shipping and handling revenues in net revenue, and shipping and handling costs in cost of goods sold.

In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.” The new section will replace Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries. The new section is intended to conform United States revenue accounting principles with concurrently issued International Financial Reporting Standards. Prior to the guidance, revenue recognition differed between United States practice and those of much of the rest of the world. The guidance also is intended to enhance disclosures related to disaggregated revenue information. The updated guidance is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods. The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2017, given that early adoption is not an option. The Company will further study the implications of this statement in order to evaluate the expected impact on the consolidated financial statements.

Page 7

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

(4)	Inventories

Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market. Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value. Inventories are comprised of the following:

	September 30, 2014		December 31, 2013
	(unaudited)

Raw materials	$	7,533,000	$	6,386,000
Work-in-process		1,548,000		926,000
Finished goods		6,651,000		6,690,000
	$	15,732,000	$	14,002,000

(5)	Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2014 are as follows:

	Goodwill			Acquired Intangibles
	(unaudited)
Balance at December 31, 2013	$	10,532,000		$	11,943,000
Amortization		–			(1,234,000	)
Foreign currency translation adjustments		(186,000	)		(95,000	)
Balance at September 30, 2014	$	10,346,000		$	10,614,000

(6)	Credit Risk and Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. The Company does not accrue interest on past due accounts receivable. Receivables are written off only after all collection attempts have failed and are based on an individual credit evaluation and the specific circumstances of the customer. At September 30, 2014 and December 31, 2013, the allowance for doubtful accounts was $220,000 and $150,000, respectively.

All product returns must be pre-approved, and if approved, customers are subject to a 20% restocking charge. The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on our balance sheet. At September 30, 2014 and December 31, 2013, the sales and return allowance was $65,000 and $50,000, respectively.

Page 8

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $285,000 and $200,000 at September 30, 2014 and December 31, 2013, respectively.

(7)	Concentrations of Credit and Other Risks

In the United States, the Company sells its products and services directly to hospitals and clinics. In all international markets, the Company sells its products to distributors who, in turn, sell to hospitals and clinics.

With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. No single customer represented greater than 10% of gross accounts receivable as of either September 30, 2014 or December 31, 2013. There have been no material losses on customer receivables.

Revenue by geographic destination as a percentage of total net revenue for the nine month periods ended September 30, 2014 and 2013 was 83% and 85% in the United States and 17% and 15% in international markets, respectively. Revenues are attributable to countries based on location of the customer. No single customer represented greater than 10% of the total net revenue for the three and nine months ended September 30, 2014 and 2013.

(8)	Dependence on Key Suppliers

The Company purchases certain key components from single-source suppliers. Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations.

King Pharmaceuticals

The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI Supply Agreement entered into with King on January 9, 2007. Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis. The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements. King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors. The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.

Page 9

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

(9)	Commitments and Contingencies

Boston Scientific Corporation Litigation

On May 16, 2013, the Company filed a patent infringement complaint in the United States District Court for the District of Minnesota against Boston Scientific Corporation (Boston Scientific). The complaint alleged that Boston Scientific infringed three of the Company’s patents concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla™ guide extension catheter. On July 11, 2013, Boston Scientific filed its answer and counterclaim, alleging the Company’s patents are invalid, that the Guidezilla catheter does not infringe, and that the Company’s manufacture and sale of its GuideLiner catheter violates a U.S. patent owned by Boston Scientific that expired in June 2013. On July 30, 2014, the Company agreed with Boston Scientific to settle the patent lawsuit and counterclaim. As part of the settlement agreement, all litigation relating to guide extension was dismissed and the Company will receive an ongoing royalty from Boston Scientific in exchange for a license of the Company’s patents. The terms of the settlement agreement are confidential.

Governmental Proceedings

On June 28, 2011, the Company received a subpoena from the U.S. Attorney’s Office for the Western District of Texas under the Health Insurance Portability & Accountability Act of 1996 (HIPAA) requesting the production of documents related to Vari-Lase products, and in particular the use of the Vari-Lase Short Kit for the treatment of perforator veins. Subsequently, the Company learned that the U.S. Attorney’s Office commenced a criminal investigation of the same matter. The Vari-Lase Short Kit was sold under a 510(k) clearance for the treatment of incompetence and reflux of superficial veins in the lower extremity from 2007 until it was voluntarily withdrawn from the market in July 2014 with total U.S. sales of approximately $534,000 (0.1% of the Company’s total U.S. sales for such period) and has not been the subject of any reported serious adverse clinical event. On August 14, 2012, the United States District Court for the Western District of Texas unsealed a qui tam complaint that had been filed on November 19, 2010 by Desalle Bui, a former sales employee of the Company, which was the basis for the U.S. Attorney’s civil investigation, to which the federal government, after three extensions of time, elected to intervene. The complaint contained allegations of off-label promotion of Vari-Lase products for the treatment of perforator veins, re-use of single-use Vari-Lase products and kickbacks to physicians, resulting in alleged damages to the government of approximately $20 million. An amended complaint limited to allegations of off-label promotion of the Vari-Lase Short Kit resulting in an unspecified amount of damages and penalties was filed by the U.S. Attorney’s Office in December 2012. On January 22, 2014, the Company agreed with the U.S. Attorney’s Office to settle the civil lawsuit, and the settlement agreement was executed on July 28, 2014. Under the terms of the settlement agreement, the Company made a payment of $520,000, the Company made no admission of fault or liability, and the U.S. Attorney’s Office dismissed the civil lawsuit with prejudice and released all civil claims brought against the Company in the civil lawsuit. Settlement of the civil lawsuit had no effect upon the criminal investigation, which is on-going.

From time to time, the Company is involved in additional legal proceedings arising in the normal course of business. As of the date of this report, the Company is not a party to any legal proceeding not described in this section in which an adverse outcome would reasonably be expected to have a material adverse effect on the Company’s results of operations or financial condition.

Page 10

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

King Agreements

On January 9, 2007, the Company entered into a License Agreement and a Device Supply Agreement with King. Under the License Agreement, the Company licensed the exclusive rights to the Company’s products Thrombi-Pad, Thrombi-Gel and Thrombi-Paste to King in exchange for a one-time license fee. Under the Device Supply Agreement, the Company agreed to manufacture the licensed products for sale to King in exchange for an initial payment. The unamortized license fee was $457,000 and $610,000 at September 30, 2014 and December 31, 2013, respectively. Amortization of the deferred revenue will be $51,000 per quarter for the remainder of the 10-year license period. The amortization of license fee was $153,000 for both of the nine month periods ended September 30, 2014 and 2013.

(10)	Income Taxes

The Company is subject to income tax in numerous jurisdictions and at various rates and the use of estimates is required in determining the provision for income taxes. For the nine month periods ended September 30, 2014 and 2013, the Company recorded a provision for taxes of $6,033,000 and $3,750,000 on earnings before tax of $14,607,000 and $11,355,000 resulting in an effective income tax rate of 41% and 33%, respectively. The difference between the effective tax rate of 41% for the nine months ended September 30, 2014 and the U.S. federal statutory income tax rate of 34% was due mainly to a change in the valuation allowance against the Company’s deferred Minnesota tax assets discussed below. The difference between the effective tax rate of 33% for the nine months ended September 30, 2013 and the U.S. federal statutory income tax rate of 34% was due mainly to the impact of recognizing $300,000 of research and development credits in the first quarter of 2013 that had been deferred from 2012 pending Congressional action which was completed in January 2013 and the recognition of $53,000 of refundable Ireland research and development credits in the second quarter of 2013.

The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable earnings. The Company considers projected future taxable earnings and ongoing tax planning strategies, and then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more likely than not to be realized. For the quarter ended September 30, 2014, based upon the Company’s assessment of all available evidence, including estimates of future profitability, the Company’s overall prospects of future business and the apportionment of the Company’s income to the State of Minnesota based on current apportionment methods, the Company determined that it is more likely than not that the Company will not be able to realize all remaining deferred tax assets relating to the Minnesota research and development credits and the Minnesota net operating loss carryforwards prior to their expirations. As a result, the Company recorded additional income tax expense of $867,000 during the quarter ended September 30, 2014 as a discrete adjustment to the valuation allowance for its deferred tax assets, representing 16.7% and 5.9% of pretax income for the three and nine months ended September 30, 2014, respectively. The Company continues to assess the potential realization of deferred tax assets on a quarterly basis. If the Company’s actual results and updated projections vary significantly from the projections used as a basis for this determination, the Company may need to increase or decrease the valuation allowance against the gross deferred tax assets. The Company will adjust earnings for the deferred tax in the period in which the determination is made.

Page 11

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

The Company applies ASC 740, Income Taxes, which clarifies the accounting for uncertainty in tax positions recognized in the financial statements. These provisions create a single model to address uncertainty in tax positions and clarify the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company has recorded an unrecognized tax asset of $1,306,000 and $1,268,000 as of September 30, 2014 and December 31, 2013, respectively. The impact of tax related interest and penalties is recorded as a component of income tax expense. As of September 30, 2014, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the statements of earnings.

The Company is subject to income tax examinations in the U.S. Federal jurisdiction, as well as in the Republic of Ireland and various state jurisdictions. At September 30, 2014, tax years 2011 through 2013 remain open to examination.

(11)	Business Combinations and Asset Acquisitions

Northeast Scientific

On September 17, 2013, the Company entered into an eight-year reprocessing services agreement with Northeast Scientific, Inc. (NES), a FDA-registered reprocessor of medical devices, whereby the Company paid NES a non-refundable amount of $500,000 for the exclusive right to offer NES’ reprocessing services in the United States for a commercial medical device. NES is pursuing FDA approval for its reprocessing services for the device. If FDA approval is obtained, the Company is required to pay NES a non-refundable amount of $400,000. The agreement has an annual minimum unit termination clause, allowing NES to terminate the agreement if the Company does not meet certain annual minimums following FDA approval.

The Company accounted for the transaction as a non-business asset acquisition in the third quarter of 2013. In accordance with ASC 805, the purchase price of $900,000 was assigned to an intangible asset and no goodwill was recognized. The Company recorded a $400,000 accrual in the third quarter of 2013 for the payment to be made upon FDA approval, in addition to the $500,000 initial payment. The Company will begin amortizing the intangible asset on a per unit basis over the remaining term of the agreement once the Company begins to send units to NES to be reprocessed following FDA approval.

(12)	Products and Services

The Company has three product categories as follows:

Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner^®catheter used to access discrete regions of the coronary anatomy and the Pronto^® extraction catheters used in treating acute myocardial infarction. This category also includes products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits.

Hemostat products consist principally of blood clotting products, such as the D-Stat^® Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. This category also includes our line of devices used in radial artery procedures, such as our Accumed^™wrist positioning splints and Vasc^™ Band inflatable compression bands.

Page 12

VASCULAR SOLUTIONS, INC.

Notes to Unaudited Consolidated Financial Statements – Continued

Vein products and services consist principally of the Vari-Lase^® endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter.

The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:

	Three Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	21,116,000		18	%	$	17,965,000		17	%
Hemostat products		6,108,000		2	%		5,962,000		7	%
Vein products and services		4,542,000		14	%		3,999,000		11	%
Total product revenue		31,766,000		14	%		27,926,000		14	%
License		163,000		96	%		83,000		(5	%)
Total revenue	$	31,929,000		14	%	$	28,009,000		14	%

	Nine Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	60,675,000		17	%	$	52,031,000		14	%
Hemostat products		18,305,000		3	%		17,768,000		3	%
Vein products and services		13,236,000		16	%		11,398,000		14	%
Total product revenue		92,216,000		14	%		81,197,000		12	%
License, royalty and collaboration		297,000		29	%		230,000		(12	%)
Total revenue	$	92,513,000		14	%	$	81,427,000		11	%

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Level Overview

Vascular Solutions, Inc. (we, us or Vascular) is focused on bringing clinically advanced solutions to interventional cardiologists, interventional radiologists, electrophysiologists, and vein practices worldwide. As a vertically-integrated medical device company, we generate ideas, create new minimally invasive medical devices, and then deliver these products and related services to physicians through our direct domestic sales force and our international distribution network. We continue to develop new products and new applications for our existing products.

During the past few years, the number of catheterization procedures performed worldwide has been declining gradually due to a number of factors – among them, the effects of weak economies on overall health care utilization rates, efforts by third-party payers to lower costs associated with medical procedures, investigations by government agencies into potential over-utilization of procedures, the implementation by hospitals of policies designed to reduce the incidence of unnecessary procedures in the wake of these outside investigations, and new diagnostic imaging and functional assessment modalities that more effectively screen patients to determine the need for treatment. Although worldwide demographic factors, including the growing incidence of obesity, diabetes, and cardiovascular disease, seem to favor long-term growth in the number of interventional procedures, we believe these recent pressures on utilization rates are likely to result in relatively flat catheterization volumes for the foreseeable future. We intend to remain competitive in this market through the continued introduction of new products and services. We expect to originate these new products and services primarily through our internal research and development and clinical efforts, but we may supplement them with targeted acquisitions or other external collaborations. Additionally, our growth has been, and will continue to be, impacted by our expansion and penetration into new geographic markets, the expansion and penetration of our direct sales organization in existing geographic markets, and our continuing focus on increasing the efficiency of our existing direct sales organization.

Page 13

Our product portfolio includes a broad spectrum of over 80 products consisting of over 600 stock keeping units (SKUs) covering a wide array of blood clotting devices, extraction catheters, access catheters, guide catheters, micro-introducer kits, guidewires, snare and retrieval devices, reprocessing service for radiofrequency catheters, and endovenous laser and procedure kits for the treatment of varicose veins. Our management, including our chief executive officer who is our chief operating decision maker, report and manage our operations in three main categories based on similarities in the products or services sold. We have corporate infrastructure and direct sales capabilities in the United States and have established distribution relationships in most major international markets. In order to drive sales growth, we have invested not only in the expansion of our global distribution system, but also new product development and clinical trials to obtain regulatory approvals. A significant portion of our net revenue historically has been, and we expect to continue to be, attributable to new and enhanced products and services. We expect to continue to further validate the clinical and competitive benefits of our technology platforms to drive utilization of our current products and the development of new and enhanced products and services.

The interventional medical device industry is characterized by intense competition, rapidly evolving technology, and a high degree of government regulation. To grow our business, we have focused on continually developing and commercializing new products. Looking ahead, we expect our business may be impacted by the following trends and opportunities:

The future regulatory approval of newly-developed products. Any new product that we develop must be approved by the Food and Drug Administration (FDA) in the United States and by similar regulatory bodies in other countries before they can be sold. The requirements for obtaining product approval have undergone change, and the FDA frequently implements changes to the product approval process. We monitor the changing regulatory landscape and modify our regulatory submissions as necessary to obtain product approvals.

Successfully integrating acquired products and services into our existing operations. The acquisition of products and services complementary to our existing product portfolio and customer call points provides an additional business opportunity, but is dependent on the successful integration of the acquired products into our existing business structure.

Managing intellectual property. The interventional medical device industry is characterized by numerous patent filings and litigation claims made to protect new and evolving product ideas. To maximize the profitability of new product ideas, we seek patent protection for those product design and method concepts which we believe have the potential to provide substantial product revenue. Managing intellectual property assets and claims is a significant challenge for our business.

Page 14

Results of Operations

The following table sets forth, for the periods indicated, certain items from our statements of earnings expressed as a percentage of net revenue:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Net revenue:
Product revenue		100	%		100	%		100	%		100	%
License and collaboration revenue		-			-			-			-
Total revenue		100	%		100	%		100	%		100	%

Product costs and operating expenses:
Cost of goods sold		32	%		33	%		33	%		33	%
Collaboration expenses		-			-			-			-
Research and development		11	%		11	%		11	%		12	%
Clinical and regulatory		4	%		4	%		4	%		4	%
Sales and marketing		23	%		24	%		24	%		25	%
General and administrative		12	%		8	%		10	%		8	%
Litigation		-			3	%		-			1	%
Medical device excise taxes		1	%		1	%		1	%		1	%
Amortization of purchased technology and intangibles		1	%		2	%		1	%		2	%
Total product costs and operating expenses		84	%		86	%		84	%		86	%
Operating earnings		16	%		14	%		16	%		14	%
Other earnings and expenses, net		-			-			-			-
Earnings before income taxes		16	%		14	%		16	%		14	%
Income taxes		(8	%)		(5	%)		(7	%)		(5	%)
Net earnings		8	%		9	%		9	%		9	%

Three and nine months ended September 30, 2014, compared to three and nine months ended September 30, 2013

Net revenue increased 14% to $31,929,000 for the quarter ended September 30, 2014 from $28,009,000 for the quarter ended September 30, 2013. This increase in revenue is comprised of the following components:

	% Change
Volume of existing product and service revenue		18	%
New product or service introductions, which consist of any product or service that had no revenue in the comparable period in 2013		-	%
Product and service pricing		(4	%)
		14	%

Approximately 84% and 85% of our net revenue was earned in the United States and 16% and 15% of our net revenue was earned in international markets for the three month periods ended September 30, 2014 and September 30, 2013, respectively.

Page 15

Net revenue increased 14% to $92,513,000 for the nine months ended September 30, 2014 from $81,427,000 for the nine months ended September 30, 2013. This increase in revenue is comprised of the following components:

	% Change
Volume of existing product and service revenue		17	%
New product or service introductions, which consist of any product or service that had no revenue in the comparable period in 2013		-	%
Product and service pricing		(3	%)
		14	%

Approximately 83% and 85% of our net revenue was earned in the United States and 17% and 15% of our net revenue was earned in international markets for the nine month periods ended September 30, 2014 and September 30, 2013, respectively.

We recognized $163,000 and $83,000 of license, royalty and collaboration revenue during the three month periods ended September 30, 2014 and 2013, respectively, and $297,000 and $230,000 of license, royalty and collaboration revenue during the nine month periods ended September 30, 2014 and 2013, respectively, due to our license and device supply agreements with King, our royalty agreement with a third party, and our distribution agreement with Nicolai which expired on March 31, 2013. Collaboration expense of $93,000 and $32,000 was recognized during the three months ended September 30, 2014 and 2013, respectively, and collaboration expense of $125,000 and $41,000 was recognized during the nine months ended September 30, 2014 and 2013, respectively, as a result of an agreement we entered into in April 2013 to develop a new hemostatic device for a third party. License, royalty and collaboration revenue is expected to be approximately $135,000 in the fourth quarter of 2014.

Gross margin increased to 67.8% for the quarter ended September 30, 2014, compared to 67.2% for the quarter ended September 30, 2013. The increase in gross margin was due to the increase in sales of our higher margin GuideLiner catheters as a percentage of our total product sales. We expect gross margins to be between 66.5% and 67.5% in the fourth quarter of 2014, subject to variations in our selling mix between United States and international markets and between our lower margin products such as the Vari-Lase products and our higher margin products such as the D-Stat Dry and GuideLiner products. Gross margin remained relatively flat at 67.4% for the nine month period ended September 30, 2014, compared to 67.5% for the nine month period ended September 30, 2013.

Research and development expense for the third quarter of 2014 totaled $3,322,000, or 11% of revenue, compared to $3,140,000, or 11% of revenue, for the third quarter of 2013. Research and development expense for the nine month period ended September 30, 2014 totaled $9,839,000 or 11% of revenue, compared to $10,027,000, or 12% of revenue, for the nine month period ended September 30, 2013. Research and development expenses have increased compared to the three months ended September 30, 2013 due to additional research and development employees being hired during the third quarter of 2014. We expect our research and development expenses to be approximately 11% to 12% of revenue in the fourth quarter of 2014.

Clinical and regulatory expense for the third quarter of 2014 totaled $1,196,000, or 4% of revenue, compared to $997,000, or 4% of revenue, for the third quarter of 2013. Clinical and regulatory expense for the nine month period ended September 30, 2014 totaled $3,771,000 or 4% of revenue, compared to $3,259,000, or 4% of revenue, for the nine month period ended September 30, 2013. Clinical and regulatory expenses have increased on a dollar basis for the three and nine month periods ended September 30, 2014, compared to the three and nine month periods ended September 30, 2013, due to additional expenses relating to preparations for planned future clinical studies. We expect clinical and regulatory expenses to continue to be approximately 4% of revenue in the fourth quarter of 2014.

Page 16

Sales and marketing expense for the third quarter of 2014 totaled $7,327,000, or 23% of revenue, compared to $6,706,000, or 24% of revenue, for the third quarter of 2013. Sales and marketing expense for the nine month period ended September 30, 2014 totaled $22,406,000 or 24% of revenue, compared to $20,462,000, or 25% of revenue, for the nine month period ended September 30, 2013. The decrease in sales and marketing expenses as a percentage of revenue for the three and nine month periods ended September 30, 2014, compared to the three and nine month periods ended September 30, 2013, was due to our increased sales while maintaining a relatively constant number of field sales employees. We expect to maintain the same relative size of our direct U.S. sales force for the remainder of 2014. As result, we expect our sales and marketing expenses as a percentage of revenue to be approximately 22% to 23% in the fourth quarter of 2014.

General and administrative expense for the third quarter of 2014 totaled $3,692,000, or 12% of revenue, compared to $2,362,000, or 8% of revenue, for the third quarter of 2013. General and administrative expense for the nine month period ended September 30, 2014 totaled $9,282,000 or 10% of revenue, compared to $6,871,000, or 8% of revenue, for the nine month period ended September 30, 2013. General and administrative expenses increased for the three and nine month periods ended September 30, 2014 compared to the three and nine month periods ended September 30, 2013 as a result of a $1,300,000 and $2,200,000 increase in legal expenses, respectively, primarily related to the patent infringement lawsuit filed against Boston Scientific which was settled in July 2014 and the qui tam litigation and related U.S. Attorney criminal investigation (see Note 9 to the Unaudited Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q). While legal expenses are difficult to forecast, we expect legal expenses to remain at this elevated level in the fourth quarter of 2014 due to the on-going U.S. Attorney criminal investigation. As a result, we expect general and administrative expense to be approximately 12% to 14% of revenue in the fourth quarter of 2014.

Litigation expense for the three and nine months ended September 30, 2014 and September 30, 2013 was $-0- and $812,000, respectively. On October 11, 2013, an agreement was reached with Terumo Corporation to settle its patent and trademark infringement litigation, whereby we made a one-time payment to Terumo Corporation in the amount of $812,000 during the fourth quarter of 2013. The settlement amount was recognized as litigation expense in the quarter ended September 30, 2013.

Medical device excise taxes for the third quarter of 2014 totaled $385,000, or 1.2% of revenue, compared to $339,000, or 1.2% of revenue, for the third quarter of 2013. Medical device excise taxes for the nine month period ended September 30, 2014 totaled $1,083,000, or 1.2% of revenue, compared to $995,000, or 1.2% of revenue, for the nine month period ended September 30, 2013. The statutory rate of the medical device excise tax is 2.3% of revenues on initial sales of finished medical products sold in the United States. The tax does not apply to service revenues or international sales. The Company’s effective rate for this tax is less than the statutory rate due to international sales, service revenues and sales of purchased finished goods (where the seller is responsible for paying the tax). We expect our medical device excise taxes to be approximately 1.2% in the fourth quarter of 2014.

Amortization of purchased technology and other intangibles was $410,000 and $404,000 for the three months ended September 30, 2014 and 2013, respectively. Amortization of purchased technology and other intangibles was $1,234,000 and $1,162,000 for the nine months ended September 30, 2014 and 2013, respectively. The amortization resulted from our product and license acquisitions. As part of these asset purchases and licensing agreements, we allocated $16,000,000 to purchased technology and other intangibles that are being amortized over a period of 9 to 11 years. For a complete discussion of the most recent acquisition, see Note 11 to the Unaudited Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q. We expect amortization expense to be approximately $410,000 in the fourth quarter of 2014.

Page 17

Income tax expense was $2,634,000 and $6,033,000 for the three and nine months ended September 30, 2014, respectively, on earnings before tax of $5,204,000 and $14,607,000, respectively, resulting in an effective income tax rate of 51% and 41% for the three and nine months ended September 30, 2014, respectively. The difference between the effective tax rates of 51% and 41% and the statutory rate of 34%, relates primarily to a change in the valuation allowance against the Company’s deferred Minnesota tax assets (see Note 10 to the Unaudited Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q for a complete discussion). We expect our effective income tax rate will be approximately 36% in the fourth quarter of 2014.

Liquidity and Capital Resources

Our cash and cash equivalents totaled $41,649,000 at September 30, 2014 compared to $30,785,000 at December 31, 2013, an increase of $10,864,000. The majority of our cash is maintained in our operating accounts. A portion of our cash equivalents are invested in a money market fund invested in high quality, short-term money market instruments denominated in U.S. dollars such as debt instruments guaranteed by the governments of the United States, Western Europe, Australia, Japan and Canada, high quality corporate issuers and bank obligations. The money market fund’s assets are rated in the highest short-term category by nationally recognized rating agencies, such as Moody’s or Standard & Poor’s.

Cash provided by operations. We generated $14,254,000 of cash from operations for the nine months ended September 30, 2014, primarily resulting from our net earnings of $8,574,000, non-cash depreciation and amortization expense of $3,615,000 and non-cash stock-based compensation of $3,030,000. Cash from operations was reduced by a $2,038,000 increase in prepaid expenses, a $1,738,000 increase in inventory, and a $1,708,000 increase in our accounts receivable for the nine months ended September 30, 2014. These cash reductions were partially off-set by a combined $2,875,000 increase in accounts payable and accruals. The increase in prepaid expenses and inventory was consistent with our expectations. The increase in net accounts receivable of 11% for the nine month period ended September 30, 2014 is consistent with our 14% increase in net revenue over the same period. Day’s sales outstanding both at September 30, 2014 and December 31, 2013 were 48 days.

Cash used for investing activities. We used $3,801,000 of cash in investing activities for the nine months ended September 30, 2014, primarily consisting of the $3,829,000 of capital expenditures relating to the purchase of manufacturing and computer equipment, as well as the purchase of additional research and development equipment.

On February 18, 2014, we entered into a purchase agreement with IRET – Plymouth, LLC (“IRET”) to acquire a manufacturing and office building of approximately 79,300 square feet located at 6464 Sycamore Court North, Maple Grove, Minnesota, for a total purchase price of $7,200,000 (the “Purchase Agreement”). Subject to the satisfaction of certain terms and closing conditions customary for a real estate transaction of this type, the closing is expected to take place on December 1, 2014. Under the terms of the Purchase Agreement, in February 2014, we deposited $400,000 into escrow to be held as earnest money until the closing of the transaction. We currently lease the building and intend to continue to do so until the transaction closes. The building houses our principal manufacturing, research and development and regulatory operations. We intend to expand the manufacturing capacity of the building and move our research and development and regulatory operations into an adjoining office building that we currently own in 2015.

Cash provided by financing activities. We generated $479,000 of cash in financing activities for the nine months ended September 30, 2014. This amount was primarily due to the recognition of $1,182,000 of excess tax benefits from stock based compensation, the receipt of $904,000 upon the exercise of outstanding stock options and sale of stock and the receipts of $705,000 in exchange for the sale of common stock pursuant to our Employee Stock Purchase Plan. These amounts were reduced by the $2,312,000 of cash used to repurchase 100,565 shares of our common stock that vested under outstanding restricted stock awards to satisfy income tax withholding obligations.

Page 18

We currently anticipate that we will experience positive cash flow from our normal operating activities for the foreseeable future. We currently believe that our working capital of $69.7 million at September 30, 2014 will be sufficient to meet all of our operating and capital requirements for the foreseeable future.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2014.

Contractual Obligations

The following table summarizes our contractual cash commitments as of September 30, 2014:

	Payments Due by Period
Contractual Obligations	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
Purchase of building	$	6,800,000	$	6,800,000	$	-	$	-	$	-
Facility operating leases		909,000		909,000		-		-		-
Product license rights		400,000		400,000		-		-		-
Total	$	8,109,000	$	8,109,000	$	-	$	-	$	-

We do not have any other significant cash commitments related to supply agreements, nor do we have any other significant commitments for capital expenditures.

Critical Accounting Policies

Management’s Discussion and Analysis of Financial Condition and Results of Operations addresses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. The preparation of our financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate these estimates and judgments. We base our estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The material accounting policies that we believe are most critical to an investor’s understanding of our financial results and condition and which require complex management judgment are discussed in our Annual Report on Form 10-K for the year ended December 31, 2013 under the caption “Critical Accounting Policies.”

Page 19

Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995

The Private Securities Litigation Reform Act of 1995 (the Act) provides a “safe harbor” for forward-looking statements to encourage companies to provide prospective information about their business, so long as those statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those discussed in the statement. We desire to take advantage of the safe harbor provisions with respect to any forward-looking statements we may make in this filing, other filings with the Securities and Exchange Commission and any public oral statements or written releases. The words or phrases “will likely,” “is expected,” “will continue,” “is anticipated,” “believe,” “estimate,” “projected,” “forecast,” or similar expressions are intended to identify forward-looking statements within the meaning of the Act. Forward-looking statements such as these are based on management’s current expectations as of the date of this report but involve risks, uncertainties and other factors which may cause actual results to differ materially from those contemplated by such forward-looking statements. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. In accordance with the Act, we identify the following important general factors which, if altered from the current status, could cause our actual results to differ from those described in any forward-looking statements: risks associated with patent infringement lawsuits and government criminal investigations, adoption of our new products, limited profitability, exposure to possible product liability claims, the development of new products by others, dependence on third party distributors in international markets, doing business in international markets, the availability of third party reimbursement, actions by the FDA related to our products, the loss of key vendors, and those factors set forth under the heading “Risk Factors” in Item 1A of Part II of this Quarterly Annual Report on Form 10-Q. This list is not exhaustive, and we may supplement this list in any future filing with the Securities and Exchange Commission or in connection with the making of any specific forward-looking statement. We undertake no obligation to, and do not intend to, revise or update publicly any forward-looking statement for any reason.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivables. We maintain our accounts for cash and cash equivalents principally at one major bank in the United States and one major bank in Ireland. We have a formal written investment policy that limits our investments to investments in issuers evaluated as creditworthy. We have not experienced any losses on our deposits of our cash and cash equivalents.

With respect to accounts receivable, we perform credit evaluations of our customers and do not require collateral. There have been no material losses on accounts receivables.

In the United States, we sell our products and services directly to hospitals and clinics. In international markets, we sell our products to independent distributors who, in turn, sell to hospitals. Sales to independent distributors are denominated in United States dollars, with the exception of sales to Germany, where sales are denominated in Euros. Sales to distributors out of our subsidiary in Ireland are denominated in Euros.

We distribute certain products on behalf of certain U.S. and international manufacturers. We pay for all distributed products in United States dollars.

We do not believe our operations are currently subject to significant market risks for interest rates, foreign currency exchange rates, commodity prices or other relevant market price risks of a material nature. A change of 0.1 in the Euro exchange rate would result in an increase or decrease of approximately $46,000 in the amount of United States dollars we receive in payment on the accounts receivable denominated in Euros with our subsidiary in Ireland and our German distributor, Nicolai GmbH. Under our current policies, we do not use foreign currency derivative instruments to manage exposure to fluctuations in the Euro exchange rate.

We are exposed to declines in the interest rates paid on deposited funds. A 0.1% decline in the current market interest rates paid on deposits would result in interest earnings being reduced by approximately $42,000 on an annual basis.

Page 20

Item 4.

Controls and Procedures

Evaluation of disclosure controls and procedures.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.

Changes in internal control over financial reporting.

During the fiscal quarter ended September 30, 2014, there has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

The description of litigation and government proceedings included in Note 9 to the Unaudited Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q is incorporated into this Item 1 of Part II by reference.

From time to time, we are involved in additional legal proceedings arising in the normal course of business. As of the date of this report we are not a party to any legal proceeding not described in this section in which an adverse outcome would reasonably be expected to have a material adverse effect on our results of operations or financial condition.

Item 1A.

Risk Factors

The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of the following risks occur, our business, financial condition or results of operations could be seriously harmed.

We will not be successful if the interventional medical device community does not adopt our new products or services.

We have launched over 80 new products or services since 2003. Our success will depend on the continued launch of new products and services and the medical community’s acceptance of our new products and services. We cannot predict how quickly, if at all, the medical community will accept our new products and services, or, if accepted, the continuation or extent of their use. Our potential customers must:

believe that our products or services offer benefits compared to the methodologies and/or devices that they are currently using;

use our products or services and obtain acceptable clinical outcomes;

believe that our products or services are worth the price that they will be asked to pay; and

be willing to commit the time and resources required to change their current methodology.

Page 21

Because we are often selling a new technology, we have limited ability to predict the level of growth or timing of sales of these products or services. If we encounter difficulties in growing our sales of our new medical devices or services, our business will be seriously harmed.

We may face intellectual property litigation, which could prevent us from manufacturing and selling our products or services or result in us incurring substantial costs and liabilities.

The interventional medical device industry is characterized by numerous patent filings. As a result, participants in the industry frequently experience substantial intellectual property litigation.

Some companies in the interventional medical device industry have employed intellectual property litigation in an attempt to gain a competitive advantage. In addition, non-practicing patent assertion entities have accumulated patent rights related to the medical device industry and are asserting them against operating companies in an attempt to collect settlements or licensing fees. Intellectual property litigation has proven to be very complex, and the outcome of such litigation is difficult to predict. While we do not believe that any of our products or services infringe any existing patent or other intellectual property right, we have been involved in substantial intellectual property litigation and expect to continue to become subject to intellectual property claims with respect to our new or existing products or services.

On February 14, 2013, Terumo Corporation and Terumo Medical Corporation (Terumo) filed a complaint for patent and trademark infringement against us and Lepu Medical Technology (Beijing) Co. in the United States District Court for the District of New Jersey. The complaint alleged that a prior version of the Vasc Band radial compression device manufactured by Lepu Medical Technology infringed a Terumo patent. On October 11, 2013, we reached an agreement with Terumo to settle the litigation. Under the settlement, we made a one-time payment to Terumo in the amount of $812,500 and Terumo agreed that the current design of our Vasc Band product does not infringe any claim of any issued Terumo patent and agreed that it will not sue the Company on any future issued patent concerning the current design of the Vasc Band product.

On May 16, 2013, we filed a patent and copyright infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation alleging that it is infringing three of our United States patents by manufacturing and selling its Guidezilla guide extension catheter. Boston Scientific filed a counterclaim alleging that our GuideLiner catheter infringes a Boston Scientific patent that expired in June 2013. On July 30, 2014, we agreed with Boston Scientific to settle the patent lawsuit. As part of the settlement agreement, all litigation relating to guide extension was dismissed. The terms of the settlement agreement are confidential.

An adverse determination in any intellectual property litigation or interference proceedings against us could prohibit us from selling a product or service, subject us to significant immediate payments to third parties and require us to seek licenses from third parties. The costs associated with these license arrangements may be substantial and could include substantial up-front payments and ongoing royalties. Furthermore, the necessary licenses may not be available to us on satisfactory terms, if at all. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling a product or service.

Our involvement in any future intellectual property claims, regardless of the merits of any asserted claim against us, could divert the attention of our technical and management personnel away from the development and marketing of our products and services for significant periods of time. Furthermore, the penalties involved with an adverse outcome may be severe, and the costs incurred related to defending such claims could have a material adverse effect on our results of operations or financial condition, even if we ultimately prevail in them.

Page 22

The medical device industry is the subject of numerous governmental investigations into marketing and other business practices, and we currently are the subject of a pending government criminal investigation. The criminal investigation could result in the commencement of litigation, indictment of the company and its officers, substantial litigation costs, fines, penalties and administrative remedies, including the potential disqualification from participation in government health care programs including Medicare and Medicaid, which would prevent us from continuing to carry on our existing business. Any adverse determination in the current government criminal investigation or any future civil or criminal litigation could have a material adverse effect on our ability to continue to operate our business as currently conducted and negatively impact our financial results and stock price.

The products and business activities of medical device companies are subject to rigorous regulation by the FDA and other federal, state and international governmental authorities under statutes and regulations governing health care fraud. The U.S. Attorney’s Offices have increased their scrutiny over the medical device industry in recent years. The U.S. Congress, Department of Justice, Office of Inspector General of the Department of Health and Human Services, and Department of Defense have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, medical device manufacturers, primarily related to financial arrangements with health care providers, regulatory compliance and product promotional practices.

During 2012, the U.S. Attorney’s Office for the Western District of Texas intervened in a qui tam civil lawsuit initiated against us involving allegations of off-label promotion of our Vari-Lase Short Kit endovenous laser product (see Note 9 to the Unaudited Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q). Subsequently, we learned that the U.S. Attorney’s Office commenced a criminal investigation of the same matter. On January 22, 2014, we agreed with the U.S. Attorney’s Office to settle the civil lawsuit, and the settlement agreement was executed on July 28, 2014. Under the terms of the settlement agreement, the Company made a payment of $520,000, the Company made no admission of fault or liability, and the U.S. Attorney’s Office dismissed the civil lawsuit with prejudice and released all civil claims brought against the Company in the civil lawsuit.

Settlement of the civil lawsuit had no effect upon the criminal investigation, which is on-going. We cannot predict when the criminal investigation will be resolved, the outcome of the investigation, its impact on us, or whether other federal or state legal or regulatory authorities will initiate additional related or unrelated investigations or lawsuits against us. We expect to continue to incur substantial expenses in defending ourselves in the criminal investigation. The outcome of a criminal investigation could include substantial fines, penalties and administrative remedies such as a deferred prosecution agreement or corporate integrity agreement, or the indictment of the company or its officers. If we were to be convicted of a crime related to the delivery of an item or service under Title XVIII of the Social Security Act, or a felony related to health care fraud, the company would become automatically excluded by the Department of Health and Human Services (“HHS”) from participation in government health care programs, including Medicare and Medicaid. If we were to be convicted of a misdemeanor related to health care fraud, the company could be excluded by HHS from participation in government health care programs, including Medicare and Medicaid. Exclusion from government health care programs would substantially adversely affect our ability to continue to conduct our business. The cost of our defense of any indictment that might issue as a result of the investigation would be material and could divert the attention of management from the day-to-day operations of our business. The consequences of the current investigation, as well as consequences of any future governmental investigation or lawsuit of any related or unrelated matter, could have a material adverse effect on our business, results of operations and stock price.

Page 23

Our future operating results are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price of our common stock.

The ongoing introduction of new products and services that affect our overall product mix make the prediction of future operating results difficult. You should not rely on our past revenue growth as any indication of future growth rates or operating results. The price of our common stock will likely fall in the event that our operating results do not meet the expectations of analysts and investors. Comparisons of our operating results between quarters are an unreliable indication of our future performance because they are likely to vary significantly based on many factors, including:

the level of sales of our products and services in our markets;

our ability to introduce new products or services and enhancements in a timely manner;

the demand for, and acceptance of, our products and services;

the success of our competition and the introduction of alternative products or services;

our ability to command favorable pricing for our products and services;

the growth of the market for our products and services;

the expansion and rate of success of our direct sales force in the United States and our independent distributors internationally;

actions relating to ongoing FDA compliance;

the effects of intellectual property disputes;

the effects of government investigations and litigation;

the size and timing of orders from independent distributors or customers;

the attraction and retention of key personnel, particularly in sales and marketing, regulatory, manufacturing and research and development;

unanticipated delays or an inability to control costs;

general economic conditions, as well as those specific to our customers and markets; and

seasonal fluctuations in revenue due to the elective nature of some procedures.

We may face product liability claims that could result in costly litigation and significant liabilities.

The manufacture and sale of medical products entails significant risk of product liability claims. Any product liability claims, with or without merit, could result in costly litigation, reduced sales, cause us to incur significant liabilities and divert our management’s time, attention and resources. We cannot be sure that our product liability insurance coverage is adequate or that it will continue to be available to us on acceptable terms, if at all.

Page 24

The market for interventional medical devices and services is highly competitive and will likely become more competitive, and our competitors may be able to respond more quickly to new or emerging technologies and changes in customer requirements that may render our products or services obsolete.

The existing market for interventional medical devices and services is intensely competitive. We expect competition to increase further as companies develop new products and services or modify their existing products and services to compete directly with ours. Each of our products and services encounters competition from several medical device companies, including Medtronic Inc., Boston Scientific Corporation and Covidien plc. Each of these companies has:

better name recognition;

broader product lines;

greater sales, marketing and distribution capabilities;

significantly greater financial resources;

larger research and development staffs and facilities; and

existing relationships with some of our potential customers.

We may not be able to effectively compete with these companies. In addition, broad product lines may allow our competitors to negotiate exclusive, long-term supply contracts and offer comprehensive pricing for their products or services. Broader product lines may also provide our competitors with a significant advantage in marketing competing products or services to group purchasing organizations and other managed care organizations that are increasingly seeking to reduce costs through centralized purchasing. Greater financial resources and product development capabilities may allow our competitors to respond more quickly to new or emerging technologies and changes in customer requirements that may render our products or services obsolete.

We rely on continued development and improvement of our products and service, which if not successful, may have an adverse effect on our financial condition and results of operations.

We are continually engaged in developing new products and services and improving our existing products and services. New or improved products and services represent a significant component of our sales growth. We dedicate significant financial and managerial resources to product and services development and improvement. We may not achieve our development objectives within our schedule and budget, or at all, due to technical or operational challenges. Failure to achieve our development objectives on schedule may increase our development expenses and adversely impact our revenues. If we do achieve our development objectives, we may not be able to obtain regulatory approval for new or improved products or services, and we may not be successful in marketing and selling such products or services. Failure to obtain regulatory approval or successfully market and sell new or improved products and services could adversely impact our revenues and results of operations.

Constraints or interruption in production from any of our key suppliers may have a material adverse effect on our business, financial condition and results of operations.

In the interest of operational efficiency and due to quality considerations, we obtain some of the components for the products that we manufacture from a sole source. If the availability of components from a sole source of supply is constrained or interrupted, there is no assurance that we could find an alternative source of supply quickly and cost effectively, if at all. In addition, due to the stringent regulations and requirements of the FDA and equivalent regulatory entities regarding the manufacture of our products, we may not be able to quickly establish additional or replacement sources for some components or materials. Unavailability of components could have a material adverse effect on our ability to manufacture and sell products and our results of operations.

Page 25

We also distribute finished products that are available only from their manufacturer. In addition, the reprocessing services that we offer are performed by a single provider. Operational, quality or regulatory issues of the manufacturers of the products we distribute, or the provider of our reprocessing services, could constrain or interrupt the availability of those products or services. Any constrain or interruption in supply of finished products that we distribute, or the reprocessing services that we offer, could have a material adverse effect on our ability to sell products and services to customers, our financial condition and our results of operations.

Our international sales are subject to a number of risks that could seriously harm our ability to successfully commercialize our products and services in any international market.

Our international sales are subject to several risks, including:

the ability of our independent distributors to sell our products and services;

the impact of recessions in economies outside the United States;

greater difficulty in collecting accounts receivable and longer collection periods;

unexpected changes in regulatory requirements, tariffs or other trade barriers;

weaker intellectual property rights protection in some countries;

potentially adverse tax consequences; and

political and economic instability.

The occurrence of any of these events could seriously harm our future international sales and our ability to successfully commercialize our products and services in any international market.

Our business and results of operations may be seriously harmed by changes in third-party reimbursement policies.

We could be seriously harmed by changes in reimbursement policies of governmental or private healthcare payors, particularly to the extent any changes affect reimbursement for catheterization procedures in which our products or services are used. Failure by physicians, hospitals and other users of our products or services to obtain sufficient reimbursement from healthcare payors for procedures in which our products or services are used, or adverse changes in governmental and private third-party payors’ policies toward reimbursement for such procedures, would seriously harm our business.

In the United States, healthcare providers, including hospitals and clinics that purchase medical devices or services such as our products and services, generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to reimburse all or part of the cost of catheterization procedures. Any changes in this reimbursement system could seriously harm our business.

In international markets, acceptance of our products and services is dependent in part upon the availability of reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country. Our failure to receive international reimbursement approvals could have a negative impact on market acceptance of our products and services in the markets in which these approvals are sought.

Page 26

Our products and services and our manufacturing activities are subject to extensive governmental regulation that could prevent us from selling our products or services in the United States or introducing new and improved products or services.

Our products and services and our manufacturing activities are subject to extensive regulation by a number of governmental agencies, including the FDA and comparable international agencies. We are required to:

obtain the clearance of the FDA and international agencies before we can market and sell our products and services;

satisfy these agencies’ content requirements for all of our labeling, sales and promotional materials; and

undergo rigorous inspections by these agencies.

Compliance with the regulations of these agencies may delay or prevent us from introducing any new model of our existing products or other new products or services. Furthermore, we may be subject to sanctions, including temporary or permanent suspension of operations, product recalls and marketing restrictions if we fail to comply with the laws and regulations pertaining to our business.

We are also required to demonstrate compliance with the FDA’s quality system regulations. The FDA enforces its quality system regulations through pre-approval and periodic post-approval inspections. These regulations relate to product testing, vendor qualification, design control and quality assurance, as well as the maintenance of records and documentation. If we are unable to conform to these regulations, the FDA may take actions which could seriously harm our business. In addition, government regulation may be established that could prevent, delay, modify or rescind regulatory clearance or approval of our products or services.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Purchase of Equity Securities by the Issuer and Affiliated Purchasers:

Period	Total Number of Shares Purchased (1)		Average Price Paid per Share		Total Number of Shares Purchased as Part of a Publicly Announced Plans or Programs		Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs
July 1 – 31, 2014		81	$	25.07		-		-
August 1 – 31, 2014		-		-		-		-
September 1 – 30, 2014		840	$	23.38		-		-

(1) At the request of our employees and pursuant to the terms of their Restricted Stock Awards, we purchased 81 shares of common stock in July and 840 shares of common stock in September, all at the fair market value of the common stock on the day of vest, to satisfy income tax withholding obligations for those employees.

Item 3.

Defaults Upon Senior Securities

None.

Page 27

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit Number		Description
3.1		Amended and Restated Articles of Incorporation of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.1 to Vascular Solutions’ Form 10-Q for the quarter ended March 31, 2000).
3.2		Amended and Restated Bylaws of Vascular Solutions, Inc. (incorporated by reference to Exhibit 3.1 of Vascular Solutions’ Form 8-K dated October 19, 2007).
4.1		Specimen of Common Stock certificate (incorporated by reference to Exhibit 4.1 of Vascular Solutions’ Registration Statement on Form S-1 (File No. 333-84089)).
31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Page 28

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	VASCULAR SOLUTIONS, INC.

Date: October 21, 2014	By:	/s/ Howard Root
		Howard Root
		Chief Executive Officer and Director
		(principal executive officer)

	By:	/s/ James Hennen
		James Hennen
		Senior Vice President of Finance and
		Chief Financial Officer
		(principal financial officer)

	By:	/s/ Timothy Slayton
		Timothy Slayton
		Controller
		(principal accounting officer)

Page 29

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Howard Root, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vascular Solutions, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures; or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 21, 2014	By:	/s/ Howard Root
		Howard Root
		Chief Executive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, James Hennen, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vascular Solutions, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-5(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) for the registrant and have:

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 21, 2014	By:	/s/ James Hennen
		James Hennen
		Senior Vice President of Finance and Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vascular Solutions, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2014, as filed with the Securities and Exchange Commission (the “Report”), I, Howard Root, Chief Executive Officer of the Company, certify to my knowledge, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Howard Root
	Howard Root
	Chief Executive Officer
	October 21, 2014

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vascular Solutions, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2014, as filed with the Securities and Exchange Commission (the “Report”), I, James Hennen, Chief Financial Officer of the Company, certify to my knowledge, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ James Hennen
	James Hennen
	Senior Vice President of Finance and
	Chief Financial Officer
	October 21, 2014

EX-101.INS 6 vasc-20140930.xml XBRL INSTANCE DOCUMENT 0001030206 2014-01-01 2014-09-30 0001030206 2014-10-17 0001030206 2013-12-31 0001030206 2014-09-30 0001030206 2014-07-01 2014-09-30 0001030206 2013-07-01 2013-09-30 0001030206 2013-01-01 2013-09-30 0001030206 2012-12-31 0001030206 2013-09-30 0001030206 vasc:ThrombiPadMember 2014-01-01 2014-09-30 0001030206 vasc:ThrombiPasteMember 2014-01-01 2014-09-30 0001030206 vasc:ThrombiGelMember 2014-01-01 2014-09-30 0001030206 vasc:NicolaiGmbhMember 2014-01-01 2014-09-30 0001030206 us-gaap:AllowanceForDoubtfulAccountsMember 2014-09-30 0001030206 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0001030206 us-gaap:AllowanceForSalesReturnsMember 2014-09-30 0001030206 us-gaap:AllowanceForSalesReturnsMember 2013-12-31 0001030206 2013-01-01 2013-12-31 0001030206 country:US 2014-01-01 2014-09-30 0001030206 country:US 2013-01-01 2013-09-30 0001030206 vasc:InternationalMarketsMember 2014-01-01 2014-09-30 0001030206 vasc:InternationalMarketsMember 2013-01-01 2013-09-30 0001030206 vasc:GovernmentalProceedingsMember us-gaap:ProductMember 2007-01-01 2014-07-31 0001030206 vasc:GovernmentalProceedingsMember 2014-07-27 2014-07-28 0001030206 vasc:KingAgreementsMember 2014-09-30 0001030206 vasc:KingAgreementsMember 2013-12-31 0001030206 vasc:KingAgreementsMember 2014-01-01 2014-09-30 0001030206 vasc:KingAgreementsMember 2013-01-01 2013-09-30 0001030206 us-gaap:ForeignCountryMember 2013-06-30 0001030206 vasc:NortheastScientificMember 2014-01-01 2014-09-30 0001030206 vasc:FederalApprovalPeriodOneMember vasc:NortheastScientificMember 2014-09-30 0001030206 vasc:FederalApprovalPeriodTwoMember vasc:NortheastScientificMember 2014-09-30 0001030206 vasc:NortheastScientificMember 2013-09-30 0001030206 vasc:CatheterProductsMember 2014-07-01 2014-09-30 0001030206 vasc:CatheterProductsMember 2013-07-01 2013-09-30 0001030206 vasc:HemostatProductsMember 2014-07-01 2014-09-30 0001030206 vasc:HemostatProductsMember 2013-07-01 2013-09-30 0001030206 vasc:VeinProductsAndServicesMember 2014-07-01 2014-09-30 0001030206 vasc:VeinProductsAndServicesMember 2013-07-01 2013-09-30 0001030206 vasc:TotalProductRevenueMember 2014-07-01 2014-09-30 0001030206 vasc:TotalProductRevenueMember 2013-07-01 2013-09-30 0001030206 vasc:LicenseRoyaltyAndCollaborationRevenueMember 2014-07-01 2014-09-30 0001030206 vasc:LicenseRoyaltyAndCollaborationRevenueMember 2013-07-01 2013-09-30 0001030206 vasc:CatheterProductsMember 2014-01-01 2014-09-30 0001030206 vasc:CatheterProductsMember 2013-01-01 2013-09-30 0001030206 vasc:HemostatProductsMember 2014-01-01 2014-09-30 0001030206 vasc:HemostatProductsMember 2013-01-01 2013-09-30 0001030206 vasc:VeinProductsAndServicesMember 2014-01-01 2014-09-30 0001030206 vasc:VeinProductsAndServicesMember 2013-01-01 2013-09-30 0001030206 vasc:TotalProductRevenueMember 2014-01-01 2014-09-30 0001030206 vasc:TotalProductRevenueMember 2013-01-01 2013-09-30 0001030206 vasc:LicenseRoyaltyAndCollaborationRevenueMember 2014-01-01 2014-09-30 0001030206 vasc:LicenseRoyaltyAndCollaborationRevenueMember 2013-01-01 2013-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure vasc:Category false --12-31 2014-09-30 No No Yes Accelerated Filer VASCULAR SOLUTIONS INC 0001030206 17176422 2014 Q3 10-Q

16091000

14481000

4847000

3762000

229000

235000

3683000

2467000

-548000

-1000

95853000

92346000

285000

200000

1234000

1162000

410000

404000

123120000

108141000

83950000

67740000

-79000

10932000

12551000

30785000

41649000

11554000

24102000

0.01

172000

170000

17176172

16964953

40000000

17176172

16964953

2224000

2864000

8027000

7666000

0.83

0.85

0.17

0.15

0.001

10291000

9197000

30158000

26432000

93000

32000

125000

41000

26716000

23989000

77898000

70061000

1868000

2275000

457000

610000

425000

556000

253000

406000

6000000

300000

53000

594000

1739000

723000

2381000

2109000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; vertical-align: top; font-weight: bold; width: 36pt; align: right;">(2)</td><td style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; vertical-align: top; font-weight: bold; text-align: left; width: auto;">Net Earnings per Share</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">In accordance with Accounting Standards Codification (ASC) 260, <font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-style: italic;">Earnings Per Share</font>, basic net earnings per share for the three and nine months ended September 30, 2014 and 2013 is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per weighted average common share is computed by dividing net earnings by the weighted average common shares outstanding during the period, increased to include dilutive potential common shares issuable upon the exercise of stock options and restricted stock awards that were outstanding during the period.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">Weighted average common shares outstanding for the three and nine months ended September 30, 2014 and 2013 were as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; margin-left: 36pt; width: 90%;"><tr><td valign="bottom" style="vertical-align: top; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Nine Months Ended</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average shares outstanding – basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,871,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,451,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,827,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,299,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average shares outstanding – diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,691,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,067,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,642,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,894,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>

0.15

0.16

0.51

0.47

0.15

0.16

0.49

0.45

68000

3000

0.41

0.33

0.34

5074000

4365000

1331000

385000

339000

1083000

995000

900000

P10Y

11943000

10614000

95000

-9000

7000

-8000

-2000

24000

22000

-812000

3692000

2362000

9282000

6871000

10346000

10532000

186000

5204000

4024000

14607000

11355000

2634000

1352000

6033000

3750000

3844000

1499000

1708000

691000

1099000

127000

1776000

659000

-285000

101000

1738000

685000

2038000

176000

10614000

11943000

3000

9000

3000

9000

15732000

14002000

6651000

6690000

7533000

6386000

1548000

926000

14258000

11385000

123120000

108141000

976000

406000

520000

20000000

2570000

2672000

8574000

7605000

-3801000

-3964000

479000

2879000

14254000

13636000

5213000

4020000

14615000

11366000

1196000

997000

3771000

3259000

-346000

192000

-547000

61000

2312000

1211000

500000

3829000

3486000

4478000

2472000

1182000

1331000

1609000

2759000

28000

22000

17616000

16187000

85000

15000

153000

3322000

3140000

9839000

10027000

12409000

3835000

31929000

28009000

92513000

81427000

21116000

17965000

6108000

5962000

4542000

3999000

31766000

27926000

163000

83000

60675000

52031000

18305000

17768000

13236000

11398000

92216000

81197000

297000

230000

31766000

27926000

92216000

81197000

534000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt; text-indent: 0.25pt;">The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2014 are as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;"> </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Goodwill</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Acquired</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Intangibles</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;"> </div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at December 31, 2013</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">10,532,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11,943,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(1,234,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">)</div></td></tr><tr style="height: 13px;"><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Foreign currency translation adjustments</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(186,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">)</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(95,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 56%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at September 30, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">10,346,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">10,614,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Inventories are comprised of the following:</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left;"> </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left;"><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr style="height: 30px;"><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">September 30,</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" style="vertical-align: top; white-space: nowrap; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">December 31, </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">7,533,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">6,386,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 56%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Work-in-process</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">1,548,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">926,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Finished goods</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">6,651,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">6,690,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 56%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">15,732,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14,002,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">Weighted average common shares outstanding for the three and nine months ended September 30, 2014 and 2013 were as follows:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; margin-left: 36pt; width: 90%;"><tr><td valign="bottom" style="vertical-align: top; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Nine Months Ended</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average shares outstanding – basic</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,871,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,451,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,827,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,299,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 42%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average shares outstanding – diluted</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,691,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,067,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,642,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16,894,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Three Months Ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Catheter products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">21,116,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,965,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Hemostat products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">6,108,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">5,962,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Vein products and services</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">4,542,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3,999,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total product revenue</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">31,766,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">27,926,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">License</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">163,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">96</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">83,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(5</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total revenue</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">31,929,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">28,009,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr></table><div> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Nine Months Ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Catheter products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">60,675,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">52,031,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Hemostat products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">18,305,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,768,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Vein products and services</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">13,236,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11,398,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total product revenue</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">92,216,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">81,197,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">License, royalty and collaboration</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">297,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">29</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">230,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(12</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total revenue</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">92,513,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">81,427,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 36pt; align: right;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">(12)</div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">Products and Services</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; text-indent: 36pt;">The Company has three product categories as follows:</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;"><u>Catheter products</u></font> consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner<sup style="font-size: 7pt; vertical-align: text-top; line-height: 1;">®</sup>catheter used to access discrete regions of the coronary anatomy and the Pronto<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup> extraction catheters used in treating acute myocardial infarction.  This category also includes products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits.</td></tr></table></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;"><u>Hemostat products</u></font> consist principally of blood clotting products, such as the D-Stat<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup> Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets.  This category also includes our line of devices used in radial artery procedures, such as our Accumed<sup style="font-size: 7pt; vertical-align: text-top; line-height: 1;">™</sup>wrist positioning splints and Vasc<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">™</sup> Band inflatable compression bands.</td></tr></table></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;"><u>Vein products and services</u></font> consist principally of the Vari-Lase<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup> endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter.</td></tr></table></div><div> </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Three Months Ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Catheter products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">21,116,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">18</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,965,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Hemostat products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">6,108,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">5,962,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">7</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Vein products and services</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">4,542,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3,999,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total product revenue</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">31,766,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">27,926,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">License</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">163,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">96</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">83,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(5</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total revenue</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">31,929,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">28,009,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr></table><div> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; border-collapse: collapse; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Nine Months Ended September 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Net</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Revenue</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Percent </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: center;">Change</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Catheter products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">60,675,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">52,031,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Hemostat products</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">18,305,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">17,768,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">3</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Vein products and services</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">13,236,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">16</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11,398,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total product revenue</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">92,216,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">81,197,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">12</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 32%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">License, royalty and collaboration</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">297,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">29</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">230,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">(12</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0px; text-align: left; width: 1%; background-color: #cceeff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 32%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total revenue</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">92,513,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">14</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">81,427,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">11</div></td><td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif;">%</div></td></tr></table></div></div>

7327000

6706000

22406000

20462000

3030000

2567000

107886000

96350000

1306000

1268000

867000

285000

200000

220000

150000

65000

50000

16871000

16451000

16827000

16299000

17691000

17067000

17642000

16894000

P10Y P10Y P10Y P5Y 0.059 0.167 500000 400000 500000 P8Y 3 0.18 0.17 0.02 0.07 0.14 0.11 0.14 0.14 0.96 -0.05 0.14 0.14 0.17 0.14 0.03 0.03 0.16 0.14 0.14 0.12 0.29 -0.12 0.14 0.11 0.2 51000 0.1 0.1 0.1 0.1 0.1 0.1 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 36pt; align: right;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">(3)</div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">Revenue Recognition</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">In the United States, the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in ASC 605-10-S99, <font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-style: italic;">Revenue Recognition</font>, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped and title passes to customers based on FOB shipping point terms.  The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.  All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.</div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: justify; margin-left: 36pt;"> </div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: justify; margin-left: 36pt;">In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor. The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order.  Allowances are provided for estimated returns and costs at the time of shipment.  Sales and use taxes are reported on a net basis, excluding them from revenue.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The Company’s revenues from license agreements and research collaborations are recognized when earned.  In accordance with ASC 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-Pad<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup>, Thrombi-Gel<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup> and Thrombi-Paste<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">TM</sup> products to King in exchange for a license fee.  The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products.  The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry.  In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement.  This agreement was fully amortized during 2013.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST<sup style="font-size: smaller; vertical-align: text-top; line-height: 1;">®</sup> radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of goods sold.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">In addition, the Company has reviewed the provisions of ASC 808, <font style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-style: italic;">Collaborative Arrangements</font>, and the adoption of this ASC has had no impact on the amounts recorded under these agreements. In accordance with ASC 605-45-45, the Company includes shipping and handling revenues in net revenue, and shipping and handling costs in cost of goods sold.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">In May 2014, the Financial Accounting Standards Board (FASB) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, “Revenue from Contracts with Customers.”  The new section will replace Section 605, “Revenue Recognition” and creates modifications to various other revenue accounting standards for specialized transactions and industries.  The new section is intended to conform United States revenue accounting principles with concurrently issued International Financial Reporting Standards.  Prior to the guidance, revenue recognition differed between United States practice and those of much of the rest of the world.  The guidance also is intended to enhance disclosures related to disaggregated revenue information.  The updated guidance is effective for annual reporting periods beginning on or after December 15, 2016, and interim periods within those annual periods.  The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2017, given that early adoption is not an option.  The Company will further study the implications of this statement in order to evaluate the expected impact on the consolidated financial statements.</div></div> P1Y P10Y P5Y 163000 83000 297000 230000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 36pt; align: right;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">(8)</div></td><td style="vertical-align: top; width: auto; align: left;"><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; text-align: left;">Dependence on Key Suppliers</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The Company purchases certain key components from single-source suppliers.  Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; font-weight: bold; font-style: italic; text-align: left; margin-left: 36pt;">King Pharmaceuticals</div><div><br /></div><div style="font-size: 10pt; font-family: ''Times New Roman'', Times, serif; text-align: left; margin-left: 36pt;">The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI Supply Agreement entered into with King on January 9, 2007.  Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis.  The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements.  King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors.  The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.</div></div> EX-101.SCH 7 vasc-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Consolidated Statements of Earnings (unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Consolidated Statements of Comprehensive Earnings (unaudited) link:presentationLink link:calculationLink link:definitionLink 030100 - Statement - Consolidated Statements of Comprehensive Earnings (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Net Earnings per Share link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Credit Risk and Allowance for Doubtful Accounts link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Concentrations of Credit and Other Risks link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Dependence on Key Suppliers link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Business Combinations and Asset Acquisitions link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Products and Services link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Net Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - Products and Services (Tables) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Net Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Credit Risk and Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Concentrations of Credit and Other Risks (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Dependence on Key Suppliers (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Business Combinations and Asset Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Products and Services (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vasc-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 vasc-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 vasc-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Arrangements and Non-arrangement Transactions [Domain] Basis of Presentation [Abstract] Accounts receivable, net of reserves of $285,000 and $200,000 in 2014 and 2013, respectively Accounts payable Accounts Payable, Current Accrued royalties Accrued expenses Accumulated other comprehensive earnings Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Adjustments to reconcile net earnings to net cash provided by operating activities: Reserves for accounts receivable Allowance for Doubtful Accounts Receivable, Current Allowance for Doubtful Accounts [Member] Allowance for Sales Returns [Member] Amortization of purchased technology and intangibles Amortization Amortization Amortization of Intangible Assets Total assets Assets Current assets: Assets Assets Assets [Abstract] Total current assets Assets, Current Business Acquisition [Axis] Business Acquisition [Line Items] Change in fair value of contingent consideration Business Acquisition, Acquiree [Domain] Business Combinations and Asset Acquisitions [Abstract] Business Combinations and Asset Acquisitions Business Combination Disclosure [Text Block] Increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Commitments and Contingencies [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, par value (in dollars per share) Common stock, $0.01 par value: Authorized shares - 40,000,000 Issued and outstanding shares - 17,176,172 - 2014; 16,964,953 - 2013 Common stock, shares issued (in shares) Common stock, authorized shares (in shares) Common stock, shares outstanding (in shares) Comprehensive earnings Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk [Line Items] Concentration Risk [Table] Concentrations of Credit and Other Risks Concentration Risk Disclosure [Text Block] Dependence on Key Suppliers [Abstract] Concentration risk, percentage (in hundredths) Total U.S. sales, percentage (in hundredths) Cost of goods sold Collaboration expenses Product costs and operating expenses: Total product costs and operating expenses Costs and Expenses Deferred taxes, net Unamortized license fee Deferred Revenue Current portion of deferred revenue Deferred Revenue, Current Long-term deferred revenue, net of current portion Deferred Revenue, Noncurrent Current portion of deferred tax assets Research and development, tax credit Deferred tax assets, net of current portion Long-term deferred tax liabilities Depreciation Net Earnings per Share Net earnings per share - basic (in dollars per share) Net earnings per share - diluted (in dollars per share) Net Earnings per Share [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Effective income tax rate (in hundredths) Federal statutory income tax rate (in hundredths) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Accrued compensation Excess tax benefit from stock-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Medical device excise taxes Acquired finite-lived intangible asset, amount Finite-lived Intangible Assets Acquired Amortization period for license fee Finite-Lived Intangible Asset, Useful Life Beginning balance Ending balance Finite-Lived Intangible Assets, Net Foreign currency translation adjustments Finite-Lived Intangible Assets, Translation Adjustments Ireland Tax Authority [Member] Foreign exchange gain (loss) Gain on disposal of equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Litigation Gain (Loss) Related to Litigation Settlement General and administrative Goodwill Beginning balance Ending balance Goodwill Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Foreign currency translation adjustments Goodwill, Translation Adjustments Goodwill [Abstract] Goodwill and Other Intangible Assets [Abstract] Income Tax Authority [Domain] Consolidated Statements of Earnings (unaudited) [Abstract] Earnings before income taxes Earnings before income tax Income Taxes [Abstract] Income Tax Authority [Axis] Income tax expense Income tax expense (benefit) Income Tax Expense (Benefit) Income Taxes Income Tax Disclosure [Text Block] Cash paid for taxes Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and compensation Amortization of deferred license fees and other deferred revenue Changes in operating assets and liabilities: Inventories Increase (Decrease) in Inventories Prepaid expenses and other Increase (Decrease) in Prepaid Expense Acquired Intangibles [Abstract] Intangible assets, net Interest expense Interest Expense Cash paid for interest Inventories Inventory, Total Inventory, Net Finished goods Raw materials Inventories Inventory Disclosure [Text Block] Inventories [Abstract] Work-in-process Total current liabilities Liabilities, Current Total liabilities and shareholders' equity Liabilities and Equity Total long-term liabilities Liabilities, Noncurrent Current liabilities: Liabilities and shareholders' equity Terms of settlement of litigation Credit Risk and Allowance for Doubtful Accounts Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Loss Contingencies [Table] Alleged damages from product defects to government Loss Contingencies [Line Items] Loss Contingencies by Nature of Contingency [Axis] Loss Contingency, Nature [Domain] Net earnings Net earnings Financing activities Investing activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other earnings (expenses): Operating earnings Operating Income (Loss) Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Foreign currency translation adjustments, tax Clinical and regulatory Other comprehensive earnings (losses), net of $0 tax: Foreign currency translation adjustments Repurchase of common shares Payments for Repurchase of Common Stock Cash paid for acquisition of license Payments to Acquire Businesses, Gross Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Prepaid expenses and other Prepaid Expense, Current Excess tax benefit from stock-based compensation Proceeds and Excess Tax Benefit from Share-based Compensation Proceeds from the exercise of stock options and sale of stock, net of expenses Proceeds from the sale of equipment Vari-Lase [Member] Product Information [Line Items] Property, plant and equipment, net Change in accounts receivable allowance Amortization of license fee Recognition of Deferred Revenue Research and development Retained earnings Revenue Recognition [Abstract] Total revenue Total revenue Revenues Net revenue: Concentrations of Credit and Other Risks [Abstract] EX-101.PRE 11 vasc-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/& MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ, MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N M);GWYIY2E^50"1=K`RK[?9HII4'Y3N^GD&&@T>8 MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@ MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E M6,S*L9B58S$KQV)6CL6L'(M9.1:S*TG?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[ M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\ M(V(T'4\4"_'L)MI< M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?```` M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O M_%[)K?BL"EJL2UI0]@)88@((EL]X>W MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/ M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M: M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+-> M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$# M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B"'XJD MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8ZA/EWA MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`;]P7AV\# M``#T"@``#P```'AL+W=OG9V9^.#HJ9+1(Q@K MM)K&Z.EV.KD'AG;DV%7=X-(O$U@9X:9<`KI))-AKM)A47*EXC M[)N/8.CY7!1PIHNF`N76(`8D=]B^78K:QH<'R&O#11"7/>2'>#X[VB(U]9GF6[ M_I>>BEL!*_M6Y(_1TYU0I5[YGR*US]UIC`VLVEMWHG1+O#\:C;IKOT$LEN[U M(L(G!+]E$)_3?D:J'>^5$8:;8N?*"??,9FK-OM"X0L_Z#"=+X\CL"_QB9F7J M&ZZ(BC(?4?,Y',H=*1=`M,*XX,CG7)+FOE.4+YO M-G/"K6AIN#1@D9)6_*382ZL;Y<=F]04XSY]"@UM6@\']<@.TG(ZPMUE^!8^@ M&F!74.B%$MYWM)8VGHXVBV<*BYTV`D.$J``CINLW#43Y2^MR):1LI?W7+;'E M&0ZM%N)>`J,X>Q0GE*4!]#Z[$O:AA3J6&`"MPM$F%"='H[[U,Z3+`J*3`-)7AI=-@5:VY=>@WG$B.]Q0!69!I(<5C0.@_KHP5!Q8AIOA!\1 MYT`MU6CV28W2?,BI2+-`I(-4A.U,J$2S0*+O,'(&C@M)*[_BNEB;G=_.B-[K\DZVTWT.J+1]]Q/]U0UEMU(%9TV!;[ M]X!ZJPYDN\7_2#*9;$R7C8>-):'YWH\`FFL3FD?C0,,T`P:V/*%!-`Z$>[(U M"R@M8QI%>-@89]@!H7`F/9A6NDDK!GPS*K@L\)7-?_AWGI:RY/6%]?`_```` M__\#`%!+`P04``8`"````"$`-`+0#D\&``!Y&@``&````'AL+W=OR[:KFM+;9PK&M M\E0TV^JT7]M___7\$-E6U^>G;7YL3N7:_EYV]J>GGW]Z?&_:U^Y0EKT%$4[= MVC[T_7FU7';%H:SS;M&,$RSJO3C9& M6+5S8C2[7564:5.\U>6IQR!M>J*U$:L"+YM^'_]VK;']:V&RS\T'$9X-9+V?7/ ME0AI6\5;US?UOP@Q&0J#L@@C"]XY#,_N!]EB3,:!*9YGS\]MLV[!54# M8W;G7-0@6T'DBS*15$5BSIF)9"H2,1:' MZD!$(NPM5:+89RZ<0].%*3II4K4-L$'$'Z2RP%7''_90H@*1V9ZJ[9P*&`)D M!!`!;DM)%`94X;0R`6O*M-VQ0025N2SFL3HR:E,1'CF.B:0J$G.?F2N0J4C$ M//[C),(!IR9Q6J*`Z38,7:U.$8$BNI:RO@WO$NE=(ILB2`:%75'>!=/R!*QE MT-/D(2)KT^$Q,S.H(K&V?_`=H!*NPWQ(\ZT`L4)5A`>>"^[HAA"%\4<4"EA3 MJ*5G@P@JC,W22M1V.BT4I[:#%U#GC=)4P"/K1W0Q.$KFIVZ@-67&ZUI$7-MR M^[FQ0#V9_6W;41Y`X]K,+=*`UE9KCV$A& MEBB+S2,^(4@\@?B"S=Q(CO4K?#)C+/P802(^=(2@CFC%B=C"!Q3(:A M"H4E4!3.0$CY3DL14;",.;2+S94 MIG`.\V6BSX##[^I$(]WK,&2FW.I])+V/9),($9.1\<5(`/+U![<@:7\8V7\4 M(&\>J@WF.;\JN:"UA.GN1C*7S3=R7B8$@8B9)1AKD\V*)4I M7,3LS.&0N?MM*)" M/^1PN.EPXEO@88(;R>#=#8<[4G5L6:T81B)!."9312(_-%.>D8'"P)G(IN9W MYKD!<2>K%6^L^Q[)Q&CG%DP[.%=E^V^3,KCL;.*YDW< MUKNP[M>GUU\2/G-Q$:P]W[`57$^;SU/XY6%XOKQV@(O_<[XO?\_;?77JK&.Y M@Z&<10CUT.)/!_BA;\[#]?M+T\.5__#G`7[B*>'BVUD`O&N:_O)!7&]??S1Z M^@\``/__`P!02P,$%``&``@````A`#\VK\MY`@``,P8``!D```!X;"]W;W)K M&ULE%1=;YLP%'V?M/]@^;TXT!#2**1J5V6KM$K3 MM(]GQUS`*L;(=I+VW^\:)S0?E9:^`#;'Y]QS/SR_?5$-V8"Q4KWB\Z?Y5IMG6P,X@@RMS6GM7#=CS(H: M%+>1[J#%/Z4VBCML" MB8&&.XS?UK*S>S8E+J%3W#RONRNA58<4*]E(]]J34J+$[+%JM>&K!GV_Q&,N M]MS]XHQ>26&TU:6+D(Z%0,\]W[`;ADR+>2'1@4\[,5#F]"Z>W4\H6\S[_/R1 ML+4'W\36>OO5R.*[;`&3C67R!5AI_>RACX7?PL/L[/2R+\`/0PHH^;IQ/_7V M&\BJ=ECM%`UY7[/B]0&LP(0B392DGDGH!@/`)U'2=P8FA+_T[ZTL7)W3ZTF4 M3-,XG2">K,"ZI?2H!PPA\K)>/J^-K;5Y=H>?*H]&7B#=L`< M:6?9@#GR/?F(M@>?:K]Y"MH!&Z7_P#``#__P,`4$L#!!0`!@`(````(0#Z1]_$Q@,``.X. M```9````>&PO=V]R:W-H965TWV)@3S^,7G/??QP^9& MZ#V[(,0M4"C9UKYP7JU=EZ475"3,(14JX9/M:AM%>GZV[DD-#GF$/>C-TO25KN^&0T0BL'7V%"*6@J,@ MX_ASH922'`8`OU:!16F`(\EC?;WAC%^V]C1PYHO)U`/<.B+&8RPD;2N],DZ* M?Q*J(^I$_$8$>C0BGN_XR[DW#]ZA$C0J<&U5`F?FSQ?+-XS%E7'5-H4)3W8; M2FX6U!Z,G%6)J&1O#@/8R)8#I%PC/A#(AH3JD@\1J:33F40\?0]$0L8 MZGW@I)*QO61F/49)^\%(A$8B,A*QCA@X`$/MYUS4^Q16%7WN1:>M#3;W:DK) MY%XRLU5=_1-'J=.#_G&H?QSI'\?-X][XGK,PB!Y6(#7ZV:NK85OYHI,:_:JK MK[K4]Y*!<70./8]`3@8C$3;$*PY&1H'X58&!![#*]3W09U[`2NR+Y[DE8Y>, M+G8C$1J)R$C$.F+@`*S3;W=`P*950#(Z!XQ$:"0B(Q'KB($#8GNG?/7,JX#H MI-:",LWWDM$Y823"AFCGP7(ZG&N1^ER9:;'N#0,75D,7]#-!P&KTRK=J+QE= M]$8B-!*1D8AUQ,`!#Y;^?B'H+:AITUQH()T)9B0T(Y$9B;7(T`BQ;7KWC("= M^[@HU"G10%I#I(X&"5N5=E9XRDXD&@'JM&B!%[]1T@QYC)#[XP+1,SJ@/&=6 M2J[BB#"%3WO7VAU?[GRQ)53:]]X:-K/C]M!;PXX5VMVN`YPVJN2,?B3TC$MF MY>@$KYHX"_B847E>D3><5/5N_4@XG#/JOQ[^ M`P``__\#`%!+`P04``8`"````"$`;\.O=SX#``!Q"@``&0```'AL+W=OG`ENGK/94).`HT3A!JIH07(`"NJ&2Z-,`1\M+8PGD1/.O(D/<+2C4CTP38E1]+\;#+Y[B9B!+A>X$$T"'UC M,-,>)AR('$-8&H&DKW%P ME,$?<[TR#1XHFTYM3S8&,UTTTN`/MJ>WI^E><&=3+6&1+>RZM.I%`X'1Q%:P M,1CPI[/WK,!X-X:P-,+/U3?O.HUZT7NE9S!C&L<0ED;=-7N;R7CI:?#0OT$& M-P83FM*#UMFK+&-?'^#KTCS7IJ5L\1%E&CQ4-BP]@QES;0QA:?-A!^G;=EUJ MFU7OY?8$&I,Y"K%UZOWYZO1"5[]T<9C?$\CL+=$;6XL%>"N_IO.;EE92L:=; M6A02)?R@N[H/E=.][4X<=T%S9N@FH.'79$^_$[%GE40%S6"IY\Q@_Q#FR&`& MBM=-P]QQ!:V^>ARW@.@#/.53O0/:P[+*[_`0``__\#`%!+`P04``8` M"````"$`03,X1*4#```^#0``&0```'AL+W=OQTA*M5`J"2VW6^_ M)P1L0F:#1[/SJ3"?$8;4L,W M1\HJ+."1G3S>,(+S=E)5>H'OQUZ%B]I5"BMVCP8]'HN,)#2[5*062H21$@N( MGY^+AO=J57:/7(79RZ5YR&C5@,2A*`OQWHJZ3I6MOIYJRO"A!-]O:(ZS7KM] M,.2K(F.4TZ.8@9RG`C4]+[VE!TK;=5Z``YEVAY'CQGU"JQ0AU]NNVP3]4Y`K M'WQV^)E>/[,B_ZNH"60;ZB0K<*#T1:)?"ZDI.MD%RYH]:^"6DQOO1.,?,!,ZK7 M?I)()HG41FC^()#[RR7AC0O)^ZA.--I*.\78_$T2B2(6[7Y&?A3"K>OK:4QM M(II!.%M#@_*EG*0;1?%2CV"G&)O122)11-0:?4"+V/1IT]!\QKI/ MNS\)Z_Z":'2*=HI1L2$_G)O![15B24$R+9+:1#2'<,L-*VEW*.'Q41Q74#&6 M\/>31#))I#9"\R>;EL$O@MV?A,<5'!]%Q=C\31*)(KI=@);ST-RB-A'-X/)W M#$I8-PB;<'0$%=,=GSF"T$;7Q%XG_+E!)!J!@M!$4AU!L78=:0X1W"S#&MYW MV[2S1EZ-ZZ:#;-6<1I(.Z5*VC(Q\I%81W:QL`>[>L-`FC@MJWCD=U-_\,3*K ML>\82R*2.V1DVRKC^;6,\JG:4M6U582=R)Z4)7I$M9PBW]FWTU@X_!;*9 M&8WOT`I:+',\D>VS'/=N$Z![;?")_(W9J:BY4Y(C+.7/'N%W@*G^5ST(VK0] MY($*Z%O;CV?XGT*@>?-G`!\I%?V#7.#VSV?['P```/__`P!02P,$%``&``@` M```A`.';2S.5`@``T@8``!D```!X;"]W;W)K&UL ME)7);MLP$(;O!?H.`N\1M5CR`LM!XB!M@`8HBBYGFJ(LPJ(HD/22M^^0=!S) M3EOW8HO2SW^^F:%&\]N#:((=4YK+MD!Q&*&`M526O%T7Z,?WQYL)"K0A;4D: MV;("O3"-;A,BJXI0]2+H5K#7>1+&&&.#7->_TJYN@U]@) MHC;;[H9*T8'%BC?UJW4I%5`WD?XA&AK]YN<6$O.%52R\J$8(<] MZ&7.4SS%X+28EQPRL&4/%*L*=!?/ECG"B[FKST_.]KIW'>A:[C\I7G[A+8-B M0YML`U92;JSTJ;2W8#.^V/WH&O!5!26KR+8QW^3^,^/KVD"W,TC(YC4K7QZ8 MIE!0L`F3S#I1V0``_`:"VY,!!2$'][_GI:D+E.3A.(ZFZ1A<5DR;1VXM44"W MVDCQRXOBHY4W28XF*=`?GR=A,LGB+(>@_W#!GL@E^$`,63O*\8L$&"U[-9\3G;Y(S-:S+'%F>C23^R9^LKILF?T>"D M7H]FQ>=HTS,TK_%H>9[%EVA#Q10$;X4=E"W_'S8K'K(EV>B,S6M\2^-LG,+4 M?@OMZS:0C*)H(/%T?BSYM[8C:_9,U)JW.FA8Y4:.G2'*#Z4HM`LC._>6KJ2! M8>(N:_AV,'B%HQ">5U*:UX4=>Z>OT>(W````__\#`%!+`P04``8`"````"$` MXU#8B#4#```K"P``&0```'AL+W=O.4@NF'^Q(" M')]SS[WF^FXN'NH*W3.IN&A23((91JS)1,Z;?8K__+XY.\=(:=KDM!(-2_$C M4_AB^_G3YBCDG2H9TP@8&I7B4NMV'88J*UE-52!:UL";0LB::KB5^U"UDM&\ M6U17832;+<*:\@9;AK7TX1!%P3-V+;)#S1IM222KJ(;X5=5N`J!:;O).3@P:4>2%2F^).LKLL#A=M,EZ"]G1S7XCU0ICE\ES[_SAD&V MH4ZF`CLA[@ST-C>/8'$X67W35>"G1#DKZ*'2O\3Q&^/[4D.Y$W!DC*WSQVNF M,L@HT`118I@R44$`\(MJ;K8&9(0^=-8)X1(X,`\3=HP"D&5WW: MHCAVE"TF7G69AZW6OQ[)PH[RES5@5_;9CC5L,1Z&%V-E\Y7,X5M[>T^91>.4 M1_&B=V8CL!B/"&!K^GLW8-?[TE&VF*%R%)_WF%'>3;/W_I(,V-5>];S6M<4, MM9\K,U)>C97]\FX6O9=WB_&(@$"9_]F_D3:"C^:NJ):3K>N>_0CGPR M_E_P3R">)#;8[8'C;N-I,"3!O=ZP6`$#]0`(-V M"_!\2MC=3RS(Q[O3\3P+8-L:F!QT7+?QF$,>(O4)PFE^;S<]&%8F&8@G!9BV MO2AQF[Z=6>R17C.Y9U]852F4B8.91P@<%?W3?E:ZC+IIIW\!HTI+]^P'E7O> M*%2Q`I;.@B68EW;8L3=:M-W`L!,:AI3N;PE#*8/S>!8`N!!"/]V8<:H?<[?_ M`0``__\#`%!+`P04``8`"````"$`R:+86^<"``#R!P``&0```'AL+W=O7(J M::6,B*`%41"_S%DM6[4R>8]<2<3#J;Y*>%F#Q($53#TWHAB5R>KN6'%!#@7X M?G)]DK3:S6(B7[)$<,DS98&<;0*=>E[:2QN4-NN4@0.==B1H%N$;=[4/L+U9 M-_GYS>A9]GXCF?/S%\'2>U912#:421?@P/F#1N]2O06'[UKE3['5":04)"QO":,A!<0`'RBDNG.@(20I^;[S%*5 M1W@66L'%KD1JM$>(X1N)!0GL>- MYSMK^Q%RFER8[90)YT-DUR+:MM:-VXT777=X9-\2NGQ@J?,%V>K[^G>EVO`U MK,-O[]V:#=!^\3.\=S(-R3V4Z(G,K`S^X@=#4.+]:)W9\'PZJUA M_!XS(G9O$O&;Q/XU8N`/`NF72[?A#![3U\NF#T48DOA2)7_4'UO#!$U/NN%B M[CK.J#%W0\0/ID@\1!;>?**R'R+>-:.,P:C5P71)7?I]Q'@UL]2,FI**(]W1HI`HX2<])V=0 MCVZW&^$WGGX"1_M;=P5S8;H?P\AO]NWN`(S8 MH6T6BM?-X#MP!<.V^9G#NY7"Q'$L@#/.5;O0 MQB'!)F4EO6B;U<\_]OI]P*O+'U_94?ND19FR?*63P5#7:)ZP;9KO5_J__W@O M6TY7^DY;ZC_7OORW/K'@O#Y16&BCDY4H_5-7),HPR.=`L+@?L M1'/XRXX565S!QV)OE*>"QMNZ478TS.%P:F1QFNM"P2H>T6"[79I0AR4?&BH;M2QY1"Z+B_>/TTO"LA-(O*7'M/I9B^I:EECA/F=%_':$ M<7^1<9PTVO6'CGR6)@4KV:X:@)PA.MH=\\)8&*"T7FY3&`%/NU;0W4I_)59$ MQKJQ7M8)^B^EY[+UNU8>V-DOTNT?:4XAV^`3=^"-L7>.AEL>@L9&I[57._!7 MH6WI+OXX5G^SQ_`9&+E!`Q+R+0XB)" MS($YGY#)]`F5Z45E=E4939[N"LQK,1Z>2=%7<_IP7PR1G3K93ES%ZV7!SAK, M8!A_>8KY>B`6`>DFS2(IU\1_EW=(.%=YY3(K'08(*2UALGRNS=EB:7R"PXQ4UDG?(")^ADI>^.GLL=I*7MJ8*,&'#7@J@%/!,3> MS/<%OPFT)^)$3D/0,,TZ"M5`U`I((X;M_HGURFDX7:1%H6QLMF#@>=>%H_1V M@Q(.2K@HX:&$CQ(!2H0H$?41DA5P=CYA!:=7.FP,US3/;EM"?:+8`IG79]2( MS*;3X5!!-FT$CC&SBSAM9&&:I(NX;61.R&+6>9`GD)Y9X;=%)J-Q1R)`)4*4 MB/H(R0PXWR4S^,O""%X:^L\SWDHVQ9PKIY,MF)Y,;%#"00D7)3R4\"_$HIY` MQ'U1-O$`50A1(NHC)$/X94=]>\,-X:U40]27-<'T&8(2#DJX*.&AA"^(B7CI MA`7"OY23`!4)42+J(R1/%HHG_8N#TXH7"Z7[MF#ZO$`)!R5NP MFF^>T+U&<&CC@XXN*(AR,^C@0X M$N)(U(O(KO!;4GO30EP1EZKVF6XNE#N'3034ZPJ*.+B*BR,>CO@X$EP0L=C& M4+=0%UN(BT22R)1(*U;VA-^EVIX\=K(3<063O5$.1/L"]7HC='H0!U=Q<<3# M$1]'@@MRV0AY6N7S)L0UHEY$]H9?U=K>(.M%W.QD3Y3[MTT$U)/P#8XX..+B MB([JAQV.I)>R#EXBY M]C5Z+5^_UM5K)6X3"ZJ04#)0X@ZQH-38C0?$@CI@-VZ;EGU/?V-:4`#I\HYI M01VD&W=-"\HA$#>N'8(J]RG>TS_C8I_FI7:D.QCB<#"#.W4AZN3B0\5.=7WW MC550WZY_/<#_,RC43X8#@'>,5&UL ME)A;;[,X$(;O5]K_@+@OQT`2E.13.>XG[4JKU1ZN"7$25,`1D*;]]SO&0+!I M[#0736,>O\R\'F#PYL='62COJ&YR7&U54S-4!549/N35::O^\W?\LE*5IDVK M0UK@"FW53]2H/W:__K*YX?JM.2/4*J!0-5OUW+873]>;[(S*M-'P!55PY(CK M,FWA9WW2FTN-TD,WJ2QTRS!\PR%.+N6J&JI2(V*M(7X MFW-^:0:U,GM&KDSKM^OE)9&WGYVHJI29]_-4X3K=%Y#WA[E(LT&[ M^S&3+_.LQ@T^MAK(Z330>XS?"/KS0(9@LCZ;'7M'-`QO1;M M7_CV&\I/YQ:6VX&,2&+>X3-$30:.@HQF=6%DN(``X*]2YJ0TP)'TH_N^Y8?V MO%5M5W.6AFT"KNQ1T\8YD525[-JTN/R/0B8):A2Q>A$7HN^/6YJU![U[%6FLKQUFXJZ4T%IWFU=D4IFVZV]3XID#M0>3-)265;'J@//A#LQD= M>V08)$E$7HG*5H7YX$4#J_R^L];N1G^'E<()Q+-"5XDGB.VP9XGH0@8,5F>N_>,*_9W7"$PXPH_$/`#(3\0\0,Q/Y#0 M`3;ZNY-,](OO1$]@N)XGKICKNVY7@#YEX._HG,-Z&TB)4$I$4B*6$HF(8#R" M>\7S=4_@K0KU,^9OK=>L`SYE5O2R=^V%87#U%TP)TW;@&<@1X91P#=N>$=&4 ML)<.`)Q&3`GP88R56ZM$1#`>P9WZ>8$S'H$X7,>4<;I/(+\O_!H2BP,:TZ$ M4$&'RR%ZP/D>1X+#U#(B(8G]:L3^(Z(C#O#[>&/F7H5;=RY]=+0`&!@:&4 MB*1$+"42$<%89,+U]?U:ZF;Q9G$+[??08J@$LS.,W&?IA[N`@H%_?+\-!X1* M.MIJS7R6T0M7T=$PX[%H+$<2(<+Z2;K#R;4IKCF3]I+3QZ%M<`\9OX=HU9FV MX8)][#45](BH[N0JD5PE9E4L=S6+)1&JL%Z1-O)YKVC3R7HU>R>@D,"(P)0B MX8B0%P_.ZV@\^+`MB.5((D18ETB[^KQ+M+EE7;JWYK0)-2DD=$F*A*/*ERY) MY\?C_(=&)D*$=0F2^89+A&9;==O@6W630D*7I$@H5XGD2"Q'$B'">D7:UN>,HW76*+0]>,^%=GAN'W:C7K\9]TX.]B3D? MFAYL0,S'?B.=\:'GP8CP?CRP/WH]A7!\#AWZ(\67[K-G3UN85NJ^_<,VY`(=D0,#>`CQNWP@YQ@W-C< M_0\``/__`P!02P,$%``&``@````A`'RO3_9.`P```@L``!D```!X;"]W;W)K M&ULE);;;J,P$(;O5]IW0-R78\A)2:HF57W;X4N?5,A62\7-N^X]D6 M+6.>L/*PMG__>KB9VY94I$Q(SDNZME^IM&\WGS^M3EP\R8Q298%#*==VIE2U M=%T99[0@TN$5+>&?E(N"*+@5!U=6@I*D'E3D;N!Y4[<@K+3182G&>/`T93&] MY_&QH*5"$T%SHH!?9JR29[)/2'SVKF\N[`L6"RYYJARP\RV3%[OJ8PAHV#C!)%VBGD.`/!M%4PO#<@( M>:FO)Y:H;&V'4R>:>:$/`G"]8>D,N*Z)7L+\%9YR>$ M+&,T;<;^ES#(E#:YTRYK>V9;,%Q"E9\WH>^MW&>H3-QHMJB![U;CFXK=6:$+ M"G@M(^2MRWB]=F<4+=8HNI::;8L/NO,&O7DO%=-Y*S%(($/C2;08LMD)./1[ M(6]1,^EHHG;F&G\WI##8P&0\FQ:O;0B\+0:L:'/F+6JZ;*$?FIK=I>:-WZ"# MW3*>3HO[=!-SYBUJNG1O,V/F4#&OEV/DZ4]K8:!-3;3S%AA>9GI0'[$'L$5- M5`,L3``D1,'U&`Q$V%GCLZ?%?;1I&SIN"M1/WBPD%$KP#L&)-K M&[91#.'A403?L045![JC>2ZMF!_U,<.'9M`^;8]`=_4)R&W_@!-(10[T.Q$' M5DHKIRD,]9P9=#2!9QB\4;RJW^![KN#L4?_,X*Q)X;7G.2!..5?G&_U2;4^O MFW\```#__P,`4$L#!!0`!@`(````(0`+ON5<+`4``.D5```8````>&PO=V]R M:W-H965T&ULE)C;CN(X$(;O5]IWB'+?)':<$P)&`ZW>'6E' M6JWV<)T.`:(F!"7IP[S]E@_0KDK(D!L:FL^5WU5V_<:++Q_5T7DKFK:L3TN7 MS7S7*4YYO2U/^Z7[S]]/#XGKM%UVVF;'^E0LW1]%ZWY9_?K+XKUN7MI#470. M1#BU2_?0=>>YY[7YH:BR=E:?BQ-\LZN;*NO@8[/WVG-39%LUJ#IZW/'O*[. M$.*Y/);=#Q74=:I\_FU_JIOL^0CS_F`BRR^QU8=>^*K,F[JM=]T,PGE::'_. MJ9=Z$&FUV)8P`YEVIREV2_.^VA?O^M*;=_E*<" ML@UUDA5XKNL7B7[;RG_!8*\W^DE5X,_&V1:[[/78_56__UZ4^T,'Y0YA1G)B M\^V/QZ+-(:,09L9#&2FOCR``7IVJE$L#,I)]J+_OY;8[+-T@FH6Q'S#`G>>B M[9Y*&=)U\M>VJZO_-,1,*!V$FR`!J#??\WN#>%J0FM]CUF6K15._.[!HX)'M M.9-+D,TAL)P8)/+&Q&!&+KPWB"!N4'6`P@F-GTB\*^( M!_*N&F'BML;AI%^T21CFX#I7;0&[AE7RUQH1%A)B8C-&(&GPG/NE27CI0NQ/ M:1P_>*V11.54L$BDOO^9%*5^8R.!'R>AC2!Q,$-;G*RMN+EH+_F3@XC(@(C4 M2*A$LLA/F:U`BT2($`E"D$@09(L<+ZZ$B3A!Q&G$B`OC`#HES2!"A.\C!(F+ MIHB3,!%'UM5:(UJ<$''2UV837,2WI<53I$F82(M(WC2BI46@JR]MC$!9DZYG M]93QDDJ82(N)-(UH:4F0R@5/2VHC41Q#42T$B4NGB),P$9<0<1HQZRV.8#]8 M3]:;`2$12V(;0>(8M-[[4Z=H(J_7AV7$I6OT^8$8T&?B7)@0[QDLD/C%>&V9 M[O%VQQ.D,5D[G.,-9E@J`IO!`F7KMA;?G8:F&SX22EV#:48+#=,A MF3;!X@`U;ZQRDF^POG$(:AR&,6GD<+"`%/7RJ`-=/ZFT;O@0 M_^IM@MJ&B@@69#&D/VY&$9S!2;XASVID(PMJ'(;1R1&)0+M4;V2$!'%TNSNS M211^S",EA=$"=JA)GNV M@7`1H03CXDYR$-:W$$$MQ#!:'N=H9QIUMH7P8"1WDQR$]2U$4`LQC%EY'#W: MB+,M)`Q1#T>9XY,,1-&DL-1`#*/%,<'#@4,+9E@P%U#P,H\7%?$B7`LG03K9-)(V4P!N-1EX!V0WPOC*K440IM1/# MZ!L.=N.N/JM+ MJ^>Z@RLV]?8`5ZH%W&CY,X!W==U=/LC+P.LE[>I_````__\#`%!+`P04``8` M"````"$`'N\WCKT"```G"```&````'AL+W=OU_B[VGQG?5AJFG4!#IJ]Y M\7S+5`Z!@DTP2HQ3+FH`@$_4<+,S(!#Z9+_WO-!5AN,T2"9A'($<;9C2=]Q8 M8I3OE!;-;R>*#E;.9'0PB8'^<'T4C*9)E*3_=B&.R#9X2S5=+J38(]@T<$_5 M4;,%HSDXF\YBR.?MSJ`E4W-CBFPIJ!5,XW&9A@OR"`GF!\GJ5#+R%>M31?QJ M0@#OR`B=]QG/LQDQ](#1D2V._#NOG&3V<^M-SHWVK,2# MG+P'TA0-(,>#(3N)@XPFT22-)H.0UYXDG:7C66^K>)#FW???)XLI&D`.GLV5 MDYR%]"1O0[JSWAV%'=VRKU1N>:M0S4IX.L-@`MM%NI/>+;3H[)&W$1I.:/NS M@A MVC```#R=```4````>&PO2;#XN)OG\\NL[/YZ]V']R)RE7Z7R23HMY]O6=ZZR\\T_/_O-_ M^JHL5PESY^77=ZY6J\67GW]>CJ^R65K>+Q;9G&\NBN4L7?'/Y>7GY6*9I9/R M*LM6L^GG#PX.'G\^2_/YG61'#[M?OAZO[B>'7PQ_>0,8R>]'Y^5JF8Y7_]Q=]F[W M@W"(-]EEKBD<[54ZR[JC[OXT.CW^\?O1F^3T]?<_GKU\_>HT>?GJN#LL+'8, MAI;I%,Q,L@_)K[/K[KB[!P<'AP='!P\.'G>_.EXOETQ/7N3EF"5^EZ5+82]Y MGJ[Z4.WO'S[8/SKLKA'`^&TVG>Z_G1?OY\EIEI9PS21Y69;K;-F=&81'J-]FB6*Y@V>1TE:[6O>%W?Y?U/@L[V?K),<>\ M+)9]C(W&XPP`^'KBH&R"I)C-"@Z\*L9O]Y+3JW29E@_/N$)MVIY]DR[P`PL$%?G.TSZT6?O(<'^[_ISA@A?A,3P1?3M'>: MNQ?IM.PM5`$9H-O$3\?%O"RF^<20_$TZ3>?C#!2B*\ID=SU/UY,<]-]+=G\\ M?9[LW.N"]CP;(\^')K*]DT8.2_KH MR#_J*9W1!(T%*R!*DM9]Q'^<+G)$JXM_F&,]6T]-\YD8&RLMLRNX"=V08(;G M6(\>3[S)5KA/'&G3`$>R';B#ORX(@1RU%!@N;C/SUGK[!&N(/Y:MW7<#;=*\HGNR"[DDQG:;+,D%1.2E[5J,].^TQB59Q?KEA:F"J M7![.Q#;_F&E%@^>V;MDPD?)Q,BE;LSC?!A:YC:D\NK5CW./I5]BZH!IZ$HA% MF*S'U?==0GV?CV6L,'JFXJZ-P<:BT'F!9X6@Q)6[,YTW-RBYN.NX*,&$&4+( MS7JX@5'9]D`]9K!LX24FJ4QP.WKAP7$+L+A0%S(Q:[H#MNB';&+``#`T`4OCO,SD#O2MSF@FC_IG)P$6ZPY;5K"XJML?#4OIL6E M$S*OC'A/2SGY%H$[MM&I>X37-24W:,#7CF4-L9`[(TX(I(=JIFY;W*N]DY$/M_2>3D3.`.Y?@Z45!>(JS23NGD#^MR M91JWRSQM4.,^_5%_%0)O9S]O>X0]G?AC(%1H]&):O+]5-%9++GF0_)WYU=W- M1C4^DU6!\A\7\S%QO@54$8?Z9HZ`6&2&#GF7D\M)SJ\311_0!2U?[]`3^N<9 MY!_G@UJPJ=JZH%D`OX^,L9=X:)-7WPQ*LG(P;OGVPS@K2PNVSM'=%_DJN5@6 M,[)IY`ANL<6Q:R-TT46:!W=6I@MDZ?38?_U9@A8WHMVC?";)+%8FVS>`W?ODQ^4SQ4"`.E.<3O(4_27;TZ85.Q7-SB!!AU,MDX36#%&$/TNBEY].W%!;D> MAR?X&(ALEOC?>/$?L=;QIHQ5DJZ2<]+)3X-L\\72\6 M4XL[T"4HE3$>TAH?B*T,`1?HB,'=*H;%531/;/NH07?T&[P>"W=.<.50?8.* M?7#0EJS\&<(@=3=;I/-K8:U*-IIFK7*2@3$X-NG<1NCU4UJ.<>B7R2GI:F/% M/9+O9"-W)69R#5CW7G*5$LF?9]D<*2=]IPP],0]:F[)F)JYF#?^08T3=,YK.DABRORR&F0VQ-@9'/B1.(SDQ2L*FX M";-$*5X;1@%"(8F\G-/]_WH_&1E4X&)*?H_IUX32R;Q8LS5(%PX M_40@G+&_EMG.'N55L9Z"@`Q`4B,X<_ZPGALADHHZ(;E]BP69'G(^,(]P$/CK M+W_\[V4RFL_7L*?70:1/(I5_;8?3\&L%3S)J#[BF?5U"= M"G?FNAF3X,FX+\*6,Q(=8-YI@3C#A*!L/?5D1/#-3"FC&L0X$,H9RSQ*LIJJ;3DS*F:@DHV:H:=I`E1D2 M5*8DRD(]1'&"/SZ11+2VXPNA^CU!$5I':K!2)1FUN8Y:2:J)C`'JVA6H(`T MF^0F,PEY'J++UC8ZU=8]_F;0[DF9F14GF5%4FLUB8K'F`AV&UD6>VBA0BD]5 M@&2]@*XZ_7:7!)2LEKGQL_LKZ7MCC]45IOH]EG`[4GM<_=O;4RC*SZ>+B;;,;^8/NW!X63%3P#1J9U+_\\;^Y8'WJ MY)`?Z4Y_X^46].RXN)R;YWV+(=LUBOCH1]9"ZUD6I#2[&[5[4E)-)[Y"O>*J M*LL:W%TJCH0T)3*-H5NA6^'DJZ*T*H,/&5OJL92FCG"C#Q@MT%4.^6N<$'@# MA+.#KX..2QX?/-K'KSA]^G2OVK"!J+WD_55.PC3X!@3&$H.+8KT,.G",Q<&> MI#($,_1A2+&%["\^YMRM:83_2[)7]Z2`D$HOEBA%H-HQMH7!Z9(4CGL&""K9 MTO(7S&"*Z2T$$]\(#L\_<`2LRP2W8TE:51)N`QDYAOW!KA<(,5]"GSH:&(.; MACK`Q_F%J=O=_!VPA$SG))NB1W`L2)@F!24>J[JRA^K$1K7:):0R,D$55)X% M)G8A0U?127M:D8\-XPX0&.U17N6+!<#++M`2@V):J-0)9@M*N*B<&;@1Y%@0M)*G M1C_GN9I'F_"I1IRDE]BPR;[I3KS9<2;&'&'>(]:6V6J]))J;`;HHO5AF^^F" M;]_Y&5';T#5\L%=!$G"Q/O\#E-+14\ITGX$TT[DZ*\[+\C+KJ5-9<[8W5WIN M7BP:W]/O-\N@V0W05TTD($+9GZ_)[I>!T\OU>8DCC"V!6V0?VPMM2(,+F3.'V&29EV\U2\EMXQ8A3#`UEG#S M)N;2=M%1JRC;GW#?7.+(/M@X]3,%^6XK+ICB0IZ,I2)PW-<7I/#'E.=P+34,HK1P'L)#Y1N#^NCQ?X/#[$1A'$C1K)@P:_"=,1!L M;'4OJ<:J?N(XA158\/BM).X4O%K-+^=JUJVLG'*FZ(THDVJ MK8SLET,.(]3V+<2GT"'&VX@Z[KQ$R#EN+R*1&,I#K_[VV#>X]EQH-AF0`D,$ MY`H#C*BRE$&TL%Y8D49SWG_>1+P9]HFG#2)V8=_*OLMVX5F?F_-@RHP>09E@ M2H[\/RO+&M<4=TIJ3",A(B(V71MC6E.*G4%NM:/34)M#'0!K`I_[>>M`CF8@ MI=0Q[K0X$>"F2\6NP<7IB-%2[:EG+!75GQE[T_BFM?MRY%'VK\5G)QBF63K. MR!V-::"+R2-]IPI5\1YRB@8$;4I30+>3"SRWI0_<,P8BJ#*W2L>),`39G1A; MFTHP_\@XPI)HN._"__Y)&O*#'$/_.>%_<%Q6HZD*HC30?'VG7,O#@G:+U9W/ M:;#]V3_^XOXC_1,M`-W8>T9K\*$^6;Z`37S,<3K-SY>Y/KU(9\*AK?C`UE&O M<.8?X'052WWXN0&P>O;G_^U>=0.JN.^A;?)OL^T>=LSQ\ET6.G4:$/R'Q8NZ MO+\L%_#IUW<6F8D$YI]Z3$N3I"I/;W%9@%MQSWV7-I;"\7 M&?5]>!"R@:CT8D8WP32_,&]+2B1"V=V_LD7R[$A];)L;-)/,;#Q1PX\@X92I M.0^?&R58YJ@&4I-Q7UL]:C+IT&E*UO0*L-$T;AQZ4T"D8)J%]A;2C,00RVL= M0:Y':,=K!]979&53PK]WV;XE&'N`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`*@A8/'I9^2#"W2AT1P*L%WYWJ-J,?3+KN5`YQSPKKX_"4^&>6*Q;-3HFJ"93 M8[P`QW6!]!">PT#"TCJZI0HI>,;)HA02ROT",)+Z%N&["%IT9'3]!4<$565* M2RS3UGFFM!NA:^1(M74(PPU`+_!:[):>^2V`QW7%2TXJ2!A-?D9^052+X&). M&1:+[GIR$+*+]=)$HURM)UX.1&WB$5E:U'2RP0=0WOX@1XCN!7F6173FE&QL ME'#;>A=^+K<6S(,!:2HU3N2WH+864.I1EA,7A-@H1QJU*S=KID1W>^7'BWQ9 MKKB>01;*_J*DH=+#5<%M,YC!D\%"V&@!M9!1%I=,UTUW8NF`>QA6AANA,ZSM M)<4Y1\Y*FM^#Z+CZ4#N=;]&%>7<[9VX M/]#]-M[^,A%Z;6R&)HL7OT;6+/@I<[9PQ1F,Z'&5H5E\.29=9CT^P0$*WHO+ M);)MS712@0AYA,TOCID"T1*WJ[V3PI)SCN/;;H'KC'2HT:\$0E/ M-RDJO=2[I4'AL[OR[N'>@Z.'NNO4_:;7W?[B$YN@=P^?/![:8/>IW87L[MLX M4+]YH3OXV$M0;U2XD`ZF8N19=B/+\V)]OB(0BGY.#WD?.?T&GHK:7'?7U8Q# M2!;!$8RE=9U+&S@$\FOH7%/QYZL$6U/$UL`$-\R:U".1!J$`AXC^PD:$ M@O%XHN:O8297.F+GP0._["QX=@X?^15+L;IZNG!/IM<]&S\"']B4<'EL<_DW MN%]_5?F7GUS^!'J,-B&X,2.,OC(!D/W`Z.5[+J=)6&IU%T`F[; MZ"GM+E>8'[L>$-(0(S;:[-KS^KH#XGI[A%^)Q\1F5O/X:/HY2"*,@]50&$:Z MQXT[Z[N39!_DRD>UBG6=E-\L'$=8_N,E`U*RF6%M(U>+#%^T1 M_]MS]E;6/"8`P_]T7\ZD*)@2P>9>C&Q2W^#<5']#^T"NGOKPJUU242FCTK#"HR&&Y(ZIKXWRHG$(BA60,ZMGU\ MK`]ZB#)L,#ZU,C1"*>TH)CX'3"MAS31'KER=%GAOXGCSXSWN@RM7UY^(4/.O1! M9G7[[-B253.XEL5P:XL=M=8;BYS,A5DCN61H:B,Z+3R6K?12P.,GDE]H<8TV MA+#5I[7K]LPCE]B$:(6/D)X'?1*[@T&JMJ=VM@S=HFG..$;T"6-#"[)#!1CG M-GG+A@HWJ;RKG\>3_R8G^R5V":ABYMA282-:&DKJQM;Z3(JYFJIB/CX9C&_$ M7:[MV@[?JT$^2J0P&D&!A.9/7EQC2D@+VF8F5K8A-Q/4"?8.?TD4#VZAK6;B MD]:"DTXH-Y"<\6R0L-C8QWS"^J)!Y4<:6\)P_:;V'H6&ROA=]3:,9"FI<';O MZI)G!>.8O4QV\5PCYJ/H_#*;D7;'P@6/J;P7DM=IK%O/]W_UPTOG$?H5JF*1 MM%B(;(M&]P'(B#4@.C9YJN8+"<./:D+'T>PI78 MVH6SA$9PLM7'@\`-.H@L=#$5\_VZ5\'ZF8):O.%XE7*'@,:WZJVAIR"?K4G5 MQ?MF35QKW0[$%80U%UH>UN(>F)$4NH=F%8G0;\TS*.KPC!@44EU1;:5D:I`2 M35E?>S0`*+`H8L9(?F55>S2AT_V<,!4,5-?M`V&.% M'+R`NB=32T;;$V+1A4J1J.BU,5S4.:W811Y%Z&<+K5CM98R&(I-0.T[7"+IH M;[V#'G")0A?Y!?X%Z5EBD*7=]PD\K:3Q[0AA#86JTEK=7%U22JW'((^8T5^5]_$`3]> MB1:,Z-#32ML&;[&;WZ"(`?B4-5E=,?=QL5S$QTPVO[_QV@MUJB?(26I[M7X' M"[<,ML1\(NRZ9>/U?AD#NA#L8U,[K>`@>6[-Q^,58)#(KQRWZF,8_@8T5Z^Q$.QMN.%=X>![ M^H%(*8;>@N1=3D^+&OS3Y,?[I_?%1 MS39?FUL0LAX#"ZM'=Z7+"T)$X/UI^KY<<_&@BV!M-E(2$B8/S.23K2FF*M\; M'>@\BL_@X&C);HHL-+5T^$F!"J&L[C5R>.W85&E6'_!82ZC%T%UR<^(RB4\9 MF5/A-ND/'LTP+`G.AZRZRV#TE^)V:ON9""N;\Q&_2 M`W4O:C"N%R'IM8"8\'[S[.'8($6F?%%D<_P:]89KD/'-:$6Z;)ZY*+^^0!%Z MN54#?DNX"1"U;N+D9]D'L.T67V-^F?'DW57R$_[ MWZ?X"]&7=N&2*R6W9*P$NAU3/D4@63WIE`?E5GB0M:9=*45@3,A@3T_HG2<> MUD75BK"GC;L@;2Q/=>\SZM"MF$7OLL587$KF@[8Y/3`7GF;P]YXBJ"5OR2H( M@@"1JX:@%^M3HHQ-,&GRZ/!@]RW7G@23T<.#$F2S>3Z<,C0XM4Y13`*CWJ#U M!VV.&TUN)E?WA)\=^`R/7HE%BR\SS#-7KL5'BCG@AE7.,;@1"33OPKNO:A:6 M;S19IN03*Z;S[)36-&4-RSX,G4V6O#">]$PAL-A5H0]V[8+5=AYY$2S9/;A_ M^%E$5%.)>CS?6$.'-_^?,_&2PCT[JWP6%0G.U28A7-&P2@)1=$YM9V:Q MI+L/IL?5&67PNT5#4%ZA,.P.\:&%@GC^V-;G&;A$,7^SIOT1T2?EAA%Q_%*W MF!;7/9L>O4+14LBQ,*[R1_HZ8\R-Y`X/(QU$J55/^T4V49J.TG)4:-5.*]9U5(1P4>(DJQVB*JF!(/,C'M!S49)4K$YW>S-1)/QQ M$\X=5N_?"@V6P.X:%H\VVB=R*"@"M>]Y6K:ZYWS>:.IBNX]/L0ZF4L6'`[G7 M'D4L*S&*N=^CX'BU_ZR^F+47TY[[W$8R.:V_Q+,6Y0TWT+(3 M:B@99SFP`(<>/6O#OS>P#,NZ'-%C3#2XVHSM#\A)$9RS& MFTO5%88&P&8&=AX^^L)>:1:5=AX?A@:#3R[R2M1\,[/V$D.=IWH8/?:86M0' MW^\\.K3M,>FJ2'#E%J:%<34)1Y8\"LY)7(6W#UH72=QKC,<,AZSV[1WU\-&1 M[:7UK1\F`/>%+WTMTC/AEYZ;7ZW)>?8;9IRO M\1+5;/V'-1H0PU"W3I/M>!9)KT15'#%%&^\>29\* M]_"=7QT_VBT"A3\%<6Y")@)73EX9H;VEOE(GP.S2^'3GAC$>/]K[P M!@K9?45V9@O"4Q;"D.;@DCP^:#`V@??1(V_!Z#I.=1MS?4A@8QV/3KZ MS/S#NM$FR%;HZU:<%CN[A;YZ44$4FU^T6F3N&G4W/#.DY+V*\P2@9VC M\+L2,!,,`YNI.0]&:#Q$'7HCJOY7:W"NE!@3\8R/_ORG=CQ883.$YX!J!(@R'@X0HRGB<5-W=H0+4D)6 MO'^I3!T'N>VIN#%"]U_W6#WU=U9S#4O']DA[+$7MF,+T-'_+E?,KG@7GGR$M M6Z&CP5+1-.@X1*2PEN'J8DWGB^E`.T>4_,AQ47$"K357VD7[T%FK7F@-K?); MZF1HGEB(D7<9`S9#"XH9`QK0A?2J)4;^*".QEV2)[-:,CAVU<+2;'FOV6T;L M"3306'GO3?%V$L4``'50E_W)HRC_J1Y4-$UX]:*V(/!50"R:F[=W0P*QI=]- M@XB*6IAAUJEHKGB8&GWTBHD)J76!I+#<:C3\38"CTG,?[Q1E:/BMM5/5UAG[ M6-M+^NT#""LZ1:Z)Y@\L.1&H#FVB0^3=.-?XU1-62>R/"622>H5D4L22\";M MHP)M)LX%47V.&R4TRGT]Q=H"\8I@3K:S)VB,$S$Z_C":EU5A);;BQ6,K-Q@G MQR!)5TZ5!6FCQUD?Y#3BL4@'Y$;=RO+YX8B=)X_=[$[P38!!1[J)/[U72I:$ MWDF"[^HQ2?&\%AB2-]E1%5\&<"I+O1#VK"[)CXG<_\*M^*/[3S\3D'PI<0\G MB!;9LUU"ZFUL\[`[$'E"F:^43M&?-0/P:SG$\<4CN! MD9*M^3C,VMEC!3E`=>:S=1H3>)(_6TT;JH1[O'X#]@M^XX;"RE@A_9G<_IC^ M(!VSI&0=S%[HM90P"+XU^M2:OT@M"#29G<*?F)9'7KVB$L"N`WBY?5:J+N\K MJ@.Y4"Q>Z16*)3JQRY+[F82T,BZ3"9*@BM"6;<7S#K3L#4[UGH!`K0FV&4,-&J3.4C;9VQ%7<`G[U>$YSW](R[Y5C]RQOVBQT_\GV8[^R;>]JXRM?'1V6$=57N\8CZS/TC[\/&=7!%H M*038?6'MB@*TYHQH`W1JS[7U@6SKBQ8^=O8/]JL8H)%[W0@A;(J/9(]HDH0U M*:K2V[(,D9@-'`>)JN5()ZC`8IO.!BGV`KSNP%E3Q,>"TI> MA)I*,T*'E;B=3>^$_C\,?L-S[>"@_`WJAIQ(D MI4*/0Z"QA+#%(=!97HA^0P`PN5%:0]Y3>-^$O*G.CY"'XPFL$99L1<&8JE=0 M65VT?;K$<@B,^(;4JV]/[T'2Y,7ST3X1#_U!<*3BJK`N7`A1XX,I_GM` M9B(8%LHNP8*3:*8=A_5833V:%'MCM%97A8@T&KE.UE-$I:Q&LHR%<+MK M0*14*96^(S%;\5V[`*HE3;+)*UEAN0VU.$[0(08T>](VPH*<.KP4B=NA^?+% MJK.WMHP`.PJT&`Y,:SX+%^=J+,VL9:*&K%+_T-=$W6/[^IEPU-QD915JZP9 MMF!S.YO&NZM=//8$L:F#@AF"PR(^&^\FN*\FWJGC*1/5Y@]8!)5#F8*G*:)/ M#HLJ36%4`3G8NN:+^?Y,R"-7W%6CK_?<,G/G:>!)Y2=D32^MS<)"6C1PZY(O M.+#'0O2@B3EOFE-KYTBOB,?:4B8[@:2";BDO=]M!*NQ$(P+I")NMJF?Q;Y/Q M9/2KD,:(#,=4@A:;=3O9]`AA2%/0BZ;PG9#U9]$3K<6BG:.;(Z\,MW&;N]0* MBFUT'1Z*Q:0SM$;-8&K;LX_BQO9.@0461#CJ+)'H<DT:(NNQATX__Y\V M%/;*TG$*CD"7O#Y[L=G'-%Y&^QN\9K?A#3)+0&&XD!*]-X(>L0O'L3,05US! M%5QC*LB^5KMBJ=[GJ')Q4O6^VC]B3TTP82KTKI0&[5:N=_'P\11FHX,1`>=(O"I"H) M(8NNB#F((VJ1-ZD)GKG42D>^WP,0;A$)KG1_*E[__3WQN$$HU)86,MH1];4@ M&#=+>:;JYTAFU]PD6\+OTO079-X5O+E]@/N9;K\C[E$?(J;?3+%DKRF"2KH0 M!GX7PV)1NV:BEFSM@1IFEW2>J8`6J"[S#BV#('F:&6_#[T`.R6DMG[6D\]12\'/=M[)JYWTZC'0?]P"NQ\JLP]KPBM++D8-6^-`*'P^;X2 MLKW#W%+-_(<1A^=H$A2I7393#+'BUW;&\+LB-H5 MS'C`KTHP\E0P>G[)`Q(4'Z?>%<-J&/":%/:S@N$.'Q_3^D:$2%>MJGYZA+BS MXRS_8.PO'W-AM7HC=EQ=9HM(N!:@!3^TQZ^^WR2=M.10_J$-&G4:(J%*4/4Z M'T>WTK]R2]'RU8REV2/>^,&'#Z38XHM(-/\7N_!ZX_P`\\O=YFWH#$HFPB-3FB[9JNC]):KSG55/65GMQ9<5V]YY%6D:CST2A_)I/F0 MJ191Q=&+2-&O&G`Y_/UTC[`L2!6WD].4(5"BS7\B0+MYE41I(MJ*\+3(QS2O MWUOROQ6]X0E/*:&[F0HKZ,F#V'#2*"]1318:?8O>4VIGO=\[:F3WN/;DG%H_ MK_8J"VY&_5%XE*$[\@2/#XBZ'Q]36+_L_6+9\7!D66_R67>=#:Y,F95&/ M;/^:=VB5Z^[WO3=8=C_>?=3]Y+/>ZV.O9(*;/PJU'<5A)ZH(FWY5OKOE[N&# M[D?0J?Y5-FCO/Q27[)X9#_9`[/WV%#IY^#?2NALUG_';M'ISC.X)FL*_W5-_ MMWEC;^.I6I,WOX/7/=+)4%)FXR:!_;U"UQ;2[L*;B/*X\JI7X\ MC^BX\8M@S=]-]Z]O)N[@,N&7P>R7TS<(OG]TK` M)"_UVR:]Q7YG-1ME(4*?+LXR*@L[H8?GNUO?C:\&=+^(<*N;>1/<<35IBX<32FKJ)+L_GCZ/-GI(3L.YJ:$J;_N8BW1V?"V94W[ M3;M4JVS^5?MO=*W84@3AU;PN)-]ZF]Z&;^.SDW0$Q.QON24U>@SOX2KH@2OS M($95'Z8?\*>Z)PVG]C?DR?,+>XV3R$D7J$M=$PUO`&]E1L1%OS_A MF4<2)#Z9?'QX?F_PE]AO`G\3"[7GG=J[;F_"NW";YAS?]OVOBO>ZE*3ILFD% MNU^W-G`2;9->>2[>ZB#240-3,4#*9HW>L1^("Y;LZKTR-6$^ M:OEV`?!6J$Z(.-_N60(-=TK)B%W\SRUZ%$G@>K)YIP3X/Z1+I0HVZIQM[RMM MI*3N9Y3=7_G9(G8OPP,L=7G%W=$!%K"$)77R^"K"\,"[AZ8#N_/Q.;G/JG1' M_PD3>PB'%Z:Z;OV:^W/WXQWUAUW`-MUUWTA*6RTT MH?16JV+/C=,[%Y(VCML,U^A<';SC5<_2NH=M+1JZ3%-^##NCJ^PICGBGTD(; M(C\K9JGE3*_O8\3K*Z)=1)Y1X+.20N,:(BQ2/Z/0G=##Q,:#_3A\QZ>[X`MO MH@Y^A@>.EI.[R.P7-(.FDI#'$G%WB5'S>H\+A16I&B[+UBEVX,J[Z0Y]V>BG MNYGG>2/C?A+>Q#CJ+14ZW<_HBAFM><*(%V.O-S)3V%@M-+&==?><6\TT-O=\ MEF\[MTZH0J@)D+E=&+ZMWLBOQ_AUD!MT9VP@4@/0\&6/&Q88U3UA^93*$WO>:[1`?=+<76&B.VQDSQ#<.&Q# MG!P#PDU!`;D>*R5V=PW+XK>UA![`>K8%29][:T%W;#5!# MS4:Y@]*DHVYRJ:KT5'7D3:Y;E9:Z<:3EIZI12HG'_H^-=/%3A#E)C(4W@5+E MD=XT\DC']0\/";V]0/3SLEP]^[\"````__\#`%!+`P04``8`"````"$`E:44 MI2$+```\7P``#0```'AL+W-T>6QE"UQ8)$%L2 M15F28SDXR69[P/4:Y!RT0%,4%$79C/E02>IB)^C_WIGE:U:4Q*6TTCI"SA*E MG?GFF\<^R9OO7P)?^^+&B1>%$[UWV=4U-W2BA1<^3O2?'JR+D:XEJ1TN;#\* MW8G^ZB;Z][=?_>$F25]]]_.3ZZ8:B`B3B?Z4IJOK3B=QGMS`3BZCE1O"-\LH M#NP4/L:/G605N_8BP4:!WS&ZW:M.8'NAGDFX#AP1(8$=/Z]7%TX4K.S4FWN^ ME[XR6;H6.-A&>4G+OOFPF.A7NI:9/(L6`.+/_UU'Z7=_S/Z\ M^_;=N^Y_OOGN7S^ZBW___'7]NY^_T3N%&B(3?+!?YF5WKUCX.I/OG,/HUM/`["`8P#W]V>Y/\IGVQ?;C20WA.Y$>QEH*7P3YV);0# M-_O%S/:]>>SASY9VX/FOV64#+[#`R'\7>.`FO-C)-)Q7SQS1%#:-$`9G4Q^O M4)L",,G&B_MMLG_98A.G:]"LZQC^.%W,BOUV2=-5CXL:A\?H*GU%],2/\XEN M65!#>MTNTDH==B)EXUD7])U-V=7@;);UK;XUE&H9%XMUOZ'"OB63R@:%UOOA MW=GHE*]LEW5Y&3Y7!F#"R671@]3=D]]#"U_GB),S=VA2/08#N/2][SV&67>; MK%SJ MWIK=,[T$F2B*'4(M:S8\@=#[Z7@F'^EL/)8MU+#@)5GH^P&^)`NUX+^9-$[S M8FS*`EG*TU(/IV[=R^%X/![UKD:CT=CL]TR3D3S/(]H+%^Z+B[,Y:335$0P` MP;@_&E\9`*1KCIBJLR+H`X#A8#`:],:&"?^S^GMZ!+(Y'>BJO4H0*/(J0:#( MJVSVT)%0^?-,@844Q;E*$"CR*D&@R*M#R15XJ-RK!($BKQ($BKS*UKPDYBHL M4"K.58)`D5<)`D5>E3;XS"OP6+E7"0)%7B4(SNW58EHUN[^WV`I(?60F;7R< MZ\)!?'M=;-8(\]1Y%"]@W:'8'NGU88Z87;N]\=UE"C/2V'M\PK]IM()_YU&: MPK[+[SL<*M MB&PS0CAZ=UJ[5SJQ&00O"S) MR0$XSH%;ZW@P`=_"2G'^-NM=LP]@TZY&<#!@1R/-7JW\UT_K8.[&%COCP52P MJQ;HJ3Y-V;"@^LPV*@*7+6"1/`#<@X@/%4@@$E2@0`"M$(`5TZ7 MU]M5\Y410HHN8*@8@3*PCQ%Y44EJ+NBL`.QG9"IQ'$*"`DN1:@@`1PD$XHB> MHOZW1S$HZH%I-"CJ@BD$K@\^8TY03W`]I"(,@$=)5E3CA![78YR1!@)!584D MT6"H*I$4@ZH:6;G"4%4B"015%9)Z0E6)I!A4U4CB"E4EDD``1I142.H)5262 M8E!5(RM7]%652`)!584DGNB?N$1VZ+)IMHA*UD\'W8/63[679>-":F_7I`G\ M7C3/9D_9S!%\P>929"J-]V/9>,@;UTZUIRCV?H-))MZ7Y<`%-];Q/K[4<^B5 M7V-[]>"^P%0TV^5Y6>Y>ZP4DQ?K&9C#R"'=BJO3#BKFNM5$NG9\CL!Q/1*/E MN*[2N"Z_$1C\VG9C@#1B8`L+JD$@USD&Z2$@*44P7]S2D+3T&VV-U(@)P( MD(-%*1&U2&CNIK=W5@U<;.^M!+U%0;*S$NT&$Z0\-:`\`$_;%.YO3G=5QJ\4 M+(?&KQ3E-#28*PZ.W_UPWDK\[D=YAOB%9.+6"/CPW3D7J/D)3IETSMSKR2GZ M'`%PR^FA?;`<-'Q!JP\)^(@X?(!P<%IQW74=GTA>'81:9C]1ARV+UA99<")/ M2ZG>N-O'%P)9!!T<=URAK.-[JW'7`%L6K6WB[C20#HP[KOK"!S[J=G8_?+%M M83VGKUX'A$N3<@!OH0,^T.=RALR4@#??.1P`L`>[%LO\X!\7M;4LL6#Y"E>` M&Y:4^9!M+L2@IUB4PAU>J5@.C1QN]%$G@IU!:B1"8N2^%C([>YB:QPM55?F1C]6^8*Q2694?^5A%D]OBJOP(4@E?)GS15E;E1[Y.F()U M@MI8^9'G?B#(_69%Y2/>$(SX3$KE.WA'.,)E`Q&.,BF5U_@H[PM&>2:E\A!RG% M\4X?"(K[2Q25'/$2#/@H`NBO\!QH>,2T!KQD#/$QC$\/+67P)2)[5&1Q,VL^_OP$MX,6).(Q%9([.(86 M`?[W=4IHQ%9$B"%8EQZ\%&Z:+Y*8$X&P1'`\1'!$JQ2Q45$$9?S#CD/,%BYU M-V)TAT75@3<8_2]>JGN%&>\I/BF=W45`J(6[M-=^^E!^.=&K]W]CCZ.` M8,I_]8/W)4J9B(E>O?^(S_F`+(:%-R@W'Q-X=@3\U=:Q-]%_OY\.QW?WEG$Q MZDY'%V;?'5R,!].[BX$YF][=6>.NT9W]#RC#Q\I?PW/)CWAL.WN\/!QYZYG7 MB0\/=X]S8W/PGZMK$YU\R."S@QH`&S:N"B,Z2?G8^]O_`P``__\#`%!+`P04 M``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL M64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`! MP[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7U MVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]= MQ9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK5 M9B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<) M=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[ MQR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF M9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F M8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8 M=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM M`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SV MN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5 M!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;U MKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C< MAT&]SAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\ M:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D M1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K. M.YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4 MALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q M/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY M2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-= M`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV M#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO M-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY( M%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4: M.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965TE,>=RO_[[]>'A:^UW;9<9,=ZF.Q\G\4K?_E MZ>>?'C_JYJW=%T7G081CN_+W77=:3J=MOB^JK)W4I^((WVSKILHZ^-CLINVI M*;)-WZ@Z3&D01-,J*X^^C+!L;HE1;[=E7K`Z?Z^*8R>#-,4AZZ#_[;X\M6.T M*K\E7)4U;^^GA[RN3A#BM3R4W8\^J.]5^?+K[E@WV>L!='\GLRP?8_:8KORG\F2T]B?/CWV`_1/67RT MRGNOW=&JU?^@S\T7B;8IN]'[H_ MZX]?BW*W[R#=H%LJS+GAZ;^L.#60/W;$^9F(-D"9%'9;(?9ZV?206-(LBSB++R8]\# M%2WDY]M32!:/TV\PIOG`K$TFBC&2CH@801&7C1[.[NFN@*$BE,$.:8![MY8,_#TG9(Z)U$DP)\%M!-('E7+[ M[!+PRH=4FT:KR4SDZ6C*1N_N[37M+.1Z`L/M^;C=]=:(TW1/9H$C#7% M6H6L);(85H.$)D&@9355$;H(`A-A*I+0.0F-*%Q%%F1&8Q5!$F&!4M,F%KL0 M-@/[XB`:8:DAU;5*9I;T8H,)F4$7E)>6[?0^G-V'EO9 M$ND,\+*KU^T`70I7V\-3`]`L"W,!W``^71NP:.$-%-'V\B3226"Q,YRZ]0#9 M)K`;86Z$6Q&L4AB(VU5*NV%W"D1"5I5.A+FC<"N"54)G[E`I:%>E2D96:D0" MV#N-0E61>1+!3T8-841%R"(,KM4I8N(X0K?",H754))Y8YU*@X*GKE&G@XL9 M-]A``U+Q:PP&;2CD>`)BU5?,'[06#+<()H&VG7$+@&4+_Z'(=E2J="M8KN;G MUD1",/1GRZ@AJ1MA;H1;$:Q2N(K;54H/XJC4P:C85#H11IP(MR)8I7`7MZN4 M7D3-I;FG2D96ZFP^,\LP)2H2)LD5%XP0$M+0W)DY9DB86"I5F`Q%YHV5*JV) M*M=TPF3P+V.ENJRPP5_L52<\0L"$D^_P%+A7.YNW#[5EBP6;@#=+'" MGY917Y?IG3R[D^<&?]G`<>YAEOV/(1&M]"'1O/V:2L@RC5,WPMP(MR)8K>:Q M'#-=NB+[-BP>'@OK9-F&W0AS(]R*8)5W62IJ6BJSGB4CGT:1R'R*E`Y1)`%> MV'#+"*"X2/N2X)@0(2Z.&^L3GN7^,I9.Q[[_PC&(8H2#2:)M4BD&'L#X:M:2 M80*.-!;@2927]AM9G+PHMX2(1"]5>;`BSQVJHMD5:7$XM%Y>OXM#$['(GJ^> M#W2>0_$X7KN^)DLX)#"O,S@`NG8]IN/O6G)J]U!RUG4W?A`W M.)_U/?T'``#__P,`4$L#!!0`!@`(````(0"]J_31P@,``)$-```8````>&PO M=V]R:W-H965T&ULE)?;CJ,X$(;O1]IW0+Z?@,EI$H6,&EJ] M.]*LM-K37#O@)*@!L[;3Z7[[+6,"MDDRY"8)\/'7[W*5[6R^OI>%]T:YR%D5 M(3P)D$>KE&5Y=8C0/W^_?/Z"/"%)E9&"531"'U2@K]M?/FW.C+^*(Z72`X5* M1.@H9;WV?9$>:4G$A-6T@B=[QDLBX9(??%%S2K+FI;+PPR!8^"7)*Z05UGR, M!MOO\Y0^L_14TDIJ$4X+(L&_..:UN*B5Z1BYDO#74_TY964-$KN\R.5'(XJ\ M,EU_.U2,DUT!XW[',Y)>M)N+@7R9IYP)MI<3D/.UT>&85_[*!Z7M)LMA!"KM M'J?["#WA=8(7R-]NF@3]F].S,'Y[XLC.O_(\^YY7%+(-\R3)[B]:T%32#&8. M>6I&=HR]JE>_P:T`@H@&4$'$?Y>A*2E3\TA%LI+1*V(O!]UL_#^03/@L4#&M-6`[Y; M#0QR]PWX>C!-GIZ))-L-9V#,B"8I\4'*$E3%>$!,S( MVS;8^&^0\[0E8DW`9T=@FT@NA)HV\-`9@2&,-Z)@943-DG(6ZQMFW-").R2F M'6$9@2R81E293*%"[V=&O02<,>Y9IZX=:F)F$'.;2.X1ED,0,1W>=Z;@",'H MNQE9V'%C39C.EC:1#(G>N^4,&F&\,P7;SK[8<6--F,Y6-I$,B1O.%H\X4[#M M#+N%KA'3&G8K?8C<\`8--3YK"G:\.:4>:\3RUM=Z4XW)$+GA36V9H]<'!3O> MW#;0R%UO0^2&M]4CWA3L>.ME=8MJQ/+F]$HR1'H1JQ,P+!GC$]?0CCNG">.6 ML>PY#9-<86[Y4^NP,;'CECFL5V]S-<%.2\8M8_KL/>CJ:Y%YLX7@)5XN9F%? MQ'8>U;IM^+R_V*F-T)GET.WX\W\&0/758B' M^T#HMN\5YI8_&.<#_A1MUV'H=C#6C)6_/G@[P4.F1^S\/;1EJ/.:Z\]IT;AE M+'].+R57F%O^'MHXX-`[\.?T:-PRBZ;X9WB%^\IOD_?SC4,?>/5!KJ3\0!-: M%,)+V4D=8#%(=W>[$_F3/BIW#^!L6Y,#_9WP0UX)KZ![>#68+"'%7)^.]85D M=7-,W#$)I]KFYQ'^^E`X=@43@/>,R&ULK)Q+<]M(#H#O6[7_P>7[V"+U,EF)IZ(728D4'S6[>U9D.5;%MER2DLS\ M^T6S`:*[0[ MA^WKEX_7__EC]MO=]=7AN'I]6#WO7C-J]PY7&W?UD=X<_]E]O#VWZS>JB57IYO M_4YG:POA_A(;N\?'[7HSV:V_O6Q>C]K(?O.\.L+X#T_;MP-9>UE? M8NYEM?_Z[>VW]>[E#4Q\WCYOCW_51J^O7M9A\N5UMU]]?@:___1ZJS79KO\0 MYE^VZ_WNL'L\WH"Y6SU0Z7-P&]R"I?L/#UOP0$W[U7[S^/'ZDQ=6?G!]>_^A MGJ#_;C<_#L;O5X>GW8]HOWU(MZ\;F&V(DXK`Y]WNJQ)-'A0"Y5NA/:LC4.RO M'C:/JV_/QVKW(]YLOSP=(=Q]\$@Y%C[\-=DQ>.`.Y2#Q]^HJ[7N?%ZG9^Y?X`VX"=Y;A9NAU M@N[P\EAZ4%?T?,`OC95+4^)6)V>=ZY/5<77_8;_[<04%!-+P\+92Y<@+U2TH MRW5N-GE_*NTAWY653\K,QVOP#S+[`&OU^[W?O?MP^QW6UQIE1E+&LR7&)*$6 MDS([<<'4!3,71"Z(79"X8.Z"A0M2%V0N6+H@=T'A@M(%E0%N(3Q-C"!U?T6, ME!D5(YK=$0$C:$Y`2()4)BZ8NF#F@L@%L0L2%\Q=L'!!ZH+,!4L7Y"XH7%"Z MH#*`%1"H!K\B(,H,/!7,1=,)[`B,M(PJALW*ZMLBXT:DB9(@4T%F@D2"Q((D M@LP%60B2"I()LA0D%Z00I!2D,HD5-'@(_HJ@*3-0+&&M-@'QNV[44.AP4E;<<"2;T?KQ_\8T$F@DP%F0D2"1(+D@@R%V0A2"I()LA2D%R0 M0I!2D,HDUL3#ANM7K`YEQHZ()GZS5QAKT&O`I-$QZJ`WL!]-TT:(UL],D$B0 M6)!$D+D@"T%203)!EH+D@A2"E()42.H9LT*DV@%R@WVC=O['I^WZZVBG#X,M M:Z8+&VF]O59&[`!I8@1(`R-`*#'0N_&.UW-BTUQO8B-()$@L2"+(7!,X<9'E MA28\N+11JH\*':]K#RYKKI.)I2"Y((4@I2"5)GIP5J#@D'HV4'_LWB`$[QV$ ME!4[4H*,D7"YFVCB0Q+QIL(;VG,R;81H3F::]`;-1$=(>),?-UJF:6>_DC1" M9'J.1#*UI2D[O3#T_.\0:?CK*<9"7$J1X3XAC$A3H8$ M4:]76_><,C`G#2AFAF^^O9H7),6W2@F=]2TC*>V;-PP&?>';DH38MYP0W[`@ MQ+Z5B,@W9V(KTCCEFYTFZBS_$VF"1W_=25?/K)&GD6^=\GQGLS$F*5:<$.)U M/B6D=F7?[P=>YTY,VXQDN!A$A-AX3(B-)XAZ'9UP=JSGI`"GY',9@<[RG5)2 MY#MEA+0;_6``'RLYF;TD&78C)\3&"T)LO$2$;HC@XP!/N6$'7[4$S.#KSO1/ M;IP];"SPL$>$[-+A[(['),79/D'D\[-X2BBHP];K]^1DSE`&/ORA!U=$B$<5 MDR4VGB#J>;I,.".RXL('NS+C;.0T\JW&GN\VA-0'@*`( M4A3,"2%>!E-">HUUO>&@[?&!IGB11:3'UF-";#U!A(O,/=?-2>/4*L.\$(ZD MI,BWR@AI1_QAX$M'EB3$CN2$V)&"$%LO$9UPI"*-4X[8B:%Z).<2X[(-/G9: M>-PC#Y&U^?6=1L>8I3@OM*)5+A#I9>8-NF*5S="0LH#7;=Z:&15CR'7L'K-C5'/*AY:KPL; MU>;)WK(=12FJ)X$OZ_,,K7=Y&4:$^'@7$^)EF"#JJ0WW]WM93]"U4\L0ZTDS M`9PYE_B6T8"PQ,"F2OJV)"'V+2?$OA6$V+<2T0G?*KSLG_+-3B35.A*)U.<= M"672.Z<9[$#Q0ABI#]Y50O$682S11**I1#.)(HEBB1*)YA(M)$HERB1:2I1+ M5$A42E19R(X1E(26&-&[-I>_SZ#L.!L$C3BYQJJ8@A`GY02).ODVR]GWG;[5 ME*5HK%=63TUEP$HT)<:&<('JG=\Y2-#TS1$8?.B+$ M_8R8%8T5[3DK.F$I,C\GQ,^G!2*CS*ZF,I&`F7O0G) M<$I/)9HA,BIH)$S%4B^1:"Y-+82I5.IE$BVEJ5R8*J1>*5%EF;*K+^QC,;\@N>'K3, M)X1XG4\)Z2.?!PV$MIQ`4UP-(M)CZS$AMIX@PJZ2,\(Y*9PZ\>G3+$GQG5)" M?*>,$/HQ'`[D1P)+$F(_7'APUV9L79N([4=UX7`G$^WF\Y27"Y0D1?"E*3T,@M\O^W# M6!+B9181,A-#6$]0ZD03>DY&3JTSK!>-N^1(2HKL2$9(.W+G><&PY7F!IMB1 MG/38D8(06R\1D2-.[E:D<:W5=MLF7G2Y8\'6J0/;S.NLZGS^.68JF MT$$:XRMX,SQ\LG5QEF1>,LN9'* M6V6$T`W537?F8XDBAALY(7:C($-FL=`CL-OI7?<3.%1TO.%3B9T:JNDE:L8_ M::=#`$7YT$B=0ILT$>UTU+,V&UKOG78Z*G:IH/0]^1'&C(1X'4:$^(P7$^)U MF"`ZT7*>XV6U?6M<\WUGM2Y(BL.;\JU84>RW,Y*B&M/SVVH,3A/[EI,>^U80 M8M]*1.2;2"0,VRG?="+I;USJ;Z&];/9?-N/-\_/A:KW[IKY-V1_"%?^J%G\"U%H5>6-63Y!KJAU4]4RX? MA%6].7"Y=PF-YV!8[2H3H[ M2VMP,@[545A>@8-NJ$ZV\@J<6V$$;5>@@P+6VD8`';%0M4FD-6B,A8O6*]`? M@Q&TS0&T4N!*FS5HC86J7R+O`^WY4#6F6Z[X'1AUW:AQX@.=5_"T[Y4W@?<90O<`HK\#KB:%Z'U%> M@;<-80!M5^"]5[#6-H)Y$*IW6Z6Q11`N6B^D00BO*DL%>/D5QM5F:AF$Z@57 MJ3(9AF5]CG=2:7(7PLOR4CZ]"\LV/@K"4>L-QD&H7C*6EB9!"&^)MW!P0KU= M+*_,@E"]8RPO1$&HWC26%^(@A-?%@=\V[L&WWM]67S;9:O]E^WJX>MX\0AWO MU)_>[/7WYO4?1WR#_O/N"-][AP,#?-T8_G^##;RIUU$?QS_N=D?Z0]V@^1\3 M[O\/``#__P,`4$L#!!0`!@`(````(0`[K]'6[`4``-P5```9````>&PO=V]R M:W-H965TJFN^5;]GC?J;[M??]F\5_5+<\[S M5@&%:[-5SVU[ND;E19OK^E(K MT^*J<@6G_HA&=3P66>Y5V6N97ULN4N>7M(7Q-^?BUJ!:F7U$KDSKE]?;EZPJ M;R#Q7%R*]GLGJBIEYL2G:U6GSQ?P^YNQ2#/4[GX0^;+(ZJJICNT,Y#0^4.KS M6EMKH+3;'`KP@(5=J?/C5GTRG,18J-INTP7HGR)_;T;_*\VY>@_KXO![<J^J%F<8'AJ"Q1EH'W0S\62N'_)B^7MJ_JO-LY`$_LVQ@<>-`05D#7$)X_T]]:-(,G]J?/5I:U6*Z8L[1#C4>\FT`O;=/= MIJ[>%5@5$-/FEK(U9C@&3#Q.'9?H)_-'F,Q6M54%IJF!!'S;S)89FR MYWMNPS*Q-[)D$[!:DWZ8-$B$](0$A(2$1(3$@R)E*08'/ZC"`QF2Y(Z-U>D'%(YN8TR[(-T9W>V;+B$>(3XA`2$A M(1$A,2')F$B.POD@S?YC1YFU["@AKB"#ZQXG)HRA7S^&N9:W$+\WPD0(.!'5 M"3M[0B(=]:U&TM8DQ^+>"*63L;04#E;^TK-WQD[P]EQD+_L*7("-X$Z83#AC M^(*,HH2)Z;-CVK=F)S5?O\>O0@$6?7'6"C(NB=1WZHK`'1CLKG' M_7M433CA89=B`Y7-P]A\K6X_B@VH87"8BAP<3N;]F%T.NN*8UQS"`F9M2*#% MI%+Q>R/T).#$&)3#J7)$&L6$)&,9*2#L2)0BH6D6V9IJ[KLDV`-L,B"1$-_46('O87 MHQ7O;VFNEJ2_!&VZ_N1PLN+N)\+):T'0&\+)T7Q\QAK62O;8A17`@CX?&GJ( MAG3Q$;%][&UG6(L5\25`FR$]0T2#>(1H$(\1-.^/@0S&'7#T4S M(P(Q=>@/K7^RC+F\B:EHFW![-/$W0*EQ+HIV_$*#[6\16CWL,$8KT>%" MUVF'[+JF6T:C!.77+_SKOPV`T48Y:'M0"D&7.MG$^[6;NDI_R.M3\6U42[Y M$1)$[[:PFM_.\1^M***>JQ9NU;IZZ@RWJ#GD,MR_J&ULK%C;CJ,X$'U?:?\!\3X)E]Q`G8R:<->NM%K-[C[3 MA"2H0XB`[I[Y^RUC&VP7$W6D>6DZAZICUW&Y7/CIZ_?JHKT735O6UZUNS@Q= M*ZYY?2BOIZW^S[?PRT;7VBZ['K)+?2VV^H^BU;_N?O_MZ:-N7MMS470:,%S; MK7[NNIL[G[?YN:BR=E;?BBN\.=9-E77PLSG-VUM39(?>J;K,+<-8S:NLO.J4 MP6T^PU$?CV5>^'7^5A77CI(TQ27K8/[MN;RUG*W*/T-79?N?R#ZJLR;NJV/W0SHYG2B.&9G[LR! M:?=T*"$"(KO6%,>M_FRZJ;G2Y[NG7J!_R^*C%?[7VG/]$37EX8_R6H#:L$YD M!5[J^I68)@<"@?,<>8?]"OS5:(?BF+U=NK_KC[@H3^<.EGL)$9'`W,,/OVAS M4!1H9M:2,.7U!28`?[6J)*D!BF3?^^='>>C.6]TR9LNU89M@KKT4;1>6A%+7 M\K>VJZO_J)')J"B)Q4C@R4CLU4ARQ]%FCO#DCO9L;1J.O8;1[S@NF",\F>/J MKCVP]6'"DP]D?&H@H.T=UX.CM?Z4(VRPWA&>GYJAP^SA^=@,3<@9NH0D>=@: MWIWCG.9`GU)^UF6[IZ;^T&"?PBJWMXSL>M,EM#R9Z$(,Z?6S[(*T(BS/A&:K M@V*0."ULB?>=O7B:OT,6Y\S$PR:F;+'G%B1E":NO`H$*A"H0J4"L`HD*I`(P M!U4&:2"U?X4TA(9(PZ/R.#!J92E"<`ONXJM`H`*A"D0J$*M`H@*I`$A"P%;] M%4(0FJT.?X<<,9>V'+E';4@B#D9+V60_F`SJ("1`2(B0""$Q0A*$I"(BB01E MZ5>(1&A@+T).#@*@G<1L[HDTF`PB(21`2(B0""$Q0A*$I"(BB02U6!)I^LCB M1858]UKP(#R*6'V!^:(4F#U_.:F<-`VH\`],@UC+TV!(?TSWE6J/$!\A`4)" MA$0(B1&2("05$2E0*,A2H*2ZVY`W#U9W0B,KP!`Q!>6(+V M'!*48I"][JN799C*=@E&`QY+R*'-T#U$''(&*.;0P*R,L@C`_50.*B!H@MX"Y M"4PAA\2`5:J8&XTS2#"4#&'[HZ7<"LZWLK> MK-!X*;?IQY/E))W1`W*R1DJ4DT*6?/)NY(CW)K,:'7T.C>D2<(@4M_<=G-\; M%$O(;<;TC#@TDL<<&LD3#E%RQYK2BBY>`2+F9HOR42N!/%') M'>!6\CIE-N9$GI&.$.D'%S3LI.,E_(%CC_68XZP]N./J2]D8VYY#HY7/(!M* MD[#_T3:F7#9/Q;4-EXI*O"&G$G.1^=%[+M)(Q-SJ[H`)MV(#+@P##TAN\?H( MA02EMW+T"J4JFE.Q+RZ75LOK-W+C9I%/DP$>K@.?^WVAX!ZY)B1IH>*6"U_B M$[CMPM^&";PM0M-\P2^<:''Q'CLN-!^3>"F MX9*6`[])'0AYZ@4<^RXYU+$+'-E`-O7&-RWPF5(*3CWPF7KC.:XW.8&]XY*> M#8_O.RZTKQ,X!$DZ-OPF=%S2M^$7D>.2[@U>S(&PO=V]R:W-H M965TG)UHFW&$UK-S3)Q*2R<'W/F[EEDE>V1%@V[\%@ MAT.>TGN6GDM:M1*DH472`G]^RFO>HY7I>^#*I'DZUW,R+O'T5H+95 MILMOQXHUR6,!^WXA89+VV.)E`E_F:<,X.[0.P+F2Z'3/L1N[@+1993GL`&6W M&GI8VUNRW)/8=C4IZ`HP#A^A$@I*X`` M_%IECJD!BB0OXGG)L_:TMOW8F1,O#N:`\DAY^Y`CI&VE9]ZR\E_I1#HH">)W M(/#L0")G$47A;($@;TP,NHGP["8&,R>:>P$!LH:)KF0OQ+A/VF2S:MC%@@P# M?KQ.,%_)$L!Z%>32@R[79`$]$&2+*&M[;ENP8PZQ?-Z0,%RYSZ!_VOGL##YC MCWWO@6$#>@-'4.<#."(*"#= MC36',&,.W8@:!1+.-$D&)ST.^&%3.L';<4#G\>+=B"*`.C(2(!ZOA`+X$83J M1@$09LRA&QD+,-<$&)QT`;#*WJ^`\!XOWP\I&HR&1B)@1:FK"146MZL@<#0> MLI'BVDK-+C0=^HGR,ZGV6Z(UW+=307AK!&3C!`)]F>Y[+\-JV,"4Q/O=>B!= M(Y1?6-'A^Z&Q$+$NQ-4.2K06^C]"#*VRW_5.`(`VJA!7&R&>/G0AB`_<;ZP+ M@:,%1#;"<49$GB[$X#4IC9NZ(YFVQWY(%>)J@R2&#DF"WRB-:8L4T"(@2FE$ M1!?B:I,D-W5)X:U%0NV*\D/1>QE*P]`I0R]V0+E;6(2.$PM>)T1KF%A\L/C&=0*P!$9+");0:(G`(NX+VCIP MG]F:5X$))B2@9?0'4B9.VW"YE?$=<#52A9@80P(1,08$XF$,!T1#W-/< M86&X)]7)D?Z9-,>\XE9!#Y`8GH-WFD;>M.1+RVJH#K@ML19N2.+O"6[$%$[G MG@/.!\;:_@73;[AC;_X#``#__P,`4$L#!!0`!@`(````(0#SK*TTJP<``"\B M```8````>&PO=V]R:W-H965T&ULK)K;)^ M`',*N)),A8/!G*%F=Z\=<()K`%.V,YEY^VW9:LO2[TDE4[D9A\^MWY+:+7=+ M<_OUY_E4^>%'<1!>[JI6K5&M^)=]>`@NSW?5?[XY7WK52IQXEX-W"B_^7?67 M'U>_WO_]U^UK&'V/C[Z?5$CA$M]5CTERM>OU>'_TSUY<"Z_^A>X\A='92^AG M]%R/KY'O'=)&YU.]V6ATZV:-P_K;:W M9^WT!\B?@WT4QN%34B.Y>M91''._WJ^3TOWM(:`1B&FO1/[37?7!LG=6MUJ_ MOTTGZ-_`?XT+?U?B8_@ZB8+#(KCX--OD)^&!QS#\+DS=@T#4N`ZMG=0#FZAR M\)^\EU.R"U^G?O!\3,C='1J1&)A]^#7RXSW-*,G4FAVAM`]/U`'ZMW(.Q*M! M,^+]3*^OP2$YWE5;C5JOTVEW>SW0$#Y;2FX1"VX"8C$XQ-X)A@8H*I"5P3S$PP-\'"!$L3K$RP M-L'&!%L3[`I`XE(&,@#I`) MD"D0%\@,R!S(`L@2R`K(&L@&R!;(KD@TI]%B_1E.$S*T6%*LY@[!I4X:O>6U MW"3W&I`Q$`?(!,@4B`MD!F0.9`%D"60%9`UD`V0+9%]':7"6O>%)(7H`#(",@;B`)D`F0)Q@"J6M(G_P_1=R.@>D42/CALC.G*C/#J`C($X0"9`ID!<(#,@F^$$769Q2\6;%&>2"_^P.1$^I1-&2D_#9BI">0/3VRQLJ* MY1U$$T131"ZBF41RYTN4VG.V4EU=,-*ZVF[H75TJ*^[J"M$:T0;1%M%.HJRK MNBM%>?89KLS*/'H0#V!@`1HR4O,S8J3-3ZNOS\]86;&\@VB":(K(13232'.E M[+WJZD(U+.:Z1E>7RHJ[ND*T1K1!M$6TDZC,E:)J0U?6Q%9K<@SVWP[D))6N_HB,SU,Q=.Q3[?!2E[9R,)&EVTR*AV;",C:NQ,N!I<22B M"Z,)(Z4\50W%CA@IM_1WPU4&+#-C&:4\9Z24%ZJA5#;ZO%0&K+QB&:6\9J24 M-ZIA>9^WRH"5=RR33K,>HZ*P>\NQW\+K[QQ+[TGN65D?%CV;H:)G,Z+&,K*D M#>6MJEAO6[H3QLJ*!^0@FB":(G(1S22BEY_EYQ*IGBY4NS=ZNE16++5"M$:T M0;1%M),HZZGN1E$IFVX455A)/!;=EA78VLHJD0CL?*NX;1;FXJ1&?$K3`R*Y M%2R1VK\D MU!>,E/J2$:OWFC?0]Q4;*?4U(Z6^8:34MXQ8O=GO@_J.C5)UW=VB&O\#=\LB MOABE&6IJ=43;6`:'XOR$W-U4#4>,5-2,&8D%G\X7;KI]=(C#1BJV)HR4^I21 M4G<9L7JCBPZ9L9%2GS-2Z@M&2GW)B-6[;3H/-E[5%1LI]34CI;YAI-2WC*1Z MM]=O@[HX;4TG.57/W)V=GF;G06<_>O:'_ND45_;ABS@933^(.I_BGA5H/.>=-$Q&A!B[,MEDML0XNA+98GO$.'Q@_IL`VM@3A,+K$? M-&W:PT>=09W?JN>_IN/[J/?M++WH. M+G'EY#_12]M(<\8H._#/?B0RQ7@,$SJG3[.-(_W'#)^JGD:-OBI/89CP#WIT M/?^O'O?_`P``__\#`%!+`P04``8`"````"$`^\ATM>8"```Y"```&````'AL M+W=O;CQ_61ZD>=3="WT`FB'@_-%96B`8H]K[AY<:08"1H_%+54 M9%]!WL_!G-">VRTNZ`6G2FJ9&P_H_%;H9/RF>?>$U`[.A3+8`>RD?+?0ALR'XV+_X^MX5X)M" M&"V,\`0\NSN M1YZ9,L'AC1=>+X+%$O!HS[2YYY83(WK01HK?+2KHN%J6L&.!>\>R?!4?=7BX M=_AHZ2U6LRBPFUYNY+>JG0EWQ)#-6LDC@L8"6;HAMDV#&,CZ[%N&P8]_V0$^ M6)*M94GP"B-(5$,)GS9!%*S])_"==IC=!.8A='_@K.AP)ZA%C06#4.PBR+`F&ZXEI(P6[%A-`5P^@Q4CD`!FKG+^+2LL" MS0&U&11FCE][OI&LV"G9JAB&PE=TUV->B[M7TYK/VLR M.&]OEV'!YS*ZB)LUKKW2T\C93G!,3G>R1RZ:@]+_/'.6YEQ#%SFM0A!%HW89 M0$,=VM'83@7!5,%25E4:47FP8^\:G!VBPT3>AO8([F-1NK(WC89Q.XJ,X MC29XMO-XZ\[IF&<>I_,)_&X9@]L3>E;=G\,?B&!R-Z1@7XDJ>*U1Q7)(<>:M MP'[5SOYV860#WL+XE@9&MGLLX1?-8&[,/`#G4II^88TT.8T)=V`L?7Q_?KV/CQP[?RY'W-ZZ:HSFM?S`/?R\]9M2O. MA[7_S]^?9XGO-6UZWJ6GZIRO_>]YXW]X^OFGQ]>J_M(<\[SUP,*Y6?O'MKT\ M+!9-=LS+M)E7E_P,;_957:8M_*P/B^92Y^G.#"I/"QD$\:),B[./%A[J>VQ4 M^WV1Y9^J[*7,SRT:J?-3V@+_YEAEQ M5\`*M-N].M^O_8_B8:L2?_'T:!ST;Y&_-L[?7G.L7G^IB]WOQ3D';T.<=`2> MJ^J+AOZVTX]@\.)J]&<3@3]K;Y?OTY=3^U?U^FM>'(XMA#N"%>F%/>R^?\J; M##P*9N8RTI:RZ@0$X%^O+'1J@$?2;^;_UV+7'M>^BN?1,E`"X-YSWK2?"VW2 M][*7IJW*_Q`DK"DT(JT1!>SM>SF7222B^'TK"V1D%O@I;=.GQ[IZ]2!K8,[F MDNH<%`]@N5L9\NC7>FNIL$9MY*.VLO:7O@>K:"`^7Y]6J\?%5W!I9B&;:XB@ MB&V'T)$`=CU%6+A+<=CI'1,-UDQT$#2U#3X`VSTUR>:]1L1)#R%,P$'W,]%@ M"+0SL0B"WBZ20TSH8"**V(XA"#*2M.#2&)"682+<.`D]^Z MB&4<1"Z"4(,<=ZGI'`MO5D\72#V(NX]ES`8QP*-?!G??&()PC"G'\2338.H^ M$;"LVB`F,OZ3*H'8,P]O"4($*Q=!N$%=N?X;YZ;!G)NB2;5!#'(34@W$EB!$ M#'KSQIYPTQ+G](]Q;AK,N86,&V*0FPH43/PVLRF:K8N04;QT$83;:@HW#>;< M6#9M$&/]EL2).S-R(8,DI(N@&17QI*2YOUX70G=LA^([OL,]3 M8F^-'ANR,;GV[=QRH#(8XG9E"-VZ'79WN@\;/F5YI:4(0I8)23),0S-WMPQ! M`#3$NH=/YXB='TCT?5<(EF@;@:"QYCP*H3QU'W=XOA-I[/K$AX)KA]Z_0<%W MA;`,!JJ98N+52*U,T@]Q+2"*]T&+Z?FI(7ZNA,QBF@G4@9,T1%R+B.*]T&*Z M2@D&^;DR,A.P27":.>4W24?$M9"$5_YS90+4E;016R4$(F\+B9BD)`;-FK3@ MVP,+0O>))76-I>>*21R1!1#GR1_2$C.*T^0[!0OJHDPS#&D2B`ANUXC\(3TQ MHSA-'FP+LMX,9330N"E&Q>IV-DHM%7>W&X-F6U7!R\6"QMKA*(0&G$G+>#N4 M`Y(B^*;!@FR@52))NME(N[(S4V$RXD'=_>_W(&H%;=A\SR`1-+QGL"\M?2UX MMSJ-/BM/8#8D)7S38$QV4B('^C0%W-XRR$DJ8M"\,OA6P8+ZN-+ZM'$E,J)6 M,:D>FGF3=$1B_R<;!(3V(6)KN444F%$)I M3I(4I=&<'A<]"[)N#%9J(-X4(Z/H=F(J)BKW):89Q9ER\;,@6T)#YV:*T*?^ M_L1(W:A%P-&5.TFB=)#JD;QZ%(*0I`J60WL=@A$BHOL,RI3IS)U,!_1&*05(?-3!6-!^-U5)2&18DL.[2!$ MA/1D@_SP)@,_])=Y?G4>%GUHF\I)'P9ZI_V-R@?I?YHSIYOX&;%7$,L M^A=PL7%)#_D?:7THSHUWRO=@,I@O(>%JO!K!'VUU,=<+SU4+5QKFSR-<8>7P M43Z8`WA?56WW0W_R[R_%GOX'``#__P,`4$L#!!0`!@`(````(0"-_$,FKP(` M`.\&```8````>&PO=V]R:W-H965T&ULC)5=;]L@%(;O)^T_ M(.[KKWQ;<:HF3K=*G31-^[@F&,>HQEA`FO;?[V!B+X[7M#>)P2\/YST'CI>W M+Z)$STQI+JL$AUZ`$:NHS'BU3_"OG_U[5B)&L6B=*/@F#J"$K M[`BQ^@A#YCFG+)7T(%AE'$2QDAB(7Q>\UBU-T(_@!%%/A_J&2E$#8L=+;EX; M*$:"Q@_[2BJR*\'W2S@FM&4W@P%><*JDEKGQ`.>[0(>>%_["!])JF7%P8-.. M%,L3?!?&VS'V5\LF/[\Y.^JS9Z0+>?RB>/;(*P;)AC+9`NRD?++2A\Q.P6)_ ML/J^*S(@(>2E^3_RS!0)'DV]R2P8A2!'.Z;-/;=(C.A!&RG^.%%X0CE(=(+`BA,D MC+QH/@DGT_L@D<+ MN;.4!,\P@N4:RO.\6LR6_C.DE)XDZZ%D>B'9M!*;0(M-VXE_V+!/W;8*6SUP MU-F"9)W;^G^AVNBMV$;?[KMV$\#N[$3]?3=#Q73>EZ1#R05D.U2<07IV1GT[ MMDKC-\]?:\LN@FJ>N5B,^S&NG61$IGT%9MW%>F[BNTU1<\F!')>M?8P7J^> M791@R&57K,5%*=9.,F\.9G!A\,J[],H[:#=VVTNFL^,:B;MG@JD]V["RU(C* M@VT2(XBCF^WZUUUDS]_%_#J,X58,YU/H=\V\WRV`?E.3/?M&U)Y7&I4LAZT" M;P;'1+F.Y09&ULVMWTD#G:9Y+.##PN"^!1Z(&PO=V]R:W-H965T&ULC);;CILP$(;O*_4=D.^74P(Y*&2U"=EVI5:JJAZN'3#!6L#( M=C:[;]\Q#M0.>T@N$G"^^3W_C+%9W3[7E?-$N*"L25#@^L@A3<9RVAP2]/O7 M_>)[*2U%BXK"4- M_%,P7F,)M_S@B983G'=!=>6%OA][-:8-T@I+?HT&*PJ:D91EQYHT4HMP4F$) M^8N2MJ)7J[-KY&K,'X_M3<;J%B3VM*+RI1-%3ITM'PX-XWA?@>_G8(JS7KN[ M&>%]["`Z7U*J?@0)7=X:1(T%VPW,7(6Z^Z^ORAY"2, M:T>4[/2%T_P;;0@4&]JD&K!G[%&A#[D:@F!O%'W?->`'=W)2X&,E?[+35T(/ MI81N1V!(^5KF+RD1&1049-PP4DH9JR`!^'9JJE8&%`0_=[\GFLLR09/8C6;^ M)`#ED)U#QP-MJ!8IJW7&]5GKV"5?3_O M1@^`]F`GM.?=CHEX;B/I&+D0V8T)0\2R,['MJ"Y-WUQ_O2T5!-TT7"RF=HX; MC4P-)+*)[8=$^B&Q>X^P;$(BUW=-P0F"&@Y-6OAV\AN-S+L%&<+S!A^;V%I$ M/(-M]8)(36(>S:8C8F<2L]B/3,*R!QTS[5W7115T8?.B1QN-1)W-F\DT-A/H M'J2M202+5UR:P$TT5:6R*[4SB3@P_[<\QK;']Q\\!5]XB^UI-QHYMS`,Q^7? M6L0\'A.I2/]3\```#__P,`4$L#!!0`!@`( M````(0#HEHM8!`8``,86```9````>&PO=V]R:W-H965T>UV-[\./7C_*LO>5U4U27M4YFU6_-*<\;S7P<&G6^JEMKZYA--DI+]-F M5EWS"[PY5'69MO"S/AK-M<[3?=>H/!OF?&X;95I<=.;!K>_Q41T.19;[5?9: MYI>6.:GS<]K"^)M3<6V$MS*[QUV9UB^OUR]955[!Q7-Q+MKOG5-=*S,W/EZJ M.GT^0]P?9)%FPG?W`[DOBZRNFNK0SL"=P0:*8UX9*P,\;1[W!41`9=?J_+#6 MGXB;D(5N;!X[@?XN\O=F]+_6G*KWL"[VOQ67'-2&>:(S\%Q5+]0TWE,$C0W4 M.NAFX(]:V^>']/7<_EF]1WEQ/+4PW4N(B`;F[K_[>9.!HN!F9BZIIZPZPP#@ MKU86-#5`D?1CK9O0<;%O3VO=LF=+9VX1,->>\Z8-"NI2U[+7IJW*?Y@1X:Z8 M$XL[@2=W0A8SLIC;U,>-=@O>#IZB\YOVX*T;+#Q%/\N90^8KR[G=DW@*3J\*S!87=U`X7E78"MN#T_1SWV!$4B8KB?ZSSVA&6S^NW3R MTS;=/-;5NP9K%&:XN:9TQ1.7.A.)Q-3I4^O?,@M2BGIYHF[6.N@%2=/`\R&)EZ?.$M%B]ZD%P.1'2(!(B$B$2(Q(LF82)K`YH4TH3OP M)Q<.=0-K#U*P%\"T'%D"CQO=4JDWZ55"9(=(@$B(2(1(C$@R)I)*(`A2B6;. M)U6B;CJ51'0>)V-)B&W*NFU[(]',1V2'2(!(B$B$2(Q(,B:2*'`<2:+<7D;4 M6HZ=DZY"Z/;)+2(^(CM$`D1"1")$8D22,9$"A?-`"O0_'B[4C:P`(EM.!DU\ M9+-#)&"$5TCTQ`F1GZAO-:Q08EMRIL6]D4N=R)(@LN5D)`DC)LQ7O]E8*SF276\C(@D8L1[Z`RSD9-63 MJ&\U>";V0G8=]T;"=<))5Z%*(D%%=%.D;]45PO_9"42]R"HALN5DI!(C)DQ@ MKQ)9*`?7KC<2L02(A(A$B,2())Q@3>@I*8DRD2&0RB)%.G,Y>HRV`HWB%X@5 M^W15[#`*,`HQBC"*,4HX8NM0R@-Z,'XF9E;*02LQ+5[G`62@RTO4IL16BPQA M9?<-?8&D/%@J1_-.6#UT12^9+RWX$I[+B1\(HV'!A`(-'48"W>PP%E:\0[): M6*C#1!AU'F,!$-H8@99R?K0@'.M'SS1K M_LGMF_"RD^((N/_0A`L9]3S@2$YF M1ZTCA=6@@<^1!6D^A()W!]:C10_NMPV96PL;+=9`N!JG-V_'KF[H%AP)JYL= MQL)*=&C#=8RZ'=&+*:J#V77(-&<73>QFH,SK8[[-S^=&RZI7>HED$AA_C_L; MKJ=NJ2G-"F8<=^8X+U>X$?W"AP,,\<%PH\S`/'1>*/>!&/YMPBWA-C_GO M:7TL+HUVS@^0(&S_J]D])-\,>87V7+5P?]@5:R>X+\XAE^=T#1^JJA4_:`?] M#?3F!P```/__`P!02P,$%``&``@````A``KRQ[=8!@``9Q@``!D```!X;"]W M;W)K&ULK)G?;Z-&$,??*_5_0+S'&+"QC>*<8O-; MK515U_:98&RC&&,!N=S]]YUA=X'=X:RDZLL1?YB9W?DRNSMPCU^^EQ?M6UXW M177=ZN9LKFOY-:L.Q?6TU?_Z&CRL=:UIT^LAO537?*O_R!O]R].OOSR^5_5K M<\[S5H,(UV:KG]OVYAI&DYWS,FUFU2V_PIUC59=I"S_KD]'WF2@*(2964N,E%47F`#\JY4%E@8HDG[?ZA8,7!S:\U:WG=ER-;=- M,-=>\J8-"@RI:]E;TU;E/\S(Y*%8$)L'@>M$D#N."^X(5^YHS:SUTEPZ./H= M1[C;31NNW-&$#.XX.-P!KF*DN_8K;@]7,Z^I=@X4)C[6YI;C,31># MB.IA0O;U]+-R@CK"*,\89JN#5%`I#:R!;T^F,W\TOD'=9MQF-V$C6^R%!18I MAO54X*L@4$&H@D@%L0J2$3!`EEX;T/[_T`;#H#8BJYT`@UB6(H2P$"Z>"GP5 M!"H(51"I(%9!,@*2$+"JB1`V%,OT%B-J`KU@,Y%JPI03W3$;++R^<):RR;XW MZ<4@Q"U""O0!TY7"C>RKU)KU* MA/B$!(2$A$2$Q(0D8R*I!()(*MVO&+3NQ!!)[!BQNAWE0:T,<7-:.FD>L.E_ M8AYH+<^#D^XD[K:F/2$>(3XA`2$A(1$A,2')F$B)PA8L)8K[.2[53Y8EAI$5 MX&1<@Z:C[EN]D7B`'B$^(0$A(2$1(3$AR9A(HF"K.S[D[ES`$V5AP\[#.QR, M(HO2!9;07J"1+!Q9L&3[+=[>R.GX@Y'()^#(7O>-0RC0ID?1X#A$-YV%'#X> MK$3X1*#NE4#6"_NA\7)A533H];6Z_4PO>+*]8*RM@J--C+G#8T[6<"_06#!F M9<%R[@4S%TKGX'-'L!+A`XI"BB**8HH2@2;DP2YI+,]$V8QE8$T5Q!/SW.&+ MBBH#1V,9B)5/'0.*0HHBBF**$H[8ZI1+`MN@3^3,NZ9QSASAFAM>$=03W>16 MW>LR?P7@2*J&Y4HN<%\XKMF[QWQIPU<(Y04D$$;#\@D%&@:,!+H[8"RL^(#F M9F&3`1-AU`TH"XH=TR<$Y0W66%"&+.E`GBO;Y-[D5H.C)Y#5%Z3/T4**Y3BR MQH%P7/2.H4!#^$B@(7P\'5YYA(EPA!F/*F3=3T+6#WN_L7ZLSQGVJ(_MZ:R# ME-8F1W*=*MOU'AM]7,%#V7@<6<-V[7.T@/ULR&A%JI+%PB9ML'*&O+ME$/)8 M]EAIYC@:,9X>4=DZ$VYEPHDY.:*L-+::JM(F?"$"9SP\Q6'PB9.4-Z]#*CL0 M$O64BWFE=I?":G#T.+)AKQQ2H;L#"V_C:0Y?)N;VPB&+-1"AQN7-_=AG,VQ7 M(F%U=\!86(D!'7-!!L2/@EW2W8!,<_:1CWV@*?/ZE._SRZ71LNH-/^!9^![4 MX_[KXG.WU!2^PZ^.N%!5;KGPFC_!;1?>=2E_7KC/,%%Z8[=PX;5O@CLNO)U, M\)4+#?H$7[O0SU(>;5QH\B:X.7>QGZ%WD@VD/'4#^@X7#UWJ`NV'NY^\X\$= M/".I#[0&,,[4G=T&AIF:P'X#HTS=\#8N-,ET#`^2Q)Z0W@DV+G:&]$:X<;$_ MA!M&_\CA,^\M/>6_I_6IN#;:)3]"%;&QOXMH6+2(>L^*XL7_]?+I;VI94I(A)Q@NZL=^HM!^V M'S^LSUP\RY1290%#(3=VJE09.(Z,4IH3.>$E+>!+PD5.%+R*HR-+04FL!^69 MX[ONO9,35M@50R"NX>!)PB+ZR*-33@M5D0B:$07Z96,?6F26TKCX(OQX(+-8D_F3AN:OI`C@NC)O6X^!Y\^1.E8CVY9$HLET+?K:@V4"J M+`FVKA<`<6-():.UZ%\.@35(LD.6C;VP+4A>0EE?MMYBN79>H!11C=F/8$Q$ MV""P@B"OU0A&_0>-R((:L:HH>M\$WD7[/4$-HB$C.H+FD(OCG=1XQ$.@GXQ M/%J9$^XKC`=X>#M*JV>%7$U[UVM^AYU'P@CJJ[1/G?E^ZR_Z6U@RLSDF]RU:G974JY%0<:4BS3%H1/^%)Z.$::\/5,;WW M7#BG-<7@2WN"][[`T;[S%L M+'X?P&(=P2^"4)\2?:'+(%R.X5=!N,*XTPZ`*T-)CO0;$4=62"NC"1CI3G"Y MB^K24;TH7H+!<''@"BX+^F\*ET,*IY,[`7#"N6I><(+VNKG]"P``__\#`%!+ M`P04``8`"````"$`U=74AEH9M/0&O$E2G?) MY3#0_OKF?NEIC;P(+[OPE%[B@?8CSK6OPS__>'Q/LY?\&,=%`Q0N^4`[%L75 MUO4\.L;G,&^FU_@"5_9I=@X+^)H=]/R:Q>&N;'0^Z2W#Z.CG,+EH7,'.?D8C MW>^3*';2Z/4<7PHNDL6GL(#\\V-RS5'M'/V,W#G,7EZO7Z+T?`6)Y^24%#]* M4:UQCNSYX9)FX?,)[ON[:841:I=?B/PYB;(T3_=%$^1TGBB]Y[[>UT%I^+A+ MX`Y8MS>R>#_0GDP[,%N:/GPL.^CO)'[/;SXW\F/Z/LV2G9=<8NAM\(DY$RF M+RQTOF,(&NNDM5LZX&>-7;P/7T]%D+[/XN1P+,#N![@C=F/V[H<3YQ'T*,@T M6P],*4I/D`#\;9P3-C2@1\+O`ZT%/YSLBN-`:W>:#UVC;4)XXSG."S=ADEHC M>LV+]/P/#S(K*2X"D:4(_*]$3*-I6D;G%S3ZE0;\_VT-LUV)L`^_K])%%?CP MJRHZ[]_2+BL08(]AX8+*."B8J<%4P5<%,!7,5+%2P M5(&G@I4*UBK8J,!7P58%P0W0P1[A$4R"S_"(R3"/L'='"&Y,4PS!"&SBJ&"B M`E<%4Q7,5#!7P4(%2Q5X*EBI8*V"C0I\%6Q5$-R`FB$PC3_#$"8#"]O-I#'; M#W4'1CS&A`58S"PE9"Q"A$N$3`AQ"9D2,B-D3LB"D"4A'B$K0M:$;`CQ"=D2 M$MR2FFG6YYC&9&"QA+DJ#&FUVXIK5=!'KHD0X1HA$T)<0J:$S`B9$[(@9$F( M1\B*D#4A&T)\0K:$!+>DYAH\NS]CJC&9TC7L[5%%;BTRV]VZCV,1A,T<0B:$ MN(1,"9D1,B=D0B(F5) M63[XQX0XA$P(<0F9$C(C9$[(@I`E(1XA*T+6A&P(\0G9$A+F1(V+D2FBV>_49-!%!.(-<0J:$S`B9$[+@!$IY5%Y6,3)%3[2Z M2=$RZBFN1!`*K0G9$.(3LB4DX(2G6/.-;7,_H>IF,G7?"!E71':*(V)N.J7= MKW?*1`1AI[B$3`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`%PS4\Q*LP.R27O'&*]S"@C+)ZR_@K"OZEJ![_ MSVD!KQ;*2N`(KY)B.)$VFO",V*=I@5_@AW7Q&ULK)Q=<]I*$H;OMVK_@\OWQT8"@U$EV8KYD`0"">KL[C6Q24(=V[B`).?\ M^^W1=-,S\PKL9,]-'#_J;G5/SV_?Q[_=7E[L#ZOGA]7C]GG]_O*O]?[R7Q_^^8]W/[:[/_9?U^O# M!5EXWK^__'HXO"37U_O[K^NGU?YJ^[)^IB>?M[NGU8%^W7VYWK_LUJN'6NGI M\3INM;K73ZO-\Z6UD.S>8F/[^?/F?CW['V M=/\6[E:?'BGN/Z/.ZEYL MU[^`^:?-_6Z[WWX^7)&Y:^LHQMR_[E^3I0_O'C84@6GVB]WZ\_O+CU&R;/6I3,7,4WQM+]]I$< MH'\OGC:F:U"+K/ZL?_[8/!R^OK]LDP^?UOO#>&-,75[L=-@*_11?NE1$+_D7:XZD6M?KOW]JX1T31EVX/^<[3RUAYV;?MZ/72& MJ\/JP[O=]L<%S4?4J_7U)\-%#V M-/2_?XA;M^^NO]-PO6>9.Y2)?(F!2)BQ:(.F[V?@ MSLJ8R?`XLFY\D<%1Y)@E(",@8R`ID`Q(#F0"9`JD`#(#,@=2`JF`+(`L7>(E MC5;#OR-IQ@Q-EC16CPG!J8Z%SF7M*'+,&I`1D#&0%$@&)`UYLV<+$-&NDZ.-.J=)7&])/T6Q<'0D:?-N?0 M-A5>#_C%'8HQXV>$B3M(XZ@5])"CD/2H(9`1D#&0%$@&)`O%K^W6CYF?`DHXF@`'M@72ABX(= M^Y"%:-%UA'26]5PU7H&O49_FX/.]I=;SG67D>"ODO+LBY?O;/HYYWU^S'W<[ M=3WSM%[WU^[C:8L@<\:=V2Y0>[O^,GG%7Y;R_>V<\-=L5UU_7VE6(QXT*R-G MD3+G9B.E:(AHA&B,*$64(S$77S]LH8XGVK.]3=K:S=Z$6`AHA&B,:(4D09HAS1!-$448%HAFB. MJ$14(5H@6GK(SX79G;NY^-4Q9'?YWGQL47RF4.S-T$,F_DDOZA[GWCJW M(Y62035&E"+*$.6()HBFB`I$,T1S1"6B"M$"T5)0W8)^ULQ&'K-V94J=AZ^; M^S_NMK15H'6M862UZ9A6-^O'B(\#[L"RR,V9);JJ#EDM[G(),M*EDM/%1KK' MS(]51S*8(LH0Y8@FC&A=$%M31NIDH7JV3AKI_J-V7Q,<),':&#*XN'.PJ*8?CC;R5XXY(Y2TCQC MMM71M*:"M-Z9,0K,!Q6W7*7$_$20_=3(5*:GC)Q]42%29[V?J928GS-RO"\% MJ?>5*KJ-$WB_4"DQOQ14>^_GVQPKSN7[;6/5'DZ\^170P'RX$*;;(AJM;D3! MQP8C5B0IB6C,J*W'Q510_RB5J:)C/@X.^+E*B?F)(#?=X'TA4F>]GZF4F)\S M\7ZA4F)^*:@AW>:T=B[=;QS>]M#GY=LBG?8&$9\,C^D8,J'1 M)ZZ.$(T9.3-H"J8RU,L13=#4%$P5J#=#-$=3)9BJ4&^!:.F9\D9C')Z/&U9( M9Y:MQ?WSFR"SU!X_AXN#,_M`I'1`#06Y4U=T$TZ\(G5K5]QB*D M73D5I"_,!&EGR!EU.K7U*)@&)J)!_"9(C>>,.BW;X?Q] MP$04Z'3EA`$]@H/5-Q6BJ&^:";)AW/2[=',.`Q( M/CMX*@P_^6&-QYZ)?G)W'6/I1Y`_=03;YX%(:6\?,HIU+1X)ZM=IZ]QTL#'' M+$,W;&0U2`5I8V9B28WGC#J1G28"#R?\V,RRYSH%-X#&4>"K9H)L'.U^O]_0 M*:PE)XZ2U=H:1R66-(X%(XDCF*278L0?H]JY_5[17&W27O&VA3W&8A,CTX.= MY@R+32HER1P*TF$P$F3'6#OJ=9N6#^M#K(,L%3UMSTR06L\9\2`+#WX3T3@U MRGCYX+?KJPI1U%?-!-E`XEX_QD#F(J2!E(+4>B5(K2\8G0AD*1JG`O$[!DEY M:\6O31?&2K#38.1M?N.@.#*@+-:*.LR&C+SIPDK%=IA%W3:,LC%K.:,L%:2- MF:'MG!&/LG[@X(0?OS9;0!@%OFHFR(9QBU',6<*)HA2D451BQYTKK`,4A3L* M82%A-_VI3_=1?L\P]2YW%U'W#+HF2*\P51J9,=Y>LC$7%,->8I$W>_1T#JO' MW(#U2$@G#ZO7IKGU..LT;$=92N:3?HSS\YBMMW48IH+T>)<)TF&8,^J8LL;W M#SB?<&C4YD<7XSB(;(IAC95&-MF(S;&YGU/0>5JI%(R#XP1I8@R1#FB":(IH@+1#-$<48FH0K1`M!14MZ"?-5-SPJSI MR'I3=8Y66L@9U]V.$^Z`A=RJ:\E=,<'+STG)]E M:_%@V'&!B';Y.J"@DBZ*N@8.!;E3%VSO1R)EJ\W=5K>'U>:Q"&E73@7I"S-! MVAER1B>JS1/1\,^)X=%%I/15A:"SL^B`H( M37V"7ZBS02IZ:CT3I-9S1EQ5"CR(X>KTN?B0P M%R&-HQ2DUBM!:GW!J#F.I2BHL@!S."-_\@BZZD`4M;\/ M&=&V4M:@D2`NCK7C-M8:QRQ$ZY7HI8*T-3,QI=9S1E*$#LMC_/B5\IA(:2`% MOFHFB`.)VOVF;F%;S@FD9#V:["6V2DQI(`M&$DC0UDM^?#(0OU^8TL[?L+C; M"I'[P5O;(J\>%L=A-5VE).*A(!T((T%VF/7CN.G#6!'2898*TO;,!*GUG-&) M(O1$-"A=SO((2\@Q7`FD$$5]U4R0#>0VBOJ]AO6"36D@I>AI()4@M;Y@)($$ M+BY%XU0@?L-MFWRN8:G?=VU&W@:X'7S^.%`I:J;RNP;MB;!K_#_E=/JF!%A7+/*F M#RBGLYY3\..3)6?N.L<&T*[#7I^-;28.R1S3B9OF&#:EL96BI[%5@C2V!2.)#3H2 M>WU^CK%?:V'_-O]IO?NR'JP?'_<7]]MOYBLKNN;C[B.VWZ=Q%[43 M=.A)'4?X).XFIE",.O3M'!_KF$(-^M:.>CB%/"9##7;NR*DFGSYVDH_44/CB M._*UT57RM,G1NUZR;+1SFRSK01XZ&I&G]A0-)N M):96@$^H.D21-SVA`WMB3NBH0^?OQ!RX\0D=IQ-S?L8G=#HF#YJ>4)V&K#5Y M0'6WQ!1CT!J5WY)IXQ.JPB6FQH8Z!;W'E&/P"17@$E.5P2?T(0"U:%/>AO%M M8BK`J$/U7=)I>G)'[[EK?`\50Q-3(4-K5!--3,6SX0G%8XIC^(3*H8FID>$3 MJHHFIE2&3Z@X2O$TO8=N]2;FJB?JT.7>Q%S=;7I";="H0_=ZJ5\W6:.KEHFY M6XG6Z.9D8JY*XA.Z")F8FX_XA.XUD@=-3^B&+5EK\H!N3"?F&BU:HXO3R;3Q M"=V?)@^:VH"NVM*3)FMT=3HQ]VGQ/?3G&^1U/6\'HY[^2("\;II9Z&8^Z30] MN:/WW#6^AZZQ)^9NF-O-^(3NLR?FDC,^H6OM M%$_]GNMCJ/2]1B^K+^O9:O=E\[R_>%Q_ID6D57]TM+/?C&1_.?"%_D_;`WVS M$=7`Z!M@Z!NLUG3%O67N`GS>;@_R"[WZ^OB=6!_^!P``__\#`%!+`P04``8` M"````"$`(I%UD%T#``"S"@``&0```'AL+W=O[?=\9< MBH%&FZHO(0S'Q\=GQAZO[U^*W'JF0C)>;FS?\6R+EC%/6'G6,_6J26VKB,-/QY(+N2L7F+;KA,$*T'9+T'1C[_PP\GW;W:ZU03\9/?TMF M_/Q!L.0S*RFX#7G"#!PX?T+HIP1#,-@=C7[4&?@JK(2FY)2K;_S\D;)CIB#= MM[`B7%B8O#Y0&8.C0.,$M\@4\QP$P*]5,"P-<(2\Z.>9)2K;V+.%<[OT9C[` MK0.5ZI$AI6W%)ZEX\:L&Z15U)$%#`L^&)'"6OK>:+8'CPKA9,PZ>5T_NU@O1 MOCP01;9KP<\6%!M(E17!TO5#(&X-J65T%OW-(;`&27;(LK&7M@6+EY#6YZV_ MG*W=9TA%W&#V$Q@3$;4(S"#(ZS2"4?]!([*@1LPJBMZW@3^B@X&@%C$4!$8- M!KJ/4(!T&]&![-S0GW-<8'KL[(6Q,2=9"AJ/E8%);VE9E$%J@%2$6G M8)S*!G1)9@<9R@1)UWN'@[2J+GEU)-"U=K,8>-1^G%Z#45L+4\[E%"+8E-%$ M]*FCJRKJ1XR98'>,%OX/"4(:4T,3Z6?#7P[+I@,-\X&MK7<`7#8`P>;D3:1G M0#]B&+`R9])'S0)2=66%(HVIH8F8!@QKH@,-#<#=]G8'--JZ<-VF][X'?5I3C+YT'7SP!5K[+L##=Q#?XX"I>!!&D_A9"&?@F&PN/&'_3R,YE/Q10B;=0*_#"/=)89"[\+H;@J_"J,5QMUN`%P9*G*D7X@X MLE):.4W!2,_!_B[J2T?]HG@%!L/%@2NX+.B_&5P.*70GSP%PRKEJ7W""[KJY M_0T``/__`P!02P,$%``&``@````A`!4C\%%>`P``M`H``!D```!X;"]W;W)K M&ULK%;;CILP$'VOU']`O"^WW#8HR2IAM>U*K515 MO3P[8(*U@)'M;';_OC/F(@QIE%1]"6&8.3YS9NSQZN&MR*U7*B3CY=KV'<^V M:!GSA)6'M?WSQ]/=O6U)1O*.*,%D0ZO:`E?4BX*HN!5'%Q9"4H2'53D;N!Y<[<@K+1KA%!<@\'3E,7T MDCM5=S(L*(/8L9^I=@]I6$8?/AY(+ MLL\A[S=_2N(66[^,X`L6"RYYJAR`C)]G[;\F,GSX)EGQA)06UH4Y8@3WG+^CZG*`)@MU1]).NP#=A M)30EQUQ]YZ?/E!TR!>6>04:86)B\/U(9@Z(`XP0S1(IY#@3@URH8M@8H0M[T M\\02E:WMR=R9+;R)#^[6GDKUQ!#2MN*C5+SX73OIC#J0H`&!9POB+'QO.5D` MQH6X21,'SS;NZL7=.A&MRR-19+,2_&1!LP%561%L73\$X%:0FD8GT=\4`FD0 M9(LH:WMA6Y"\A+*^;@)OLG)?H11QX[,;^_BF1]1Z8`6!7L<1A/H/'!$%.6)5 MD?2N-?1(#PBU'D-"(-20T`1Z\7P7M1IA$/2+H='47'!7^_B`U0DY,UVBSF5( M:CHFA:U]8R41!7H!2M$Q&)>R<;I$LW,9T@1*MVN'09I55[S:$NA>N_.'G=1^ M/9^$T5QSD\_E&J*SR:.QZ&-'MU74MQ@KP?889OX/!4(4DT)CZ5]?F):_?V[F*@0QM8#TI] MS-;CLAX+!14'&M$\EU;,CS@*?=QDG;F>TSO?@T&M(49?NA$^^`*S?1O@Z3NP M[S#@G#T(H[/^DQ`.P3'.=AIN(;GQA]TTC*;G[/,0-NL9_T48Z3$Q)'H?1O?G M_)=AM$2[VP7`G:$B!_J5B`,KI973%(3T'!SPHKYUU"^*5R`PW!RX@MN"_IO! M[9#">/(<<$XY5^T++M#=-S=_````__\#`%!+`P04``8`"````"$`GAF('CL$ M``"5#P``&0```'AL+W=OZ75:C^>*3@)*F"$G:;]]SMC8VH;;FY3W9<0QN,S MQV?&@[WZ\EI7S@OI6$F;M1MZ@>N0)J=%V1S7[C]_/]XM7(?QK"FRBC9D[;X1 MYG[9_/K+ZD*[9W8BA#N`T+"U>^*\7?H^RT^DSIA'6]+`R(%V=<;AM3OZK.U( M5HA)=>5'09#X=58VKD18=A_!H(=#F9,'FI]KTG`)TI$JX\"?GHZ=;[\>FQHESU5L.[7,,YRA2U>1O!UF7>4T0/W M`,Z71,=K3OW4!Z3-JBAA!2B[TY'#VMV&RWV8NOYF)03ZMR07IOUWV(E>?NO* MXH^R(:`VY`DS\$3I,[I^+=`$D_W1[$>1@3\[IR"'[%SQO^CE=U(>3QS2/8<5 MX<*6Q=L#83DH"C!>-$>DG%9``'Z=NL32`$6R5_&\E`4_K=U9XLWO@UD([LX3 M8?RQ1$C7R<^,T_H_Z13V4!(DZD'@V8-$WF(^CY/%/8!YTOR0HN'C&>;540/^]]=A,^IL=>>6#6@-[`$<3Y"1P1!3EB)I'T3AG>24<6 M(>5A$P*A;$(SJ+_IRE$:X22H$4.CU`RXDSXA8`U"SDV7_>!BDXK'I+"<;\PD MHD`M0"H&!N-4]D[7:`XN-DV@I&MW73-T%FR&I$E+)&KLSI)OKP:GN1LUE=Q" M`YU-&KU%=!A137O=8D2"7:$O^),[#%%,"KU%3T*8!E:U#$YV&O`KINW[ZVE` M9S-X;]'6KUN,]:=F)%Q_'*0>Z'5C:2*0R:*WF!*$E@2#DRT!;K./:R"\S?#* MI*E@F`P9<$OIT3Y9!P+&HB'[)H9^W[.IW]" MO>_)QF"8S)*P>J$HB02,-VX,;//6SE`F4XC8%J*?.)$E;&=:EGX@1-_\]$SH M_;`70C>90OR<'AF.FZ0RF3K8W]1WKU%!W-0GPW&C5"9];WRW5<)QUU`="V*& M)XM;"V+<*@4T;%M3B,0NB'&SE.=G>6:L27U)5S,GI&<_&40!?XL$L#^Z[ M,(&3>X+-8#1R#R/B"#8:6<#(8G).JNX!HSD!C`AA1R-X=Q#5.!J)8"2:C#.# MD=GD2`PC\>3('$;$Y<"*`Y>7[704F#"%!+0F_8'4%*=MO-S*RY$5>`=<)ZE" M3B93`AF93`CD8S(=D`UQ*?.'P'`I:K,C^99UQ[)A3D4.4!B!AQ>83EZKY`NG M+10@7(THA^N0^'N"ZR^!LWC@@?.!4JY>&ULK%;;CILP$'VOU']`O"^7W(.2K!)6VU9JI:KJY=D!$ZP%C&QGL_OWG3&7 M8J#1INI+",/Q\?&9L<>;^Y<\LYZID(P76]MW/-NB1<1C5IRV]H_OCW$&W]BN5]OWN_;O-A8LGF5*J+&`HY-9.E2H#UY512G,B'5[2`KXD7.1$ MP:LXN;(4E,1Z4)ZY$\];N#EAA5TQ!.(M'#Q)6$0?>'3.::$J$D$SHD"_3%DI M&[8\>@M=3L33N;R+>%X"Q9%E3+UJ4MO*H^#3J>""'#-8]XL_(U'#K5\&]#F+ M!)<\40[0N970X9K7[MH%IMTF9K`"M-T2--G:>S\(?=]V=QMMT$]&+[+SWY(I MOWP0+/[,"@IN0YXP`T?.GQ#Z*<80#'8'HQ]U!KX**Z8).6?J&[]\I.R4*DCW M'%:$"POBUP[IPYDMOZ@/< M.E*I'AE2VE9TEHKGORJ07E%+,JE)X-F0.$O?6T^7P'%EW+0>!\]F7&?RX4"W M$J^]>""*[#:"7RPH,)`G2X+EZ@=`UIA0,;2V_,T5L`-)]LBRM9>V!0N6D,KG MG;^:;MQGL#^J,8<1C(D(&P1F#>2U&L&<_Z`165`C9A)%'YK`']&3GJ`&T1<$ M1O4%3:'^QBNG\0@'08T8'LW,"0\5Q@>NULBY"0E;2%_4;"@*R_G&3"(+U`*D MHE4P3&4-NB:SA?1E@J2N=]<]0[!6TR:MBDQTC=VM>MXT'\>U&S6UN$4&@DT9 M=42?,+J:PF[$F`EV17?!>H=-P+H;$X,TIH8ZTLV"O^J72POJYP';6&?C7\\# M@LW)ZTC'@&[$,&!MSO2/1PRRF!+JB+G^1:\D6E!__;C)WFZ`1IO3-Z&.!4;( M\``W5'V;3+GA/-P*HKZO.UZHU5/\BI.-&0 M9IFT(G[&ON?C+FO#55,^^!YT94TQ^-+VZ]X7:.3["1Z[O?@!!XS%)T$XBI\& M?:S8`^+&WXXS()P-A9?!+!=1_#+(-3]H2]T%82K,?PZ"-<8=]L!<$$H MR8E^(>+$"FEE-`$C/0>[N:BN&-6+XB48#-<$KN!JH/^F&ULK%9=;ZLX$'U?:?\#XKV`R2TK3NJ"EJ-G6?V/*_[;[]9?-1\!0JZU_TKI)PU#E)U91%8B&U3!R$+*B&E[E,52-9+0PDZHRC*-H&5:4U[YE M2.5G.,3AP'/V(/)SQ6IM220KJ0;]ZL0;U;%5^6?H*BJ?S\U=+JH&*)YXR?6; M(?6]*D^_'VLAZ5,)^WXEKWG)$Q"8-IM"@X[ M0-L]R0Y;_YZD&9GYX6YC#/K)V44-_GOJ)"Z_25[\P6L&;D.>,`-/0CPC]'N! M(9@<7LU^-!GX2WH%.]!SJ?\6E]\9/YXTI'L!.\*-I<7;`U,Y.`HT0;Q`IER4 M(`!^O8IC:8`C]-4\+[S0IZT?Q\%B%8_01FC,@Z M!.8-Y/4:P9XOT(@LJ!%SB:+W7>!==.P(ZA"N(##J"P0AR]:'WX%IZ[&"O<40 M*.\>M!A#LA[BJIQ_B4ID@>*`W/0*KG/;@CZ2V4-BT^%&5+6_1@>"QCC9B;AU37]DP,EH)SLEPQWCF9DOP[L9# MAS1C#6UDF`:2)(XE/R_P]06_-X#,?!0`^"*&[%UR@ M[]9W_P$``/__`P!02P,$%``&``@````A`">=C,,Q`0``0`(``!$`"`%D;V-0 M5=$RV'AY]Z\!'#2%+)!N8=#7:Q.@8QD%NP(A0I(9-X:KU1L1T M]&OLA'P7:\`E(5?80!1*1('WP-R-1#0@E1R1[L,W/4!)#`T8L#%@6E#\W8W@ M3?CS0I^<-(V..Y=F&G1/V4H>PK&]#7HL=EU7=)->(_E3_#)_>.I'S;7=[TH" MXOO]-"+$>5KE2H.ZW?'MFV^R$#85_IU52O9V3'H0$526WF,'NV.RG-S=+V:( MEX1>Y)3D)5V4A$UN&+E\K?"Q-=SG(]`,`O\F'@&\]_[YY_P+``#__P,`4$L# M!!0`!@`(````(0#\[8$HZ@(``#P)```0``@!9&]C4')O<',O87!P+GAM;""B M!`$HH``!```````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````)Q6;4_;,!#^ M/FG_(-<6@O'CFPGM/OU.R>TI)N;";[YY;GS M/SR87ZT)&-1@KM!K%)\>#.`+%=2;4)YE4! MRB6G@\&G!-8.5`;94;ES&+<>SVOW7J>9YIZ??5AL2B2F[32.'ID%3V<4U\P(IAS2\K!VTHQE:9U)?VGS9%<`SI($ M`>UB,^QBNV,Q3,^�)'^TCOH66"&_L<%\))L+?YC!D7H'PV[')N6+2,6T+; M*E+4!KU6#O-%IZJMMM!=YKL8QEI9+47&'&3TBDFF.-!Y$RFMU#M,3OYO,W=X MFE>;I3JGU\R\U62LBW>8O)G9F.U5>Y>S*V9%0WUFP&(8C82#A'Z"\_$I%*&E M>#4QL\R@1G>NO-K:VMU!#:H">@=<+Y7PMR*(FRK$H8CQD@?WOVJ=/0LI&PW< MNA4>.D6*:BD>)="@R=A`)AR]$_:IL;J44C\W0D#I'##1J!/E3!-ZDXL7)UYY MM\%3)H#-)\-&!E0K^@TV=%[Y#H!]+HC'(A?"M3+Q7E&I#O.(#@Z%/L4F60!= ML/6!W%Q55BBP%GT5CT*]D/?.+ZUO';MBO)8%6U96<52J1\W!U-@LPWS#M48V MF/>P1:>4?;#^BH95':3==\@!]A-P3,@P_8!B:1^^&VX?KC_>TV"9^B4$6/L86I].@[?KJZ0>U/:+^AP"&%I!`JR]TS]]3!]%^K)WI<+/<%6 MOGUY]Q=)T^LR?).V^Z\+Y`8?72.]D_$*>Q-D6\R_&_Z?\-!^AM*3X?'@;(!? M@,X:2?RWHOWVI'\```#__P,`4$L!`BT`%``&``@````A`!HS&57:`0``,18` M`!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4 M``8`"````"$`M54P(_4```!,`@``"P`````````````````3!```7W)E;',O M+G)E;'-02P$"+0`4``8`"````"$`_GO?E-(!```<%0``&@`````````````` M```Y!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"``` M`"$`;]P7AV\#``#T"@``#P````````````````!+"@``>&PO=V]R:V)O;VLN M>&UL4$L!`BT`%``&``@````A`#0"T`Y/!@``>1H``!@````````````````` MYPT``'AL+W=O0(``#,&```9`````````````````&P4``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`/I'W\3&`P``[@X``!D````````` M````````'!<``'AL+W=O&PO=V]R:W-H M965T``!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`.';2S.5`@``T@8``!D`````````````````:B(``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/(%K!0W!0``9AD``!D`````````````````P"L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``N^Y5PL!0``Z14` M`!@`````````````````WCD``'AL+W=O[S>.O0(``"<(```8`````````````````$`_``!X M;"]W;W)K XML 13 R33.htm IDEA: XBRL DOCUMENT

Business Combinations and Asset Acquisitions (Details) (Northeast Scientific [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Purchase price allocation [Abstract]
Term of agreement	8 years
Amount paid for exclusive rights		$ 500,000
Acquired finite-lived intangible asset, amount	900,000
Prior Approval [Member]
Purchase price allocation [Abstract]
Amount paid for exclusive rights	500,000
After Approval [Member]
Purchase price allocation [Abstract]
Amount paid for exclusive rights	$ 400,000

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Details)	9 Months Ended
Revenue Recognition (Details)	Sep. 30, 2014
Revenue Recognition [Abstract]
Restocking charge (in hundredths)	20.00%
Thrombi Pad [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Thrombi Gel [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Thrombi Paste [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	10 years
Nicolai, GmbH [Member]
Revenue Recognition, Amortization of License Fee [Line Items]
Years to amortize license fees	5 years

XML 16 R9.htm IDEA: XBRL DOCUMENT

Net Earnings per Share

9 Months Ended

Sep. 30, 2014

Net Earnings per Share [Abstract]

Net Earnings per Share

(2)	Net Earnings per Share

Weighted average common shares outstanding for the three and nine months ended September 30, 2014 and 2013 were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
	(unaudited)				(unaudited)
Weighted average shares outstanding – basic		16,871,000		16,451,000		16,827,000		16,299,000
Weighted average shares outstanding – diluted		17,691,000		17,067,000		17,642,000		16,894,000

The entire disclosure for earnings per share.

+ References+ Details

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E-S4Q.6,W95\S-V)A7S0W,#)?8F)B-5]E.6)F M,3$T9#-F,&(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-O M;3PO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=F5N=&]R:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7U1A8FQE#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D=O;V1W:6QL7V%N9%]/=&AE#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D1E<&5N9&5N8V5?;VY?2V5Y7U-U<'!L:65R M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN8V]M95]487AE#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;V1U8W1S7V%N9%]397)V:6-E#I%>&-E;%=O#I!8W1I=F53 M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO2!2 M96=I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)UEE2!&:6QE3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)T%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S$P+5$\'0^)V9A;'-E M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%L='D@ M86YD(&-O;&QA8F]R871I;VX@'0^)SQS<&%N/CPO M'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO#H@1F]R96EG;B!C=7)R96YC>2!T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO"!B96YE9FET M(&9R;VT@'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78@6QE/3-$ M)V9O;G0M6QE/3-$ M)W9E6QE M/3-$)W9E3H@)R=4:6UEF4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[(&UA6EN9R!U;F%U9&ET960@8V]N2P@=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN M9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@2!F;W(@82!F86ER('!R97-E;G1A=&EO M;B!H879E(&)E96X@:6YC;'5D960N)B,Q-C`[(%1H92!C;VYS;VQI9&%T960@ M9FEN86YC:6%L('-T871E;65N=',@'!E8W1E9"!F;W(@=&AE(&9U;&P@ M>65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@)U1I;65S($YE=R!2;VUA M;B6QE M/3-$)V9O;G0M3H@)R=4:6UE6QE/3-$)V9O;G0M2!D:79I9&EN9R!N970@96%R;FEN9W,@8GD@=&AE('=E M:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E3H@)R=4:6UE6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M3H@)R=4:6UE6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E6QE/3-$)W9EF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E"!S;VQI9#LG M/CQD:78@3H@ M)R=4:6UE'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S M;VQI9#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E M6QE/3-$)W9E6QE/3-$ M)W9E6QE/3-$)W9E3H@)R=4:6UE6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)W9E3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-S4Q.6,W95\S-V)A7S0W,#)?8F)B M-5]E.6)F,3$T9#-F,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M93'0O:'1M;#L@8VAA M6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z M(#$P<'0[)SX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I M;F<],T0P(&-L87-S/3-$1%-01DQIF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM M97,L('-E6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M2!T;R!H;W-P:71A;',@86YD(&-L:6YI8W,N)B,Q-C`[ M(%)E=F5N=64@:7,@2!H87,@;V-C=7)R M960@;W(@2!R96-O9VYI>F5S(')E=F5N=64@87,@<')O9'5C=',@87)E('-H M:7!P960@86YD('1I=&QE('!A2!N M96=O=&EA=&5S(&-R961I="!T97)MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ M(&IUF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B'0M86QI9VXZ(&IU M2!R97-E;&P@=&AE('!R;V1U8W1S('1O(&AO&5S(&%R92!R97!OF4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[(&UA2!O9B!0 M9FEZ97(L($EN8RXL('5N9&5R('=H:6-H('1H92!#;VUP86YY(&QI8V5N&-L=7-I=F4@6QE/3-$)V9O;G0M'0M=&]P.R!L:6YE+6AE:6=H M=#H@,3LG/E1-/"]S=7`^('!R;V1U8W1S('1O($MI;F<@:6X@97AC:&%N9V4@ M9F]R(&$@;&EC96YS92!F964N)B,Q-C`[(%1H92!#;VUP86YY(&ES(&%M;W)T M:7II;F<@=&AE(&QI8V5N2!W87,@86UOFEN9R!T:&4@;&EC96YS92!F964@;VX@82!S=')A M:6=H="UL:6YE(&)A65A2!A M;6]R=&EZ960@9'5R:6YG(#(P,3,N/"]D:78^/&1I=CX\8G(@+SX\+V1I=CX\ M9&EV('-T>6QE/3-$)V9O;G0M2!H87,@6QE/3-$)V9O;G0M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E-S4Q.6,W95\S-V)A7S0W,#)?8F)B-5]E.6)F M,3$T9#-F,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E MF4Z(#$P<'0[)SX\9&EV/CQT86)L92!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P(&-L87-S/3-$1%-01DQI6QE/3-$)W9E M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[(&UAF4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M6QE/3-$)W9E#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@8V]L6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E M6QE/3-$)V9O;G0M3H@)R=4:6UE6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQOF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$ M)W9E"!S;VQI M9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B`C8V-E969F.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]E-S4Q.6,W95\S-V)A7S0W,#)?8F)B-5]E.6)F,3$T M9#-F,&(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P M<'0[)SX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<] M,T0P(&-L87-S/3-$1%-01DQIF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L M('-E6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6EN M9R!A;6]U;G0@;V8@9V]O9'=I;&P@86YD(&%C<75I#L@=VED=&@Z(#4V)3LG/B8C,38P M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=VED=&@Z(#$E M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E MF4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ M(&-E;G1E6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W9E'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE M9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE/3-$)V9O;G0M M"!S;VQI M9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG M;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'1087)T7V4W-3$Y8S=E7S,W8F%?-#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQD:78@6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)R=4:6UE6QE/3-$)W9E3H@)R=4:6UE6QE/3-$)V9O;G0M'0M:6YD M96YT.B`P<'0[)SY4:&4@0V]M<&%N>2!M86EN=&%I;G,@86QL;W=A;F-E2!O9B!O=7(@8W5S=&]M97)S('1O M(&UA:V4@2!E=F%L=6%T960@8GD@=&AE($-O;7!A;GD@9F]R(&%D M97%U86-Y(&)Y('1A:VEN9R!I;G1O(&-O;G-I9&5R871I;VX@9F%C=&]R2XF(S$V,#L@5&AE M($-O;7!A;GD@9&]E6QE M/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L(%-E3H@)U1I;65S($YE=R!2;VUA;B2X\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'0^)SQD:78@6QE/3-$ M)V9O;G0M6QE/3-$ M)W9E6QE M/3-$)W9E3H@)R=4:6UE2!S96QL'0M86QI9VXZ(&QE9G0[ M(&UA'1087)T M7V4W-3$Y8S=E7S,W8F%?-#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)W9E MF4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'0M86QI9VXZ(&QE9G0[(&UAF4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE.B!I=&%L:6,[('1E M>'0M86QI9VXZ(&QE9G0[(&UA2!O&5D('!R:6-E M('1H2!A;F0@;W1H97(@9F%C=&]R65A2!+:6YG('=I=&AO M=70@8V%U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^ M)SQD:78@6QE/3-$)V9O;G0M6QE/3-$)W9E3H@)R=4:6UE6QE/3-$)W9E3H@)R=4:6UE6QE/3-$)V9O;G0M3H@)R=4:6UE2`Q-BP@,C`Q,RP@=&AE($-O;7!A;GD@9FEL960@82!P871E;G0@:6YF28C M.#(Q-SMS('!A=&5N=',@8V]N8V5R;FEN9R!R87!I9"!E>&-H86YG92!G=6ED M92!E>'1E;G-I;VX@=&5C:&YO;&]G>2!B>2!M86YU9F%C='5R:6YG(&%N9"!S M96QL:6YG(&ET'1E;G-I;VX@ M8V%T:&5T97(N)B,Q-C`[($]N($IU;'D@,3$L(#(P,3,L($)O28C.#(Q-SMS(&UA;G5F86-T=7)E M(&%N9"!S86QE(&]F(&ET&-H M86YG92!F;W(@82!L:6-E;G-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@<&%T M96YTF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B'1R M96UI='D@9G)O;2`R,#`W('5N=&EL(&ET('=A2!W:71H M9')A=VX@9G)O;2!T:&4@;6%R:V5T(&EN($IU;'D@,C`Q-"!W:71H('1O=&%L M(%4N4RX@2`D-3,T+#`P,"`H,"XQ)2!O M9B!T:&4@0V]M<&%N>28C.#(Q-SMS('1O=&%L(%4N4RX@&%S M('5N2!$97-A;&QE($)U:2P@82!F;W)M97(@2`R."P@,C`Q-"XF(S$V,#L@56YD97(@=&AE('1E M6UE;G0@;V8@)#4R,"PP,#`L('1H92!#;VUP86YY(&UA9&4@ M;F\@861M:7-S:6]N(&]F(&9A=6QT(&]R(&QI86)I;&ET>2P@86YD('1H92!5 M+E,N($%T=&]R;F5Y)B,X,C$W.W,@3V9F:6-E(&1I2!I2!I2!T;R!A;GD@;&5G M86P@<')O8V5E9&EN9R!N;W0@9&5S8W)I8F5D(&EN('1H:7,@ XML 18 R29.htm IDEA: XBRL DOCUMENT

Concentrations of Credit and Other Risks (Details)	3 Months Ended		9 Months Ended		12 Months Ended
Concentrations of Credit and Other Risks (Details)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Concentration Risk [Line Items]
Threshold for reporting customers revenues by customer (in hundredths)	10.00%	10.00%	10.00%	10.00%
Threshold for reporting customers gross receivables by customer (in hundredths)			10.00%		10.00%
United States [Member]
Concentration Risk [Line Items]
Concentration risk, percentage (in hundredths)			83.00%	85.00%
International Markets [Member]
Concentration Risk [Line Items]
Concentration risk, percentage (in hundredths)			17.00%	15.00%

XML 19 R28.htm IDEA: XBRL DOCUMENT

Credit Risk and Allowance for Doubtful Accounts (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	$ 285,000	$ 200,000
Restocking charge (in hundredths)	20.00%
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	220,000	150,000
Allowance for Sales Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	$ 65,000	$ 50,000

XML 20 R30.htm IDEA: XBRL DOCUMENT

Dependence on Key Suppliers (Details)	9 Months Ended
Dependence on Key Suppliers (Details)	Sep. 30, 2014
Kings Pharmaceuticals [Abstract]
Initial agreement period	10 years
Contract extension period	1 year
Period of written notice to supplier	5 years

XML 21 R31.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	91 Months Ended	9 Months Ended
Commitments and Contingencies (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jul. 28, 2014 Governmental Proceedings [Member]	Jul. 31, 2014 Governmental Proceedings [Member] Vari-Lase [Member]	Sep. 30, 2014 King Agreements [Member]	Sep. 30, 2013 King Agreements [Member]	Dec. 31, 2013 King Agreements [Member]
Governmental Proceedings [Abstract]
Product revenue	$ 31,766,000	$ 27,926,000	$ 92,216,000	$ 81,197,000		$ 534,000
Total U.S. sales, percentage (in hundredths)						0.10%
Alleged damages from product defects to government						20,000,000
Terms of settlement of litigation					520,000
King Agreements [Abstract]
Unamortized license fee							457,000		610,000
Future amortization of deferred revenue per quarter							51,000
Amortization period for license fee							10 years
Amortization of license fee							$ 153,000	$ 153,000

XML 22 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2014

Basis of Presentation [Abstract]

Basis of Presentation

(1)	Basis of Presentation

Goodwill and Other Intangible Assets [Abstract]

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

XML 23 R32.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
Income Taxes (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jun. 30, 2013 Ireland Tax Authority [Member]
Income Taxes [Abstract]
Income tax expense (benefit)	$ 2,634,000	$ 1,352,000	$ 6,033,000	$ 3,750,000
Earnings before income tax	5,204,000	4,024,000	14,607,000	11,355,000
Effective income tax rate (in hundredths)			41.00%	33.00%
Federal statutory income tax rate (in hundredths)			34.00%	34.00%
Additional income tax expense	867,000
Percentage of pretax income (in hundredths)	16.70%		5.90%
Unrecognized income tax asset	1,306,000		1,306,000		1,268,000
Tax related interest expense			0
Tax related penalties expense			0
Tax Credit Carryforward [Line Items]
Research and development, tax credit		$ 300,000		$ 300,000		$ 53,000

XML 24 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 41,649,000	$ 30,785,000
Accounts receivable, net of reserves of $285,000 and $200,000 in 2014 and 2013, respectively	16,091,000	14,481,000
Inventories	15,732,000	14,002,000
Prepaid expenses and other	4,478,000	2,472,000
Current portion of deferred tax assets	6,000,000	6,000,000
Total current assets	83,950,000	67,740,000
Property, plant and equipment, net	17,616,000	16,187,000
Goodwill	10,346,000	10,532,000
Intangible assets, net	10,614,000	11,943,000
Deferred tax assets, net of current portion	594,000	1,739,000
Total assets	123,120,000	108,141,000
Current liabilities:
Accounts payable	4,847,000	3,762,000
Accrued compensation	5,074,000	4,365,000
Accrued expenses	3,683,000	2,467,000
Accrued royalties	229,000	235,000
Current portion of deferred revenue	425,000	556,000
Total current liabilities	14,258,000	11,385,000
Long-term deferred revenue, net of current portion	253,000	406,000
Long-term deferred tax liabilities	723,000	0
Total long-term liabilities	976,000	406,000
Shareholders' equity:
Common stock, $0.01 par value: Authorized shares - 40,000,000 Issued and outstanding shares - 17,176,172 - 2014; 16,964,953 - 2013	172,000	170,000
Additional paid-in capital	95,853,000	92,346,000
Accumulated other comprehensive earnings	(548,000)	(1,000)
Retained earnings	12,409,000	3,835,000
Total shareholders' equity	107,886,000	96,350,000
Total liabilities and shareholders' equity	$ 123,120,000	$ 108,141,000

XML 25 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Earnings (unaudited) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statements of Comprehensive Earnings (unaudited) [Abstract]
Foreign currency translation adjustments, tax	$ 0	$ 0	$ 0	$ 0

XML 26 R22.htm IDEA: XBRL DOCUMENT

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill and acquired intangible assets

The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2014 are as follows:

	Goodwill			Acquired Intangibles
	(unaudited)
Balance at December 31, 2013	$	10,532,000		$	11,943,000
Amortization		–			(1,234,000	)
Foreign currency translation adjustments		(186,000	)		(95,000	)
Balance at September 30, 2014	$	10,346,000		$	10,614,000

XML 27 R24.htm IDEA: XBRL DOCUMENT

Net Earnings per Share (Details)	3 Months Ended		9 Months Ended
Net Earnings per Share (Details)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Earnings per Share [Abstract]
Weighted average shares outstanding - basic (in shares)	16,871,000	16,451,000	16,827,000	16,299,000
Weighted average shares outstanding - diluted (in shares)	17,691,000	17,067,000	17,642,000	16,894,000

XML 28 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 29 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net earnings	$ 8,574,000	$ 7,605,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	2,381,000	2,109,000
Amortization	1,234,000	1,162,000
Stock-based compensation	3,030,000	2,567,000
Deferred taxes, net	1,868,000	2,275,000
Excess tax benefit from stock-based compensation	0	(1,331,000)
Change in fair value of contingent consideration	0	(79,000)
Gain on disposal of equipment	(24,000)	(22,000)
Change in accounts receivable allowance	85,000	15,000
Changes in operating assets and liabilities:
Accounts receivable	(1,708,000)	(691,000)
Inventories	(1,738,000)	(685,000)
Prepaid expenses and other	(2,038,000)	(176,000)
Accounts payable	1,099,000	127,000
Accrued expenses and compensation	1,776,000	659,000
Amortization of deferred license fees and other deferred revenue	(285,000)	101,000
Net cash provided by operating activities	14,254,000	13,636,000
Investing activities
Purchase of property and equipment	(3,829,000)	(3,486,000)
Cash paid for acquisition of license	0	(500,000)
Proceeds from the sale of equipment	28,000	22,000
Net cash used in investing activities	(3,801,000)	(3,964,000)
Financing activities
Repurchase of common shares	(2,312,000)	(1,211,000)
Excess tax benefit from stock-based compensation	1,182,000	1,331,000
Proceeds from the exercise of stock options and sale of stock, net of expenses	1,609,000	2,759,000
Net cash provided by financing activities	479,000	2,879,000
Increase in cash and cash equivalents	10,932,000	12,551,000
Effect of exchange rate changes on cash and cash equivalents	(68,000)	(3,000)
Cash and cash equivalents at beginning of period	30,785,000	11,554,000
Cash and cash equivalents at end of period	41,649,000	24,102,000
Supplemental disclosure of cash flow
Cash paid for interest	3,000	9,000
Cash paid for taxes	$ 3,844,000	$ 1,499,000

XML 30 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Reserves for accounts receivable	$ 285,000	$ 200,000
Shareholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	17,176,172	16,964,953
Common stock, shares outstanding (in shares)	17,176,172	16,964,953

XML 31 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2014

Income Taxes [Abstract]

Income Taxes

(10)	Income Taxes

Business Combinations and Asset Acquisitions [Abstract]

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

XML 32 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Oct. 17, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	VASCULAR SOLUTIONS INC
Entity Central Index Key	0001030206
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		17,176,422
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014

XML 33 R18.htm IDEA: XBRL DOCUMENT

Business Combinations and Asset Acquisitions

9 Months Ended

Sep. 30, 2014

Business Combinations and Asset Acquisitions

(11)	Business Combinations and Asset Acquisitions

Northeast Scientific

Goodwill and Other Intangible Assets [Abstract]

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

XML 34 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
Consolidated Statements of Earnings (unaudited) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenue:
Product revenue	$ 31,766,000	$ 27,926,000	$ 92,216,000	$ 81,197,000
License, royalty and collaboration revenue	163,000	83,000	297,000	230,000
Total revenue	31,929,000	28,009,000	92,513,000	81,427,000
Product costs and operating expenses:
Cost of goods sold	10,291,000	9,197,000	30,158,000	26,432,000
Collaboration expenses	93,000	32,000	125,000	41,000
Research and development	3,322,000	3,140,000	9,839,000	10,027,000
Clinical and regulatory	1,196,000	997,000	3,771,000	3,259,000
Sales and marketing	7,327,000	6,706,000	22,406,000	20,462,000
General and administrative	3,692,000	2,362,000	9,282,000	6,871,000
Litigation	0	812,000	0	812,000
Medical device excise taxes	385,000	339,000	1,083,000	995,000
Amortization of purchased technology and intangibles	410,000	404,000	1,234,000	1,162,000
Total product costs and operating expenses	26,716,000	23,989,000	77,898,000	70,061,000
Operating earnings	5,213,000	4,020,000	14,615,000	11,366,000
Other earnings (expenses):
Interest expense	0	(3,000)	0	(9,000)
Foreign exchange gain (loss)	(9,000)	7,000	(8,000)	(2,000)
Earnings before income taxes	5,204,000	4,024,000	14,607,000	11,355,000
Income tax expense	(2,634,000)	(1,352,000)	(6,033,000)	(3,750,000)
Net earnings	$ 2,570,000	$ 2,672,000	$ 8,574,000	$ 7,605,000
Net earnings per share - basic (in dollars per share)	$ 0.15	$ 0.16	$ 0.51	$ 0.47
Net earnings per share - diluted (in dollars per share)	$ 0.15	$ 0.16	$ 0.49	$ 0.45

XML 35 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Other Intangible Assets

9 Months Ended

Sep. 30, 2014

Goodwill and Other Intangible Assets

(5)	Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2014 are as follows:

	Goodwill			Acquired Intangibles
	(unaudited)
Balance at December 31, 2013	$	10,532,000		$	11,943,000
Amortization		–			(1,234,000	)
Foreign currency translation adjustments		(186,000	)		(95,000	)
Balance at September 30, 2014	$	10,346,000		$	10,614,000

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details

XML 36 R11.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2014

Inventories [Abstract]

Inventories

(4)	Inventories

	September 30, 2014		December 31, 2013
	(unaudited)

Raw materials	$	7,533,000	$	6,386,000
Work-in-process		1,548,000		926,000
Finished goods		6,651,000		6,690,000
	$	15,732,000	$	14,002,000

Revenue by product category

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

XML 37 R23.htm IDEA: XBRL DOCUMENT

Products and Services (Tables)

9 Months Ended

Sep. 30, 2014

Products and Services [Abstract]

The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:

	Three Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	21,116,000		18	%	$	17,965,000		17	%
Hemostat products		6,108,000		2	%		5,962,000		7	%
Vein products and services		4,542,000		14	%		3,999,000		11	%
Total product revenue		31,766,000		14	%		27,926,000		14	%
License		163,000		96	%		83,000		(5	%)
Total revenue	$	31,929,000		14	%	$	28,009,000		14	%

	Nine Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	60,675,000		17	%	$	52,031,000		14	%
Hemostat products		18,305,000		3	%		17,768,000		3	%
Vein products and services		13,236,000		16	%		11,398,000		14	%
Total product revenue		92,216,000		14	%		81,197,000		12	%
License, royalty and collaboration		297,000		29	%		230,000		(12	%)
Total revenue	$	92,513,000		14	%	$	81,427,000		11	%

XML 38 R19.htm IDEA: XBRL DOCUMENT

Products and Services

9 Months Ended

Sep. 30, 2014

Products and Services [Abstract]

Products and Services

(12)	Products and Services

The Company has three product categories as follows:

The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:

	Three Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	21,116,000		18	%	$	17,965,000		17	%
Hemostat products		6,108,000		2	%		5,962,000		7	%
Vein products and services		4,542,000		14	%		3,999,000		11	%
Total product revenue		31,766,000		14	%		27,926,000		14	%
License		163,000		96	%		83,000		(5	%)
Total revenue	$	31,929,000		14	%	$	28,009,000		14	%

	Nine Months Ended September 30,
	2014					2013
	Net Revenue		Percent Change			Net Revenue		Percent Change

Catheter products	$	60,675,000		17	%	$	52,031,000		14	%
Hemostat products		18,305,000		3	%		17,768,000		3	%
Vein products and services		13,236,000		16	%		11,398,000		14	%
Total product revenue		92,216,000		14	%		81,197,000		12	%
License, royalty and collaboration		297,000		29	%		230,000		(12	%)
Total revenue	$	92,513,000		14	%	$	81,427,000		11	%

Dependence on Key Suppliers [Abstract]

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

XML 39 R15.htm IDEA: XBRL DOCUMENT

Dependence on Key Suppliers

9 Months Ended

Sep. 30, 2014

Dependence on Key Suppliers

(8)	Dependence on Key Suppliers

King Pharmaceuticals

ZIP 40 0001140361-14-038645-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-14-038645-xbrl.zip M4$L#!!0````(`+F$547V:.&Y75X``.C+!``1`!P`=F%S8RTR,#$T,#DS,"YX M;6Q55`D``Q[$1E0>Q$94=7@+``$$)0X```0Y`0``[#UK<]M(CM^OZOY#KV]V M-JFR;%&2)=N99$MC)QE?,K;7=F9OZ^IJJT6VI-Y0I+:[:5OSZP]`DQ1)41+E M^"%E5#6ID4DT&D`#:`#]X$]_O1_Y[%8H+Z_H^ M(W#-E-!"W0IOKU;#WN][RF=`;*"/\:=\NS,T9GR\OW]W=[>'3_9"-=AOU.O- M?1EHPP-7[,3PO@R^+@#'USVN4_#[&?B[)D$#!T?[]#8%U;(,$-`Z^__SZ^=K M=RA&O%:D![OWI@VSU+3W[MA;LW"&_W[3MH MYC1K=:?6=))&,,X#SL=IJS[7/>HA?H%-6ODFGI#EG<"+$O#(J+D\'.W#VP0P MB$;E@)Y1^V8R%OL`(91TTP9A4*%-&-0*[=PP"HR:E#,1ORP1E1LI!08RKUW\ MMD0"`9>N+F]%K[")DV^BI5O>`%Z4@9NQF@,/;TH:B'MW6-X`WY3P<`O>(&V` M?^RYX8C@ZD?->@Q5Q3#!H!G["2WI6).-7(D^(\LZQO%ZNZ/E:.RCP="SH1+] MMSO882WI;.]>>SMLWR(BAP`C&AAQ;YCTWNZX!.?4'1.FY!%L"BT"(\TD?I8^ ME1X^[TNA&!$F94_"P[Q+IUYT$R_1=H9$(O$R3HUJS/NW8RS1(GF:Z3A[%LELH3I!F9R.$ M:-7,6'DX]9K329'';QY#'DVG`9:Q8?)HUIP&&/13R&-SC"RG'SE[>5QY=#;> M_736Q_TT4W$V-U.#QM--!INC5+G)\0DG M@UPL^L\;B'(O^EVE>#``G@/3O9?ZGS=#%8YZ\I)[OXI13Z@7$.#4V,0`Z4H? MQR\\(.-^[$M7&DLC\R3`V?)!G"X>EW*W\PX#^.,BCS_MEZ*=DK-?1L_W%5FO MIAS:B#^`>J1<;A5D-07Y*/SO7CU2'K?*45$YSJ4;^EQ^'/6&WZ]VS#"Y58]8 M*7[C?L2Q0M_U_?`.:W"Z&WA7ML2N4::D)>G;#Z$Z#:.>Z4=^UZ5JJ-YLM:DF M@)UW"?QR23R7;CU/M8*J65LU^2[4Y*F+?`]1DVON"WTE3*2"/["*S$IAZT6V MZK%>ZO&$WB-3=-R8>MFW%QUSXGS*R/_:`&94@X\B'"@^'DJ7^V1J7ZXWU9SF M\K3S+EZD/_YRO0WSB_7\K2X\JRZLUV)$=;]P!@U50-,5]W_EZJO8]`!^@8Y0 MB6`^QULGLH(3V2K."RO.6GD<7)I//4X',H#/H=8G`".#@0A<*?3/DW,.8:VX MZ$\?3TB3/H:W(%<4#/@*@7M/8]'.*68"G!>Y9K,5KKJ,8@U<**EE2O@( M)=;D=4[Z+Z'\M(]B=:_9>;(PO-/H),K?.'PTY=\J]DM.RYU:H[.R@C4.GZZ$ MOX):?8(_N@,ER'C_:-I4QOSW6&7;ZL-&Z<.3%N7S^=Y6,]9?,S8H"]RJTX:I MTUKEAJ!$;5"BL\`-1^*&WW5\?HB M$U&]_4R[7'^.M`R$UEWWWY'4DE;%:#-2J,Q0<&VNP:YH)-S-'OHYC";;DN:Q MNYUL'JHH_[RDWB[Z'X0G%/>[X[$*;^/B9.%9#!ILZ*Y94J$%[,9*MICIQRP/ MK;FR/]?IKF?2VYN[$^GMRG36[U][-K!=F)>SS%_TL-'G0H[Q$\XR,((%9?W M-SQ[6[1-O)S3ERLTKTTP5CACNU64]5&4]3H]7,VC_")&(1!JOG]%*>=TZU$J M>I2MHFP]2B6/\IN002*Z;N!="W4K7?$=Z\M"AK?^I:)_V:K-BZO-)GJ;F]!N M2$$Q7HE;$40;6D*L=+)Z'K-;+U/1RVS59>M=5O`NG\$C!UII1*'F6K*%N/4LFC;,M[+U[>VT3_LE6;%U>;3?0VVS+? MULNLX&6VZK+U+BMXEVT);ZU+>)OH@;8JM=8J];)>*@JDU:Q<3-N1*Z`15\BZ+'G'-P]V8@SO^?-WQE^O3AZ)N%E![\A:TK"@^;'&.GX#C M)IPY/U"9GJR`RS%FNCL503B2P>(.EPFWV.,LTN1MAN\J8FLM'.TQ_'SH@!S, MP9Q43\4@5)-JR/]4JW7!U#PT-_;!YP/Z&"2\\(0\3M_@"Q8K]Q5^*J[T\V]] M[FO@::9EVM,)?;T/^I':Y3[[A^"*O0\\AL:5[3>&LV`(]=X:X'(2:LDE`(O0 MI/2_7O@;A7<"N8=3"0'CL M3.M(J"Q%%AAA/R%H`FD!EU-V'EJ*%J(I4O9;Z$[#_1G"LQ#A4>#6=XG5A40D<,F0):N.7D_`.]PS(T1;*(6)98W"PQ]#YY MO9P&^DIK_/U7:IJE*(>K2,B5&$AM8'8V[)R/Q"PE4P!\OYR4W[K7)U\^=Z_8 M]<7G+S=G%^?7[.S$$M/'N/,@('P%-CX6>")>_9)E`@G!B$(`%A.4S;8F8MF MAI!P-`K!GDSH?MUEUS0-L(O(X.D?O`6IA"YJ00TL>`9ZEDCZ:"-#ATK/:)9G MGG#E"+SAVQT@V^DXG7:KT<@1O:"/6?>4]9::$*^0M M[_EBEP7"L+"??#A9X^\?&H<'NZ"8#,8._JC7Z0\9V,\PXT,,)W>QS5BX1MX* M/S6%](;JN*^KM*MS81*/-\L(?0DVJW"-HL*UZT<.D/'3?I4>UI]E>Y?U8I9; MK<-O8?F23RR_,<0\>F.X;QBK'IZV"W!K-@P?1!LDP)M#S2/LL>4_Z\AL%UVP? M-LNHF\7^!/15$5ZK/6,7R^F+1I%/X=*%&6(D%H[&2@RQ>G$KF+TOAKW"BX9> M[[)SZ\IN^'T)(PDBPI-#8[$@#D!PT8?F#Q%_[:!U6&1OE3[7C^D*8UJ;<&TBHNLUQ^#TQ%FM+]3<19=PQFDW<%``B3K:BW,K)O/-+CH3\$M]-)(>W'< M!MJ9YVEA9\_&1/'KS8N9<(KQTGHP4?Q`^N*XU*FO(P_%KY(OYJ'^,&4J)W2> M4*LHM=,H2/,;>JR2_M0/G9:SO,?YOHM>?X,7/FP>'92Q/.-]OH6."I)H=SJM M*G2<#'$E"[/6/I>*W7(_$JB_;G+S)/6N)=Z=A.I3)#2Y]^8$OY9JOUJ07EII M3K(M,XMFVO9Z%H!B@I/.W'.9;Y+$O!/GV[QK1@K/1._&RWX&+VSSZ$=/]70<#3EMB.FBVOH_WHFS>>O&7:3'SQ M=JNPA$/_K++Z,DNTT+)_AM&T%K^+HZ94Q^; M-SL_#LR;&&/RTV`0PUSA^V/N87T414]_ZS%WT[]]KF%03J\O/WR6VMQ@HYT< M49ENV&I4WDG/#+%I_<]3"HU*L`^%'`P-O&^,[]^P6P%3C@O1/??E(#AF)AQG M&GE)HS*PI*-F&VF,7RA$GA-,1:YFV"J7_EU,?2_TO3<,QSHAR1?]N.-7CO,: M.]_/#,N^\5;CBD6]@M<.!T;NXW%Z>S&E6C@AZHD/)@P@9\9$A[,3":$T6:D*;4)+JTH,<:/ M8VB-"STZWKS+>'+C-"BR&;(R\>QBU66/O3I_?_UZEW'VX;1;4[0\1EVE>"&S MA"EP)#RT$9A*J(-==C<$L-XD1R;6"AC@`VP!S(Y*]*/`(T_(:9J@0OQ!7'O' ME!4;BWO7CZ@*1%X#S`_`^B`*0/0C'XW?_-=AP^F\F<,HS-6(Y`M,>$`T?:Y) M$VH.L\!H))0K@>H\]7L6K=.NOR%JI6;C2.D($8,4&(]OG20\DM86RKI.&)A% M>M;/XX$.PI[A8+E>?EPEX@:+18$#WV,^62J^EA5?MKL;P#@=\"%'AP#_!1%R M+@,YBD84$8!*JE$RX\+<$VD!`X_Y./*%'0,-"8P@0J=H93]'N1>"!(+0@&C! M[;C@0H&]0J@#I3'E5VR'Z[UR?LL'Y@E0=TU85!AA\* M](Z4XBBVJ3M.'0-G5J$X]IKFMC%),%D$(1N$H7Q%@J+=!MTB.@JB=`X)Y@T1BDDE6,743%XTH?*2,T3!T& M*)615)$D3/,H):9ZX,@"-!M,I5'_$-.,*'#@V!B()>OH<8V&"N$`02LQ`I6F MMF`2R$_>($($@-/H135FNR9I18T>M#!;[Q2* MW96Z>D&F*A4>VZVCC6*J4:$@YQP1/V&4+;`?W@KV1<.<:T?.Q#9&W* M<_=3W)\K79@OPDB9-'U('T,<_JL,(``.#8=HG..5^&RQ<%_-O'Y=3!ZF1$$^ M+`:8/0UY&=Z$%02`3"!)"V+&,_4*'3-/2V.0'U,FH?A8XM8DURXT#"+I80'$ MV)-+('QW&(1^.(!D8@*"#Z(^Y)<1=DC&H\'_XF],+#YBV]\AU^%QIZW#QIL9 MC&Y\*TV67QBY_XY\&#HG&;I9-NT`2C):?0<9$79O$V`%7E^.=JV@DM1J$?]< M8>H%TZRDZ@>(%5M,Z4^)G!85$BGO4K]IF[)>IE(25D8PG>.HI#+Z#-F2FO9Q M*T.?%(VS+WO7>XF*AG>8,H/49V5!W8O[L;05.!!>(&:2]D2HS3H)M96W!\H: M/9O+EW2`&:,QOH@392+(YWT!4L!GM0C21FJ%7TAL;;;;%'4D``/0E)J>X:.]54X*K68J<+;PIQO MS]Y5L)VBF6(FKA>Q2\H&!M>W)PI?OM94;E&/K=4 M1E.3F#:Z'@*I[),TF;*CX,96H/I8O.J'=-20W0J8"K,&TA&C0#8'PZ:+:IDOJKO.7]>Y/YF<*$0=.0.F3V_ M^YIXQDH_SI8](2R'8$;_$E9KK8'A.3#AD=V&$4QY'O@3K%5!%$'K(7C,V12F ML6XTB""DPBD,RP:[U6.T1::HP01)>]`9H<-Y2@]+S@=2>V;XB!PAPN"S3)Q' MNC_DGI6>C7=`B\_!Y=J%N"/BOXXQP:G0&.VPGR.)*V7`[PB/N=/("$`83F8B M05P@DS!>J%'XV!:7$TG-MS=7WLJ"9>VB&['8L&W??AJ-#=+)`6CJ&W)U&)&F MT[F=*$%6NTSXH!;6'TF,)Q?P0&,L/M%AE8[QXD1F0A?U^S><]X:,O&X6) MV<^ZN&K."D_;U&*OATMKOOVK!!UJ^U?I?NUQ]RO5U,?#B483MTATY)-+QI)_ M'+Y[?,0'0B>+"%-AE9AEH\Y`VWS@)A=9K4OX0+Y'\/\2"LPL;KKTO=-_1Q"K,M*38:=3%RA1@: MC\DV&LN"UTJ]Y>-9J]%Q.+N;1I6ET1MR)NZ%&QEKC=;%VNBAE27Z2SJW+PT) M\\S0PA-/5Z-H0;I!ZTLE<`&,LH?1<#R8?0YCQD!]_61;TY2?I5*9!M8S4K&R M'2OQK\B3Z83F8VV?;#"&IOA?LYX*(UPH3Y+?W()R,(L]%Q-,!12++$\(.D3@ M6O3[.(_0`AT!E4[YB8_#5;.@1LG`2X?;E4/3#S2?0UOR$.0D"POSP&KHW]J4 MCT_/0Z#1DXTGP3BD'%+'AHPH`I@=``)"265=6[(D7,C<8OE[N-1.OVDS`,[8 M,Z3@),\I7)S85=W)#!D$XPD-(]6S-!-"+=QD[=F.%>X,B*.`,#)TZN8NC'S4 M-SQ*SWL^+F32Z:EDQAARS/3;]RORF&&%FZJ%HJ]Y9M.V)Q7?V3!DE M1\EA:L,-.)#OC,>@O=W\UJ=/Y)7*9HX9=(4DR;[VRC8II7%%:>TBB5INA@K7 MZ&N7W-M-__@($0*2/7VI#3FA3[$/*11+PD#4R$\E59.^$.7\S!%#Z60._64+ M9Y0>)?SF@C@JI\VE+EBV*2,*XCT8@#?#`$WT/[0..M,CV6TGWE1B,KOADFH: M@:013#,M7&9/:^?<:^&`A]VFU1?*[FRCRYV2C2(0`#C4,VX$27:O)/&KW03B MV?TL^,"IVVUW"3,V'YO9C57H?X9UYZ"9;H+KA:"F,?H`9@HV`GM+,CV(AR@$ MG2,36X9*DD>/5ES"[IGYQ]VWM7W\&*L%;IY089*-D@\'4,_(*(I M6\>0RQO(.,CZ[%U2K,9:-MI%[:-K9_2H'HSKUA[`?TRTM5ZC2]LDB/;;W MN,2"J#!2I=?$@(!*B M&[Z*\C^,>B/B"&XU&JZAB\WI:!^96.BW<.&QO%',K;?X] MK#5:VEG)9OI\J4?W#VF:5]4;ETM/<_F225< MXU.)>1AJNE_'@MCU8ET\I.3[=C71'D+!84*4YQHO:\7@VNV#. MPM772]/`HQD_O'I)EP6!W:BO]`4__:&$#ZQ;&48GPPCD,1%!BC%.^M_2#Y/A MM_F9MOA0&_.7-/[2CN6\*\PJ4.4IGGK&O2+A* M*QT#[R0@SXJ@6X\1*<\553WL8NWPY%QX6TW*`&[_EH$]@[4/X'W72;/J'[SE MP&$G[S8:\6`5EM]I;(P)_Q2)J6Y1;XA?[M*N["#IRO8P7CGI[R%#`H@&H9]M MBW$2^L-JT?^06H<_\W58MQ2D@!`PB(8@!\BCC5M+GN)2<@)Y*I:>76G#,87B MC*1S$`WC%Y%,C?O:[[CY3ATRO=Y\TO&@,5$GR-@0%9.P)D#E4.UH72-:21TD M=I].5M)'*X6H[5'0`&_(\^34;>)XL$__"9_?8>[J2>$JK=O+%+[.#']&P$J% MFJ;:-!N-J0JN4E$B6*+#26T$*Q'AZ8T&V;OK.P%+-!O:6:J8?_V%F:N'P/70 MKWK'WSQ-X*;]'!AS9JD,VE)2F$O1.J$M61IT>''BEI#809[BV0^M)\(&[_9` MBDD&X?,38_FCL9:-FJ;'/R=HY2+Q_>ED6AMHI:1P/)Y,MS5D=50K$P7O=D?; M0I<+VMLP8G@:XV-AW,GF%.[W%\,,P]I%[KEK&+<2)XWGS/+TM538 M1SIXK1;'4:;<<5$<=U:NS0QP2H>07K[(I4>N#,("637#X>@T"#_!YJ$0D/&+ M1Y6&SY3MWSEXQ:`6(.F@NY>D.:"&_*,&9>+69$);\KI<6R8H'!TUV#E^:9`6LL9RT2@_%,FTX;#L(-?_#S-*J2 M,W?<)]V=>='01Q3FZ1]"9?^4Y=#[@#=R,>L:?A()1O[FH*H_'OL1F+O(VD83 MDMI_[[C,7-AO*#R^*:+V=RB$LH1ZNRVN4:LL(RW=1<3X-"TWG`X."O(^55,2+?N>*[94E]6R5`N99&:*;L#U#4Z^\<698:T>4N[JY>_.=TAMUU?J*+41L MN$VQ(:R[H%+]`X,L-4MRC#*>3SVJQRNR>$6?;HT_;!1J>4YW8I/3B;OR7,KP MV@=((IZ>&2(S>SLE>\8K;U&A%Y%Z$24B)%,6WIH63;V%W=ZY:H,:4ZMXH5A1 M`,*P@AG>1P>H,65V[?B\5E)F4+R40NX`P%\0V4_ M\%X!/=3)#^65-IXP[V^/X)$W/X]8/%N-S)] M^TSA>8P>G[!#*6EK#P8)_\HC:ZC:ISLMY",QYF\O'AS?=U8OBB2H#GKA8.G[ MVRFK5G!<_C@VY05&!GR!JC#TZ$49Z"^11&O0/>NPY#U*ZL]<0-^A@%9^Z;T8 M8*EELC][V7:>7'W]MQ?\?PN3/V3R3L^C"-NE0&7X]@D5GI2GH^0IX;L>K0V% MJN_P=[]7J-]3A2IRWWREQ+Q72LQ#@Q-.^W]XI!2GQ\0/EX&=AZ,,,[$P=N M=LJ]D61134M6P6JM"]<)[!G&@1P7U*IA,#:?5T_XG`#>^%5OG6W/T>$_YH?U MT=[/R:,%_B#ISK?*]HG+A<#@1U%14+!V2:(QM9$Z&5-AN(NM MUAK)?W&>2]%+B=Y@*$5/BMYEM%YO+$5/BMXE1*\WG;93]&KPG.?TGZOPG&<\ M7Z)&WSE%O,LMY1K`*+24*Y0EOI3'ZFC:/`>F(O)?G.=2]%*BUQTUSX&1HOG>4W? MEJICT-];]"=W@DO@L+?@00X.HP;BL/=NSC8.0ZV!..R]T[.-PV!\,@YB#W8D M%F'&>X5K0DQQ*4S.N#(NC$G)]3&8-A:3LJNDA'2]$[W,YLJ[L,'1%VK,9BMO M=(_?+:8_WOT9F&`UL6+#%AHTQN=Y.`(.\-G&K[#G#OQ/XMO3;AAFZI*4F;@Y M&)>ZQ]@_%\)XX<7D->+QTJJ+*&?KY^5B&=5HO]>_XGR\FD<`0O4Y;FU7BJO; MA0$'6A;'(K->%,.]7-S&L-\_$X:BSC_>YR>Q_<(`,L.T3-&94O>5]Z)1+I9P MQ#K3F^Q'JB+*_Q6C1WJ*&U^,'PV?>OE44>@/#A&J%#C70,&RHE81!6\,PPU$ M4V!F>[D7N-^)IM!?>!_XQ*WT$\J6#+OC=,V$@[-4#'.1"C']T?!(F$&Y,\\C M40NK8E$3=GXWG=>4?I/`1U6$PL!R3LCLW%($?%085(R)?6!#OYG-DN-%H\6# MG6:UDU0X!8I64:B4E=?Z_73EA//0Z67@&7L0= M-G>_QU=.*V#8GPRS&&4GJ`K.E?3%QXU:J8B1A$D,2!%*AE-,S6?BL"8I=+'7"JIRB\> MFP>6\M&<%Z_IQX?\F#,_'PT'.TBC4TO^_7BK=?\G2Y/],!6CB4?]KXKCC.6* MCJJ#I$T'_1R^[IJC1N@+:921-J@"^GM7MSV+U^2XF?TS\'@#WA(8)49(#'": M`LVHI=*SQ^CS.F9Q1^B%#KO,E]C%96N#&=8$Q?/V-#(.G6F_PD^P@7TFLWA MG9-[_W725JS$O+7C5P]_ MRU(IA.FSG9CT\UPX(Z>51DLKVKTSM8X2)6LTGT@)L8'&BCX?X>T%MS-WS/V">)52OIV)EL^MIF)W;%BBZ7B5T\$G=0WYG&K+J)X$[9V-ZGWSM*LHS^:9K#8/UL-$?LDC!J&OSE MW.7>I&GPEUH%H\E8.PY^QYD]F9:U!:WX_;BM5G^0KA@>CG;\M$7VI]UAIHO, MSFF)7=L1F((]E\-1@+C9S93LOBR[+X?E58?7UWTYM7YXM^6M5;0'Z;86:4W? MB>F^Z@W#A7:/[4UI0^J%W5<-K,Z.VQ%]A154U#%XTJH2D6`63L]2+W%>Q;#AZIA72JEY=)2K?9&AQ>8!" M95=IKK6LT=2^&DWAF55#Y#2VP/ML[S57CJI"?3^?LD1U3+];N5]?4224QI85 M17JM6]1Z0/>5M\P0CJ9&CN:!:G177XJA@FMBZ[U7G2BZDRC%JB\DW_] MLO=24WO]AM_)KP#M?6<;*9,3SKH4L0RMO_Z:.MLY9PRW9=NN,*G-$!ECBI_( M)=7C9,RS6JX#<>D:O=C38I^-!;01+NM+;3*J7"E5S,":U5:UX?+&BJM<5Z76 MU718^;(J'6AOVDJJHJ'5H("I;_!&-!%AW3[+K]2^#P[;]XI\]1W+&P!29D[P M8+'FN;7G#625)$`C]C-:5^T/+N8ZG$TV:I7BIL(E5U<#5]=(JSY:D&L#+EW6 MKUS:[%;.;N&;EN$'55RKA%U5;H;Q@4N44=_T![H`EBC%R/!^PM8!"&O M2@Z_0Q85+6'>SZ;MN*:_^8#'[''")BI6A1=J M7HIJ,EOW@Z-YQ9MA59V3]&%OU,];MUNS5`IQ*4T#?.M='.)R!1&[_?[%(2Y7 MT'`\[!X+<<';2-&(\NZ1O'L4WCW2NM=W^2A>&GL3G=MXR2AUGPCKG>GV1C$] MQ0L>_HGE6WTG6>O3M!4[6#'8K7G*/P/7]&:FPG_M.H^FAYLMO)<4S\^\5_%V M4'F_=6<)2P";SFS?U26`"/6G2E^&^+K,P!T]8)"9FN9$T+\9J6`!!J!177R`'T=AMA9614&&FC? MT@#]_K#94E'ESAS`^X-OE2?=4V8!C*Z;MK5!>=+%O;7PVMJC;@7BX!DOE/%@-199 M\?PDEZ)4F_$/,"(#1%%ZP'VSF>?X.DTL;K/-P!X%'E8G?&`PXDED`J*7(5/_ M;&3",4S`G-=01A%=V.:_4&2^`5>$RQ[^[H'X&;R<\HR!5#AK7MH`J&/ZT=W` MN>D".?\,=!>6&GX8)EBC0JD@)2H*V.`0^+._!/6PU)$ES([Y1_4D`98>K%W> MR`N\]@5@A6L0;[>3?E&>EB;@B$3""J,6\[GB^&_=!HPV:<(+4H7U6[X9]F-B MS0-[1F[!!Y=9^$%1^GE8RG66)>"K-FIWERT"2W=!RG"YX/\1AI;Y![/,I>,@ M%76^]"(V)18772=]X&0&(Q[R@;ZL3LV@N!`&IZ)JP-#S4N6AH< M)W$8@T(A4/F`0!9`^?(5E!I`;8PD2*"^[90YO!5KF*!A04@!_A7\L8LODIK MD98Y\U.8(X$'3L$;=>HH1[DB@Y+(A/]8WW. MB>"$.4I^9N@5;RX0BO$XJ&%"TL6?H``Z425=K#3&)17LT)..LKT&-\<54YD@25_7 MIHAO)`7N!A[^71%GV>-5*12ETJVNC5F/M#PU?3;Q%(>,B=4\(@--;^ MTF6,WBOBW>QWK!):"R-*0B'0$N0.J^,C=+HE)$8/C4^>J"#>(1%!(K'92XIM M'W8O&K"&`4V"/.62$ZQG5!A)J%%RQA_1)GI@%;!LJF[[,`OI:.%;1^\%N,*( M6P2$()WI1>M(5'5.RLY*WX!\\DI,0''`%R7%Q>`#_[N(2[=P4:9SB+.+\+R& M`4E2;!="3J?&$?::[P3P7]QUX.\EL"+%H,]8G@FOWS[7^\R)WF;B1WD&T04U/XZKQ^[BN402^Q'_50::.ETF%Y MV0L+U-JC80(F:#Z'FQ2WR*EBE/%Q4 M<][2L7#SFIPLM<<&^%:,^>$&]8'AB`5ID#0H7`1@47L.)\H,`%T$YHQ6N(-^ M?0(V%2;5,2K(RR52I(TT$G]HBH@[404LCF[YW).+B0)PT5OF*MS:JV181'"2 M+">>?])TNW3'4O<2%L\&#B4P!Y+%GY$.XEMWM=\=)7;N:F\TX?\D[V?'[GCK M!NM^JQ+O[F@W*"KW9:Z6-8H2!1M'%JXM=H9.&-?]=#P M1%M*"A"$'5"2T305&?S$T.)%+W]AZ^`!-".2*-R[XO^'`3!?_64)=(C3GPQV')3QT<$6+F#S,%T6@BP#Z'#]?*M<+>^0P&YX1K3 MPQ8[S'S$W4L.O/1^^-T'._PH_N;$8^YQ=Y)%XN"4E\*L7(G#J58=8K?ZIAQ6 MXH-3NUQL2]S^^>I'J-P2ZFVE6!3$)VQ=).RF<-+V]#'*'1J'2/0:.G4IC4>' MLYD9ZN;FS*+9&#BGPG M,ID2G2I&A;>!W^H>$S4E.*V.AK( MY+AG@Z=PVC8=:#.SA/A1`7H.9H-,UFM1:'^(O^I.`9 MN&O"<#L!AK=^#E\ZF<+CX5;>\*%I*@.W"'G[DZR_4ACR8MBK^<[/#J".?]@?NHT8[UVG37H(M[$G1+)HD/]A?G(3RSHN-]T M7''H3H&73*9X$5:&]%AH-(L:0B.Y9AK&$$DCV3QE?VF_5(1PO^J5O24N732L<05% MQ^JPW]+6$E*@I4!OHS=2^S64GI:]4LYNQWYSW#_@06?M.@;SZK1DLF5%O44H MU>%@TK@5*INE7+_D37O-LPQERYQ6UH"Z9=N>=.;)6:V%;%'R'%HIC-314&M[ MCY++',TT"JS6T*^)*V#:;6$[D3JM9.F^']6=YLM.&K+6?YEMUE`=U]`'67;2 MD*OK.:XN[*)1_>IJ4">-Y-\YN>'[:CQD0GL[<\#Q/;P,1V^=G':O#0?92X0' MYZD2Y`*I]]/>CLS[`A`G;DVKRAM>+B\+=N(=\<91A!WTAFG*;H][;K`*7?GK M9R[`%@.+\H!Y@?\]@-W8LSL?A!JK+#'7X^\?13U`I-?=!6?N-%5#782XW8DV MT$Z&6E4^.;9Q4`KBEXZA\#1SWS9WX&J@*T#)0;<,=/?,75%))(_YOL7""DSX M_H+77/SU?1^3X*5@(K#=+"W3X9"NP". MF>CH-K'/1R[>N_J,I_=_IO3^N"*+5_1>$@U(P]%@(.`T5&(D>6%)7E@*+RR- MKN_"TALJ3*M\,;T_:"7=I*JTO@6_W)\'5E3Q9P_^;;W4E#Y[B!;M]AZ88:[,[*]-` M@&>BU";5=\9BM3J5]<>"B0*0=$5=07'`%DBZJX3DS`&.86UHG^`^'B$IDZW:"9"$?PNML])R7F,9:E%B!4S%,UPA6GL_%-L.I M@X4#=Q6[)!:EE,7V8L`:_M_T>MU$<4W>22-;*[/Y6H)TP@VOC#X+#+PQ"`X1 MR-X*RQ0_8-U8UM'QKN(CFW&)->=*_$.\O.G.9%PX4@=Z?HOD0,<:5Z.QA,G9 M+NG4;=W:_$M4P0V;2H`NP/N)!I6+YF`]87G\Q"5'8E>X](4,I-GGZ1:I*OH^ MK+IK>J*N/,C>D^DO"[$="UH%;KC.%6_),E+Q2*LWK@Q?@=W*'D MBMBVJ)!VVRV&5)^W-TFPMR?:H>1V."]6F/=@L.NH34%H.:A`(Y.4#C".$`KS?X M-2_'1Y_&7YY8=K(_R91C+#YS0_`MQ<%.?SK:$J@SX_N>U\,_!M_HTW/Q=S"> M%L$V9]Z&8%N*N[U)Y>A^CAKLE$8W^O12>KJ,;S^ZCGREW0A1M2T^?H.,5Y31S-88,F%<(5'%='!!,9/*!Z(&C*JR$$Q?*X7 ML,-F3H,GI-&ONF?@08%RYU@!Q<]55+*OE)>)HX+O>`R:^K>NL6JUZ-Z,$[N\ M`Q2%`V$S3@TC-_@$XS&S9$NGM6L"!&M+G):$[9UBR$Q[C@&I2&%&(4;L'N<& MHG6=[V`_S140MO-_Z;4O=-1!7]UU_M\K.IUR48%8O+4E!O$IA"]BEQ1H%Q&I M[)1SQ_%MC/7$YRW@2I7"*VQ3>["GU@=^LN&L35M8!!`%?2%Z9NG4DQ+CA%9S0`C$LGL&:B MR2D)`'SSS\`6C7JC@'!A^4.CHU.8T-S=[_3&MO%HXPO#'J`830ZY__>H2Q4V M,A+]';?B?3"SE0Q7WR$M$\DT7T5+:IAZ95+OX32/N)"&?1?Q>&XMCL5X\!X% M*R0_K&XZC<$^9X^)PR[^+>\/B\=FO.>M`'X>`*<)`V2=O1'5"3/=SPH$*L_M M$\3U?AT7U&[8CM78\,YK8LDE))*Z2FUY*H@-\M5E2P8"^\ABUTD,_$:,>Q\/ M>Q.->J]_/5NA]3/`TERBE-HD/!>B'%MO_JJ)4FH/5!%1WEA@]?"(DI_CD05W MW*VL1C&EYX,.$X7VX\W@26I!TZ:9K=V>J2H%N]3"G4['S8"Z7(^"\5AK!MBE M9+_?RW2O*@0V3S\TDNLD[ES\DB&IZ7?=''9?Z\4U1)%%43>@M0-X0[D M+D_*,(LM[K=_XOFL^!+0CNG=N]1V)N2667*<_R%UR]<#^+/E32K=HTYYD M3\W+I\PYWW"0J_LE?RI6:N)JYK07Q1TNQD@P MM2Q+YO`S`"[^"#,]\!/ZXL3>;OSZ2TR=PQ->`*62?4Y,2C0I+P. M/--FN'I4Y2?7V;Y^%GYT[XA/XB_H_;-M?@Y-5#,:I;@RS&0*G83+K8O!'G^C M*K>63D$Y8_CEJ]/]..Z# M,YO-39\G-=XMP1)U>&+ZFST]A\/!:`N%0\%(8J#W,`X-0Z,D!SGQM%F;9-$] M`H8FDZ-D#D9?JX(GA'S$#>VTV`D1N=C M5F0?>UG56WC>2Z%7CFWYJJPD>L+2K_$=DLT(L=R.O3O'/+9!YWBDC;)X[)RA M+L"+7(D?:9-Q><#?\$-&<6:^=84BO/.0`_VCB6>2L*<(;U]&=S!.3,K.(K%S MHEJ1*&?(CD#B"S.&)PB-^FU83I)<1^DER5+AMF-)(O'=!=OO8*FF<%#R\G5_N%[L/[? MQF^=I5%XOY_1^'OGJACRYP:@W,+M#;6LFC^=`B76WT0;;*V_70"\T6%G M@3?_Q7W0?5:UF'CLN&P93B0N718RESU-RWCHE2*2$;,S(J*-IZ/L>MV%R'^Q ME8/YB95S))RH#"(CK3NI#X]B##D&C^%TE'5H=N'Q*S/M&`<*H3#WT<3*%14Q M!F<,D<$"9V*Z(G@-AH-+X%6,42?@U9].B^KT>[KM'Q?%X&Y_1:RBR01.8JA" MZ&CC45'%=B9\BK'H2'QZXVP!R=WX?`2>HXOI.AO=\GF!'6J._2":I5?-,P'` M%SX_".*;Y.PEL-9&1WQ61P+K2+' M8MCK9LY1*G8LBG#D&(.L@6#5Z"$5X\A1B(S'HZ(NTGE=BR*L.<$$:_U>OZB. M/Z]O4815IR"F]:=%.78VYZ((LXXTQM->K_"NZ6S.11$>'8G/1-.F1;>SE3H7 M17AV-D/;:P+.Q?AZ/IS[V5AM!N?;M*!F\<"S1T]\]!-VY\H_&2P5S[V]YX'A-^`G[R9%J6\@\JJZ#LJ3\1#O9Y'@_%1P(5%(Y# MHS2AQ,0E*PB_Z@V3=_7Y;6,OO/!LZ*Y+U_9U7HL=>+,(N4#5$`UQ"]V,.:9S MCH7WAVW39LH*$%EZX@YT7BE$%[^#;_"0WOO^B.H&OCCDIT8F8'-\%$[>Q"4J MU+&O<,=Y2G2(KC%D8M<>#!+^%56CF*2+=U34-[/JME^9[I,'IP,R`+%AOE[A M;C.$Y\$&=GF56JHJ>G&@P@<7NO.52CTK0*'.:W!?R4LVCVR&`%]",$22^JPA MB5NS-)(7D9%1':J@Y5Q_2[E7MM3;MK ME<:6->%^+2JYZ_YVM9VSM@B\2$O?LGWVJN[7>]ZNBTGL&M&.6.NJPQH:EI[$ MU2KLA)3HJY5H39T.^NV4Z!H,6X4]6D\U;#D:O=C38I^-!;01+NM+;3*J7"E5S,":U5:U MX?+&BJM<5Z76U718^;(J'6AOVDHZQYXS2X1!`5/?X(UH(L*Z?99?J7T?'+;O M%?GJ.Y8W`$2-(BW6/+?VO(&LD@1HQ'Y&ZZK]P<5_N2=W)8_M)&%+MK3+(B_IG` M@%+WJ-JN22W?>4\1GL@'7,M+Y:O.C:DQ]VK'W%9K,Q&SL:U^M\+85I/S$_<> M'BU-GW606^Q[H==:D..5AN]D=JO(4U"YO6>W8[]YKA_P(/.&F_@>W5: M,IE>6>^!B3H<3!JW0F5B[_5+WK37/,M0]DBNLF()+=OVO#=MTUNR&57BD.FT M,NVOO*,X&FIMSZ>]S-%,H\!J#?V:N`*FW1:FOM9I)4OGJ%9WFB^S/F5>6IEM MUE`=UW!G7V9]RM7U'%<79GQ6O[H:E/69_#L_`W1?JF:4]OD;Y9K`ODT'G/4% M94UB=W@/V]=ZBA/XGJ_;A/3.K-!PC!L^Q*<`4V4^SZD#KM>8%-&Z=LI4SY*' M4`O3-JI+Z2]=QJB(9;$*E?`BY@$I3^Q,M2J;E!*:4R8TU#)GJ5*Y/0VYN$?FU"46VVMQ2*5@J%U!12*.2]$+F3D_=")(M:M=U(+-F6I;IL MA?5RXGF)>IF`G6<:9XW0MR]Q^H)9;)67+AZIDW'UF2L-(?_%>2Y%+R5Z@QJ2 MIAI"_HOS7(I>6NOUQE+TI.A=0O1ZTVD[1:\&S[G)=XI*>LXSTPK\[8,@>0.D MKJ5<>=K.6!U-F^?`R,M'ST+TNJ/F.3!2])Z%Z(T&S6O?)47O&8@>;-NF#>^E M#?V;[I;WXS9^R#/7?<%;4D$3._AXG#>:-I7V_"26_L63CE\TRLO4\6 M#0C.M!SB:#?80S3"3PQA>P-7W#3VF_(":TVN/SYWTG)MHI, M2ZQ&FLZ6EECNA+D5>275)AN=.:]$LEZF%#U'O7-M^6R?F)_C75T"$N&=5[H2 M9,9E^R3T5FP2&B*F;VBOTB9]+;6EU)926SX3"97:L@'>;TN>"YI)&DD M:=2>D&)"^;7LZL$;W5\R,%WAN85L,-#P6DJ-2Y[L::JF-:_LKLS;O7SN0>5Y MNY/FBEP%Z'XK=;/4S67SPJ:CH=3-397H:];-X^:*7,VZN88=1H.O:/P76SF> MK_N7V&'(7-!:;WF2ES+-P)2D&ME[1`<=GF10TI>_9+7 M+'_]DBJTCF2_EAT3_,I,.W+@Z8J*)^Z+G-44R<9#OE-2]-G';RZ!5#PY;&M.[LGM^%J_,Y%FHOGL%CZZK2&XCQ7 MQ,&&@M4:^C5N!6A:FT6_7;NW3&RBA0?E7,F1X_:)7\?7M-L4,I22W6I)[8W7:DTI4BIY4HNT]>"D2%FKAVZRQ)@$:$E?J:.NU=+&WB;+)1JQ0W%:[V4+!QRZ".3+NC;'F[#JND,9+& MZ)3C-;P5*HV1-$;2&%5MC`9M,T8[F_"$KZ=E)K\EBFQ](EN?%"YH;-JR\TGN MP?BYA4FVOY"=3R3K9>>3UNJ=:ZN4+FOYRUK^S99066>VNUK4CY]P<&3O M$UE;XGQ&KJ_V^M47FKPB%C84K-;0KWE+0%;EDE6YY+HYH@N$VI]6OS^Z(A8V M%*S6T*]Y2T#VS3K[EBT3D&CA.8ML>/*L@C73GMK39*U^*7K-*^#QC`*%4I); M+C5KT1[S16Y=KKN5W;@(AJ>J(KK;'3+W]"9"Y52@BVK[IN. M+:-G,G10M@1A#=;NBOC74+!:0[\&RK\,G4ECT7Q`F[%8^EUI+*2Q>+;R__+0 M'NUZK85L@7+<\8ML@=*PN(.L.C_MJ4/M8JW,VEDSO:EPM8>"C5L&L@6*-$:7 M9H4T1A--'?0N%H)LIRIM*ESMH6#CEH&F26.T;U^9;H&2>E_\_=>_!%YGH>OK M[^^,)9L%%OL\?V?[IK_YS9RQ#_;<<5=T2":*QKYWG=6[KSYS;=UZ$WA`(>9Z MKS>WXD+3C3V[$]>9[H%DKRW'^./'?_\W1?GK?W0Z=VRQPOJB7]C:`8;8"^6M MZ1F6XP4N4_Z![ROTP?]V.OR;"#3^8?1=_%DTB6(`%>$?7]C\;R\,[(C0U;J: M[]!?TW[WQ8]Y;(BH?J@72Y9I2<9&\D9=8P[UAC$LW?/^]N+MW>W[CZ;GW^-' M+PK*QB$H0YGLIOO"[+M>]^+P:DG5S1@A5"D54$D0X4"96%J"86QI7XRE&%9Z MX#L15O'8%T/J-GD]\.[P]S1W+:1OF6K>LC>+,4;KI>T\)/#933%M9F;:YHL>F_:A[ MYB-35FR&F.,6:B M`4<4`F.IT!)CRD\!V/>/ILU*"Y;((@(.0)G.*YCZR[FZNC@8O"<'7P` MFM'VG=T0>T@[YIX':@6^<74#B9?#*2(W.C&Z$0`&JXUCZ"XPQ(*'<]VESU[% M_KEROP0V"74&"%F>`R\:5C`#?D;WP@@%S#7FKDPFVXS M)_!"(@(YD32"XSXZ4_`3O(F^6YY`Q8(4B\3*-%P'M+-/D`"G_C!][]61=D8J M6JEHSZMH\XN?%5>T#Y;CS$">8$]'RTB,DE:);SMW,$5=RN4M:(&E0$M5="0T MJ7GP?YS5@VEW'G14!K`^N`K089]IS_0%BY0H;GEXF@I][XR[[9J&XX$7!D3QN`+6P:NE[V&-HN+@Q(F^?\,C6.]O M[NY)[SESE_T9,-O8T"`*+"P]Y7J>M+[WM3VN*_4CO>?G>WFD#`'OP2`^$L=? MJA&-P(DUG9D':@^W0#Z;J8K-HDNYRL,F&R=`8^/`D&0QQ0C4T\B@9D+*'"P= M_QW&,,EZT13'1!1DEVC9);IH+ZM["FK)-M%M:M=ZA;V"99OH9\MZV2:Z+7KG MVMI*RL:GLO%ILR54-CYMKZF^-EF4VE)JRV9+J-26#?!N&Q:.:7?K6DDC22-) MH_:$%-M;C$BVB9:M2$\L)J&I6@/KE-U?D:M;-LDVT;!/]+$H?CU2M*SN<2LFK7_)DS6TIR%B6P2S<&13:)E^=VSK;V!.AQ4;^.NB(,-!:LU M]&O<"I"-/J6Y:`.@C5@L?74ZG4IS(2)BUPW35LW$VDV MI-EXON+_"I7&2!HC:8RJ-D:#MAFCG5UCBG2*B8@G6Y_(UB=% M"QICKS?9^:1-'0BNL/V%['SR;%DO.Y^T1>]<6Z5T6[&(&DD:21IU)Z08GNOU=07?\Y2++4S:7K*/?4;E^3NKFI$GW-NKE9%_I;7(M+=CXY M>LW+(A[U9O9-U'ZW>5L!63_F^D6OVFR2-F622D%NM2!K8W4\DNVCI.A)'=J( M;'S9^X2#(WN?R-H2YS-R?;77K[[0Y!6QL*%@M89^S5L"LBJ7K,HEU\T172#4 M_K3Z_=$5L;"A8+6&?LU;`K)OUMFW;)F`1`O/663#DV<5K)GVU)XF:_5+T6M> M`8]G%"B4DMQJ29YHJC8=2R4J1:]^)=IKKLBUTW6_L@,7T?!$55QGHUO^ALY< MJ)02;%EUWW1L&3V3H8.R)0AKL'97Q+^&@M4:^C50_F7H3!J+Y@/:C,72[TIC M(8W%LY7_EX?V:-=K+60+E...7V0+E(;%'635^6E/'6H7:V76SIKI386K/11L MW#*0+5"D,;HT*Z0QFFCJH'>Q$&0[56E3X6H/!1NW##1-&J-]^\IT"Y34^^+O MO_XE\#H+75]_?\<6*]B-?6%K!ZAE+]Z:GF$Y7N"R>T#^M>48?_SX[_^F*'_] MCT[G3K<8O[P$>[L_&+[>Z?"G\7"6!3_?V+.?PU?>?5WC29QB`,(PY!',GJ0K6X:&?A^\5VF>$L;+`R,_CP M-;/9W/2]#S:($(,?;L,!SJ(T$@B4G3@7/1-K0#//+XT=_^RS'4U7(X*[YXYP M3'X+2.)[B@]XZY['MD1LQT1'+8M^1J?O&+M:0`LL"*TWFI0"]`9<-51!NI4$ MK!6#F8^HI53%WF;*]FP>6,1PJ->ZA3\=(TN]R?`` M6CD370*7`N+6ZW8KQR4:BEY["QLI?QY8RDWX_C]^IE9Q_WM&!OZ^_]O[S9K= M?#6]WZ.G[QTW!"R$BT-UR%>\-O*1S-1%/FU8-_FXG_Z%^8%K-T;R""@!4Q&R MC:K7/_51[6B!*TNUDV3M-VK7`:Z`_LA)SV'YYG(4(LQW[M/W\:\-YW6AOG,M`)\J3SN;_F76U"< MN-;'HVDAB=\U??/P+[?BQ]U1(;EO#_[EUOUX-.A=%_XE5_]D.C@+_J(O'/@Z MM.=&_T!5_H?IKH>1,-B6NCYLQ!5QH49YSYC7N5^ZSNK!5&[UV99O]*A[QO=B MT,28-.*]$XXGAL/1#@G"[^@+?9[?N"[NE/&T@APC`0.`(%RA'V^U[O_\]2^E MYS\3)3R?79X6`$03J/$3LRY-"P#ADI3X9!J.I9NJ\M/JX;\N1@L!!<"PC(@Q M/(D6HEL@ZDEGKJQ=AJ$W'H5+(1>_]WE^2V_Q$&DYK3](:KW^BQ^[K[K#J0!_ MUPQ5@KK'0=D&51N-BX(J0H^WNCE38)^GO/MJ6(%G/H+,H5+W.N_9#+2ZI=RL MUZ[S"'_`D*8S4S[;":7S"=BV9*`#E#O#A/G,.?B8N:+'Y\/I8+9H,C[7CDW^ M:WC%9IYW8_P9F!Z)"Q>Q<-)X3C[C[QS$SW,!>P@Z?97Y3;QJL\*[VJX@[3Y, M3B?O_9-S/>0%9(J0=W!^\E9$N?YQE#NW=-TS=X4:1E^XC%1O"7SQ6U#;X9<' MU7QY9'^\G80*/S-9A`!W%;F2Y/6/#-UG"\O_BQ[Z`:^>P6Q9X':MT@\Y-.EL=^/;:VE@1\V.70RI^AUD-)Q4`Y\;B M4O:@1_9@DC:\66#JQS:SXSPOMN.3L=WJ?5(';\-)RV';[34-VV*\/1+;TWF[ MNR!V'4S&V4.4;^S9G9BZH&0/&HM],::?AKUV,O:YM?;J8#M-+#`7(]?&\@J0 M+L;M2R(=;HEW%F&ID_L"F"\<%A#\-TE(2I%F.FH+:8K)R-E(T\$=^LFT.8,, MU"#<9V!'#5">W4$N$G>ZF,MX=@=9J\Y!/IVW9W>0B_#V2)>QWS1LB_'V8MA6 MYR`78?)I+N+IUK$Z![D(TR^]/:C$02YT=G)M#G(1;A^/].F;_MH37:`'M/*3=-VN$[OL`GC-%YR>Y?+DX!0CE9.@82#'/TQKQA$5/LA6_HA6UHO6SHB65XBJGI!-Y<-9EFBD`7: M1?HWUKF(_FWI'I#T[=WM^X^FY]_C1R\*5J@X!&58&:/;_3:&T'?W-?E]<;AF M!_4"#LL:CA"J5"&22DH9TOM/E$V+14.LO"J@O,)E?U^AQV)(Z8'O1$C%0U\, MIYR%>'HF8F.$.^M<$TT*7CK4T?5!;?J%JF;1K>J[A2CQ)2UB07*KYG M33?2W!G=%'LR_:4"GC`F;\&P$2M*36=7UI#+;UV3?"?UU1[@Y+4828^SLW= M&V74'7:T;N=N.E45)"P2[[Q"1(-]KR"JIK%?9O!]?*YBR1UC"6C_&9B86N\O M=1]&"UQQH<9P@06NJ2L/3%DQ'_X'+!.+]O>&;N.3F&K?*R_-[W##Z04ZY9FQ M1W/&D("8A@44C7?O"H,MA>_]`%_`)\A<(*!!7)B;7X%P8`)G&+Q?F;9.Y8[@ M17@3(PW`6_W!M+#.`S%-]QQ\9X,WXD'_PQI"5K\T'[^+PE8S9@$\[D99(G,, M(Z#=%LP1RO*ICK-_L9)!0'[]<@7#HP2L7=;1 M*:>1XZPJ)O!;_*`F,*8Y@X=_`@>1%+K2ZWZKN/'VWJ#=\JNZU-`_`3!SOMFI MB3+UO!H`$>A&T$"$H>MBV(+O,[/81T)%$]_.(,E2/55'.`-UP7`'0_4`:Q0 M"R4=1Q&K,Q[DH$I-RBHN.#T.9)`F93K,!"H!H4&]`971WSYX$2NZ?V! M7UFXV\7UA+`@;(DA%!)>%&M2,O!V%OC,!Z]2P#Z1AO*%)DP;&!#=.:`!_^6L M@.1V,-<-6`8HMAB^H7=\&MX']N+4$1@YTQXT0%N())%($6WNX+5AA`,GH3#` MVB>*<3NEAPHX^1F??]+3QC\`DH$+*\^#M[#H7&;5BQO)1`#!&;Y#@64+>P&? MHE9<'_!0L+>;$LFAXSI5@4>50L0!4.MP>4BV2G*R<=O)=58/GHUH0FE"(S656SUEVR1B3EB?=0WSC1\Z2[ MA/M*#\T$?+(!YX)Q@8EE.?0]N$^1&!B=*I^MA,76%;HX!\1W;(9%%@,6+K?0 M["1\C+ENNN(E\D@V`$=VV,BKL4QR*D(O)/8K<#0.><\T+Z1G%I0R(`AF'OT/)$K+KI`,XP!X`BHH=-K]FV2 M`:3(9HYB.WY$92S`%'IV*#L&WLM"9Y6$`ND(XK!"3\^!M]T"DPK:)O`LL+UF8HP&U<_@KYH&1FR41N M+WK.#CH)N`6_:*4;+*#]*DS\P39>*2_QV7YHSM\JW0I><'*J'U3WPDM@-@\76$I(-0B7T`N.5NZ!BA M+PX"H'65#=@,!1:E[:Q@[V>9>3D4 MP,@S80GJB:0Q/^-86GI@&TN^D^.Z:NL3DVN5%6R3#"I,-@.SX&ZREE&4+E,S M4X`/!?O11]8AXNQ8HND[I3#A]D)[TO>QJ@"GDD#$1(T`27/&])(@PM3S@,(6 MXO[H3)EQOQ7#O*W1G7>^SN/A0.#_!O<;%1T@T$NS[($MP'[#JN(FV(^C%62, M/%Z/%*@-;J;K@%_KD:#Q*`"MO#<\BOS^YNZ^+O7CZC/3F;NT[S(V>,N+\A:] M8NY;9S!,TR`1H/"79AREH'-"E7]+TL/O!Z[Q?J#PF0`BL+[\TAG?3>10R65S MBVL-W2-_']]>.,[,PZ9'L]9(U)YU3T0SV9,PC;3O\FW7*I^UDG MU37@Y'IOVD!.4X\*Z2&F=[BKT5U`[K4#_Z.\!'WT&K8=GA<`?Q:!R5E@N(R; MRMQ/WS@SO''*TTQ>AAO.7O<'8%KT+^V'[Y0[6,[XSJ@[`JF.WTLY\I@/XNI& M&,2)CO=>)8;*.`@VT,L38S^9%G:26EO@QR8F'.9.F`Q9QZ/S``.B#+Q8)9`C M/^H1]@1.X`E'(`K-QH3Q(L*@GO?6#(E.]A#PLCW=$-MI>Q:Z"2;;\GF2*)FT M'<)P,2E0<'M@X%7ZY"(/D,19`9$2/HQW`X+%'U*1NEA&HN/5F,])$&^!!FZH MS4,Q42,@W,0Y*Y!O3AO/!^8_8>`[#?<:>8WJGNL4QR.O8Q7PT!TW#EX48GMR M7&LK8AZ)*>Q9G"RUF+VD9[/HX-:+:@[S$)>^`-6S$!$F$2,C"A-5LI,%ZQF] M&DT*\[$Y!N909Y)/;8/78"5.UM=T_]Y#I\&T;?P%-2:\.,>K"F^903E.B@8R M"LMUI`K1P)WS*OH8.4A.)E)(3"&>[?*7:2F0BB;:H4BE+0RI[!S)#>-J"8#G MX!IZZ-F2`B\1_V0C@/7.Y3^\&,!QO` M;%C1D@OAQ#3\,`+"(XC$7N[&,[&U7'.'(6UW0.ZI2R+Q;1Z)>#2@MZ74XT8) MQ=,`HF2#4($!.""&2&S!J%1J0?C6N_`E47/B8#+!K19>Z-\Q1`3(!X05$(V= M]!PXQ$M1QEUQ,**J.OE#)`NQX(C`QR?7]`%4E`U<\1BS$XY@MB(+E;;XC;_^ MB=Z^=^Y"I_$P;%&1FP-#13`6SC9.`5HH+?BTBM+:J!\G-Q::[R(XE6J/,6D% M2N5::$S';<"I7">(?O=8G-ZR-1I@.A&RE;^SC1*N.&]WLE7\T6<;/HF^D(E6 MSSW1:G)]B59[5LBU)EPE';_P*-B#M>/2`>`?;$.];AR;(K0\C`8+RF(=SX&W MXZ!1RM^]P8-!F)OV:%1!20R!QTFP_P4WFSQI-UB+WCB!-0M3D5)A!/!&_@2G MVIQO^.:+)B7WDR;>\&R31]VT>-%PKJ=Q-'%"B(?4+OE;,Y!$T.A\6Q!ZH7GG ML;$S"JJ-AXC"(]C`XDD5CMV)S_WHS"&[)=R/[LQA?$L9Y@O@T"O3-E?!*LXK2=(^.7X&@PCBY$;4 MQZ0D8XDZ`#;#OC@Z%SCIZ3.A%2D68I-/)S>82<@3"_&38+%T`C^B,,>(D-L-X+=KQ*7R/M.*'`F>`0"4H>@\ZCDPI!@9,?!TGA\51?M<7$AQVIW(JB2E)K((UGBVPL+# MN5#U&Z9K!"N/,HA@"![/!9:)G(ST,,1+9!>2V-`#BH9L>`H0#ZCP![&"8+\!;9L;V$3@J&&F1M;4&=EK2G`_YW'"46Z M%<^$@\'?,CJ!V=8%VT>.%',KK(U4DCOV=6VZ/!4#5:901FY*1+A1I531I#`Q M!7-`]H=K#FXD8-/QU[]\?7`M^./_`U!+`P04````"`"YA%5%0"<#F2D-``"O MJ@``%0`<`'9A`L` M`00E#@``!#D!``#E7=USX[@-?^],_PYO&P1P8)S0Y M/SH]/CD*((GHB"0OYT<9[X4\(N3HM[__^4^?_]+K?8$$6)C"*'A>!->$1S'E M&8/@D<99*B3P8#!\N+V[OPG.CD^./QR?!%=TMF#D99(&IQ\__A+T@@\GIS\' M3Q,ZY30)AI"EHNW@(HH@SOAQ;#TFR8]/\L=SR"$0 M6B?\TQLGYT>3-)U]ZO=?7U^/7\^.*7OI?S@Y.>W_Z^O]8S2!:=@C"4_#)(*C M0-!_XOF']S0*T]SD#?:W9Q87`L[ZJ[:,%/*_7D'6DQ_U3C_TSDZ/W_CH2*DH M'R,:*+?BG@LW M'T=TVI5A9!SR MYSR6B#G@)0QG?6EU'^*4%Y_D_=`[.54![R?U\>\7G`L]"LEQ^`SQ^5'YPY2D MTK+BPWY7JE[#&!B#T5/XMM3E&Z3?:!)EXL,DK9B`(U:FN8C+)F^`XH*5K0]9 M5(@6?Y8040_YBJ+/L^DTE]832)@6_&-&IS5/T(:&;:CZ*5B2!RD-7#(H&P%3 M^<4KR`E>_=.9[P>,SH"EBX$8/.E%,KKY3T9F,MX(S2N>QY"J[K&3^N3U!D89 M?&Z7H#S^LS\>7VI^I1WE,'6E'[K[U#^*:";FPR%$0.;A,A,-I8:X<(4J("RR_^ M@&7`8!:2T9MRS4-J7:%Q;^8D8?)"1`ZUFDYOWJ(X MD_O(7R@=O9(XKL$5S[*",8;%)U^W,-(``9PD_P*6P?L&X_WT8C-/U;SA"D=[ M],8]"9])3%("7.0VCRF-?DQH++3D,L=)%Q4O8%>[RPUX_86 M3EMU`P9;31OP;YH?RB/>!$;%4=V&2=+8/]2LPV#]'NT9H+Z\K&)J:BL`%0J1_A]4"S"Q#0,-)MPX*)CI?H8`U#1<:3*+\F]B4LD.Z M"&.GXTU49;?7J3QWNL,LO,OK@OQ;^U?2+GM-BIY(G]IZ[VV440AGF^0@%S.^ M)OJM0Y\QPS^,R6^CNFA#84QEL96\7K-E(#\,=#0TN_5JT"S?OU"*@0NFLWP& MAD;I'6P*K!EP.P&>QE1[YVPY5/1]Y!P?)X:N^MRO]M2]^/]]7W:QOQ;4U;#] M!NGZF*8R7+7/E*,JSSHLWY%*"""H`KA+2&!<.[)Q4*V*=`Q4W8TOO0LHUJ+2 M<"K)6A;F&&3H`DVOZS*M0O-;T3%B7*4DR<00>IC)UWKE"[R7,*8,5C8!_TH2 MRL2,>I>DP(#+%SW*4I83[E=()W0DJ_%XF@]/+7;VVG()CWMJN3//W@H+R$NR M3(JCQ1,+$QY&TKPO(4FDWDLKZX?\+3A5SS;B[&[T=P$]NDV_EN+-'K67T:R1 MUOZ=M:E>25Z,T[&%0G6_EJ+#`W.>RC6.FEVJYI@>KP[,JX^[<\VRLB6'HU)G MU=-5'R%("V=92;L+.D:_T$;FE4)!5:8.R0DD/ M`R==*9O3TOGI?JQAR`Q/*\B_%?7%E+*4_#OZC3Z&K4K'Z\RI&*CULH M7+^I4'[R^SV)9/ M3,A=LWIH=D>'?N[3I2X/][3:^5=`7IBF7U\:GJZOB"D__<-!T-X_7<*OIIDN M;G2=JCIJA;JH8,'4'^U)+T>D[[HBT''?>8VC!Z%V0.Y MXR4>I"DCSUDJMS^?Z"#4%+IWTG:YKF1?;7L/^"Y]T61`[5E/Q_*]\_FP_CTF M?EUA/`!&9(H1,0@Y7,/R=W52;,%JO=#8Q-KEM"E5'#`Z)\+CEXOO'(1^MR0) MDTB>%@NDSO/7,^IS:D/&]82+9NSR.QHB@-%R7S<"+FLD5'F]S%(?)V(4RF]/ M&LD!+T9[/HXJ/;25C/6W.K21T>DBIBDLZ&ZZJKI60:JAOD^B3?/^[5\4ADBM M[SC/Y+?S/#"Y8_@PUMX]B6>H`-+&<*CH0W?"#J!F:\N_G?E!N,CG=9'+#&&6 ML6@B1D.^Z#5<^HEG*'"%8#@X7#7MA&UPA6C+QTVO5AD6W2+]**?T#5I7BV9T MJ_[-#@;ME]ML+7(]"Z,]U],R=A[L!#L,HW=!S^9U MND6G8(*?INW-X(=I$QL$.\K:EID`&H'-.35YG)/SX##8NENV`6&31OU[/:HV MABXS3A*Q%@+^A=6WU+'DIHA7(S\XC#7K@%U&MUI+/A;>[3BQ<^<:[Y'8:5OU M[ZC$H/VJZ*)I8F=AM"=V6L8.+\.:,8B(;F].]VAUR=7F(^_"DLTWU&H8)@1I MI"\O[-F4ZM_^1'5(WR7EKU6K%?+@R-?W>#C(#PTE#3M@"^2X6RK0Y%.Y=+[C M>^G8W[<3%=6H!J)#0PS*V"UP8I+OWRY*'=&5Z[.=P<9`;XPV-?I#`T_3+MAI MO*DU500YQ&&ZLBO7$7IC$L&>F-;0II(VFE?O@,=.=@<4VX]58#A]T>\2VJUV9KNO?&.5W/%Z\L/R37A,\K)R:9L_I.(L+Z-!X5M@Q]Z*?Q=8U4.F/%%(1&N8Q$E#:YS.2K2'!IXFIN]T`BLU4R1' M)QZ%'F,Y:FVKS'W8LQ-9Z^ORMI%U:`#=9==M`>`MU=!=\M8QO@_^K;UV>$*_ MQ-<,'_IW^CRZOK6H7!!0?29);N/RM>$7$8;EJT3"2*8]M7IHX._&'5L,J[TI[-_5NL4F)>YK6I#4 ME6\3\_-K6UK57C0Q?ZMR#$=#'GY?^X[KP1KF63NJ![.E55V_B;NQEKF&-"0Q M[^R-VT*51?T"+]VCU:)V\U&':W:EQJV\_7P"H^*2+7EQ*@APASL<"$*7V,'S]&J8BAH0Q#A].ABH\+`P>HP-K M)@X<%FD^%B(JK?])V0]9ZT;EBAT%#C='%1TV#H_A@384AP^;N+:71JD'\H=\ M[UM\\C]02P,$%`````@`N8151=Y57+[.#P``%M4``!4`'`!V87-C+3(P,30P M.3,P7V1E9BYX;6Q55`D``Q[$1E0>Q$94=7@+``$$)0X```0Y`0``[5U;<^.V M%7[O3/^#JC[+LM;9MKL3-^-[/7'6KN5-VZ<=BH(D3"A"!4C;ZJ\O0)$2*>). MP*2B-490F5`/I/3S>7]_>7?5. MCHZ//AP=]R[0:HWA?)'T1I\^?>P->A^.1S_TGA9H25#<>P1I0FWWSL(01"DY MZIU%42\3)ST,",#/8'HT&##K$8Q_^\S^,PD(Z%&O8_+YE<#3_B))5I^'PY>7 MEZ.7DR.$Y\,/Q\>CX;]_N1N'"[`,!C`F21"'H-^C\I])]O`.A4&2A5PJ_CK! M4:'@9+BU)91@?PT*L0%[-!A]&)R,CE[)M)^[R'[6,%*(O];D\YAH[7T:9K]N M1:DB*%%="CN33T9;X;+@Q^RO:=*GE=SK;:H9HP@\@EF/_?_KX^VVW#-EPU&( MED/VP_`!HVD:)N0LGHXI4C`$Y!(D`8P(-9GI2=8K<-HG<+F*0/%L@<'LM,\T M#1@5CC^='+/Z^K-,V]#8M_.4P!@0IKM_`]T\:T,,I'$7IA7(:S[G9SXG9@UG9`VG8H[G8(XG7RYG72ZG6Y[F69XF M6%YG5EZG5#Y&#A]C1L/1HN$XX6:^Y&:BY&BT@V"(CAEV:XQ50.R?I(V\X`LKFG#(5_C(*6-"4PM.P]M[0Y]1\L5!@L0 M$_@,"LBVEAXH;C%M9`D,@\AI4"9FWRK:MPO094Q>PW#N^7D0L?%EO`"TJ_;# M,RT3/J+PX[C5O`N%*4.0CI%7=`J7K&_C&<)+ZPY4KJ_L7X##PL7\GV4OMUEF M&"?#*5P.-PKMJ%OYFJP1(L)P"[=+:JUX&G"^H4#M,)&&PKPJ&_7.UEKRE) MX&96=T?_K!@&KPE;&&V['^:N5;_@WIYI[_965B6#@7L7#,93O\9-YB1M>M(: M.JJIMAOKRM6(&S/*)9@;,ZIEIQLKPA6V&_5F.05')+1+O#AK`6:9*D?CCU8. MSU6(FJE,5PP5Y'$==1I6&6PWMI4)?F\=%F]OPWF'XL^(S?:6-\C\&=/=!_4U MX!3&,E.%L0B%%0L1.]Z%<'5^7E_ILB??ZB;.E@@G\']9N[N?W='ZC`FX!H`& M`F[I_&&;-HZ""8A.^PTTT&DYB]U*P]!C%?P'!)@\H=P+L+.OCEU=5!BTK&@U MVAV[SG`U;KJ$*^SDJSG+A>D,HV4S;%&CZMF%^+EGX44O09QB,NL(3P'.SX#Z MY);(]4VG9=VVJL6-&U91W"?/2HDO3^PRJAPO#%-YD+/L`V-9,OK,3A"#Z6D_ MP2G8/*!S-SI`7$79.NVT3\"<_<.*DF4\9@&99*"D9#`/@M60474(HH043S+R M#HY'^0G>/^>/OSU1`_>S,XSI<)XY=?8*][M!J4Q>W0(9GX23Y+%,";C'(*07 MLQW%-K88OP0V&G95;GA1\HI-O;Z@.-@]>:+_(D&83=-_J8PK.6,L2^?U:ES: MZ_`IR$-O*":G"6I:$V6&<4TQ&AF;^/T1[-N'`Z%8=7/&#\=JE> 31T M-^=Z6F"6.7@(IEQFB'XNQJG:SRW-O6T[!J0,L0RGH95L5*II]S-WSNW<@$B& M8^WG*HZEGP\61U&(;G`L:??<'DD"Y"VR)K#?)DL"!XNF.$Q7[;*D/T?TQ"VB M7V"(H@#>+"<++J#"W_-`.;\?'IRJ(!NBR5&?@_G##LP?AYQLH\\$LL=DI]6- MH3?>G[)/O[J9$_\:1&FV7J1^_C,-(CA;PWB^]6Y[)5F4J[4NGW/:HGQKZX>= MKP6@K.D];NY5D_RPA+!^-,K4ZD1:IJ4.SAYQ9%<=Y6[/V#CK^#2-=F*-JAL@ M+[=K5=:P';:1U77$./-*<<@\+>.'E\N5-RVVLND6>LY>5+*D6R:I%M"AV63FXVT;FUY`D2EIQ*X%/*IE! M-9L*0^^92[449Z?8Q$OR^J&3--7KEE`.$KZ.-A8D"SS^7H)V@6+S0*-`Z^L! MC3X&6<2N3Z"-L6SK0,-()WJCLJ/C(`+D$20I%FU!:0ES*,,3/D"Z*&-N2A6> M@7H/\S8Y,H,7#K5%WHJ+S"-1ED@MF`,H$W2Z?P#(`D53"ODC6+%#$_'$B4) M6@),\G,5Y'Q=/*KO+E@5W^T]&!9OJ:EJH(8:UT:YR8H-YKL1AH:\[2)*_+C! MB%!G0@"?LS/#EBQ2J]%BDTS-`;-*NW9AX@QZL<+W`7TM@]<^^+ST93/TI6E*._P=IR,) M"(_FZ'F8):WPFA'@I/B#87]2PCY__.WK>`_DW8,\3/:@I7F;NB4BCL,57$0: M&"ZLI)\%WRT=U?'FVG`0_1+@WX`@K:L6S(.2"789'>T`M5&3:6PK\V;T;G+O M]^W;3O+=(79QON20*,FG%LS)(1-TUVIOT#-E%JO2('K`*`2`?82#G$T(G="% MR9[SFM)Y!$KIEAJQ!@3(--9R4Q;K9VU9J==/]_PS.^@PQR`_#,O'5RZ4ARH2 MZC2:6I'I@RA2UXDLUR68`8S!-$_V[F$L^#6O@MJOG495'HL^G#4]?L[O7Z=) MBD'U_JD<+(,2>=!:)3H-JGG,^D!KZ:Z?]V^A$5^SB,`=?`;3O1/Y7PF8I=$= MG-7(8E"D8(M6D6[3Q3QJ`[YH*<$\[%5PI1NN*MZ%1W1[:LL9**=)H9!E/J$ MD"O-B?"7=E-;F^,9F4OL<@_Y`O;G>3*1(IW%%>DTX!I1Z0/-5Y8#_-=N;5Z] MWUU,/>`M=S'E!-#:Q?Q;JT2H!K"^#);4.3)&Z7R1L(-=^_V^MCPW!<&5[S0O M3./5)X>&YIPAG]IE"(UFGC%X#))DL^-*9[]IO#\BJ`4+3D@$NTT&W0@-6"!1 M661QCCO40T#^V\[D0J)T9!OG'&R:O2`>V[8.]]\I-AH=SD&'6BCGZR\!6Q&S M]V5O>S/.R0?S@B+:2`JV>C9"01H>K73K0$JU[6$)$_6=V$+?&P,WSG(WT34D M^3..JF1[9R@LH*]//R1A2QDBM,69B%1MO!^:U`XB=($HO/,6SIDB/8+AC"O^ MW@IVCDA"YT?4.6IX!L,+A%>(+JK`;O+$/25@7"ZO'H-RG9BN\KL%9%\!8GY4 M3#%"&)CPLRDIV`OE$D)+5K[S?!C`FP1J`+9"K9_67]TGY>(J$^'N.!\&BAIA M&8#'U]:)H_3O^47%ZD6!Z>N(Q?-_^4N'6[ZZ_?VEP]]?.OQN"/;]I<.RRNCH M2X?=\"S_:`V71=S?\DK9^^WPWIHI"Z[A&S/W5-?[D[=Z6^;VZUAM'P:F3FS> M0W!!*V\]0_@EP--:JKJ8&VD)%Y,DA7#K9PZI@\6'ISB>$O9B"4KTQ5X=6);> M.[.H7;JEYJN)-&I:'Y4>7&JS?/91VU8G)@Q<)WF;6VI!6=-J8Y-+GR;:L9DQ M0J;V\%Z^N!T7SM)D@3!,>/M;_':5`DXNWF>6 MKDK.IE(<0">*]+2!%'9:I%63'*`=TEEOJJVUF^ZGQ]N>W%7 M^%GR2;2TTQ$MMBVEH@ZW8^MV'E(ZK0$>,`P!.P]?V%6^2/!'<$&&L2QJC6T MU"2U($0N:J7<:F56LXU;&VN>WO,&\/)^MMV;VE]]\7\MEES[OW8<9'DT)@#6 M-/G9?MT<1GT(('M?V]5K&%&WGL$CG"^2_;Y*1[1(ETM%.XZA09PF@,K5=F*C M=G.7+>+<9=M$19=[^]='3(I4;A2JBG2<)!9QFY!%3WTGKJ&.PP68IA&XGW&" M(N?KTE^\[)MM\>(2FG'Q-\W4Z=*I82V84,O<5/GRZF%D]#B1<5)Z"BGQ7+0# M23UKPO!GHHI;CI5_\EA;7L*:/?GVLH,J`@@X(HM7T0,5 M.2,-M>^3'K4<6W<(PDLFNF"(-*W8A"/^CJ)_03A9@(`DNQ//_,^HJN2*SZF* MY;HSOQ6T:Z0?I@K8BH'L$ZIBQ7YR$`\`0S2]GUT#JCV(SE8KC)ZY;_#5D"Q. M_,@D#W9RH!]_TPF"U)*?]BTPR>W2M63E5&A_I-=!4PRZV M!!6:_31JKM6G%Z2/=$U8AG1)^""1%@7;'.F2YK9>*YR?)F9;OV.`GV'8_G'> MW*7;>(;P,I!M^&I(5@^4\R4=+GE2AN;]+#=W$21@CC`$^XXKY8HECUBNK::D M4>5(/\!*&Q*KSI8Y8I6=R'(4W_K:@WK_\?9%?\7C;@,I<-\`MYT&/_.67/_N M=6$7"W:!@@^#2*J*2EWJ($!2!&>.65UA)W96=^OCJYC&MOX7G()2)+GSU[0& MKUZS%_E'VT^FG:\Y`YY$\V#C=IVFU,;;[HGI\G0MZA.`WY["0O;PH#<)OB$#%*;\?//G"6W>M\:LYA-J M+@F4.#K!MT0>(F9AH>L!:#?45[%!#RB=1`EZ^Q;A1'%&>'RNHI+ M`XN2VQ>S&Y0\/*K85TQ#\A@9KG\)2+1KEC]G_YD$!-`G_P=02P,$%`````@` MN81513VEPEFS4@``/G($`!4`'`!V87-C+3(P,30P.3,P7VQA8BYX;6Q55`D` M`Q[$1E0>Q$94=7@+``$$)0X```0Y`0``[7UK<]PXEN7WC=C_@*GIB'9%2+8E MS_1LU4YS0I;L&D>K+*VDZMZ)BHT.BD1F1]('G/N;@`0>#?_^-QFX('F!<)RO[\W__='S\$\Q@'I8P!O=/X"(IHA05^QR"6Y3N2VRA`-`V/$ZRH@RS"'X'L/R/!;UXB:*P MI#^YI_YXGZ>-@7=O6E]""?*OXT;LF%PZ/CD]?G?R^K&(OZN;2&YK.&G$'T?R M]6_"3^^'-_1N*XH-)1+3[<_&3P^`ZOGE*(4W<`7(?W^Y^234_N$-D7B3P?(R MO(K:S)GVT^9("GW',SO]'7,$]0_"&+ MW3><=66K\;=EF!\`*F-G\W^`^U9SFIJ22Y?XKX%?^%C"+(9QXYG8EN1.ZIHF M6VJYM8VB@=64]"(HY_X<:K"`T>LU>G@3P^0-Z?C('\?DC^.W)W5'\<_XTM_/ MMKAU^'_EQS1<-^;H+_GS=]Q[95*2'\#<>S-L+=$?M!=WJ6B?1Y#Q,&K!W]/[ MU.A)#0)=-4UD=)MBMZ2X@-GQ+[??@206R0;M)4"N_?N;KLWCWWF6#T,3YE'3 M(/RGXD?4$F\BA/O+77D\^#VK'&U%44"*AU<_"VKO1S`0`R4"`MTWAP'=^3[/ MB5]-/1;&'.0,R+=GZURMD9\!<:MD6W'63H-[MM[H+KI`]I%84.:3YF';D9\B&JNK8.BN:ZG;N`.Y662K?'` MO=SS02T7'6!;)#H;XGS#=I$N]2$'O$2UP7U3U+:;E*(\E/9$AQ@=V3@H0F_@.BG*/,S*S^&6A8Y,9(!3 M5F0V5(<&[:*5:UL.6(Y*@]GN%B#W?("M(&!([P'SP#N4'N*79^FPA3,N4?(P M_93%\/$OD%\>"&2&I3(K,[]&'EJT7!QSC2NJ8HY.6PY7]P"]"?!='Z`LBAO2 M?,SL)><$4'!VA*I+@LDN@RE%)Z.?#+HNZ5 MU4=\A9UB44@Q+XQ&4A9>&3$V;;\TXIM7O3;B:74OCOHO1NE]/UX=B6*(M!\X M__41H\"^0.+:6P3DU:LL-')!+WCT,MCW5/C`']D\,/3OL%D!VONW&(!7MRQ@FABR#>.>315R6]$.K.22 M'^@8ED5SA<5=??GO9SD> M`:\A:4UQEL6?419V5^[P7T48T>7T/\/M_>A=_D3M^@D9:T\$^<3?:H,+\USS M*#/'8M!7`KB2!5CMN*<'^HK@UPNT#9/L_RV\W'$BQI"5P`_);&B(\'U6&Y9+ M"U&$]AEY=W:-TB1*8'%V3R;+(O9]@%JP(;M$<"ZOA::M4ECE14$8C:(0W7N`/:R/QH$$>L'C02(&]%CD`&2\*F^L,]RJP_G/ZO M?SUZ^_8M[??^@!M/_Y%DU6>`Y"+^X]T1T=E!G(H?8+KP5+(65,;$4X:42SVN M%H=\$NN+T^\Z?"+MDA./+\10CA6R1+:A65.:/<#\'K%?OO'9QG6DPS..8L>P M7773#U8(XLCA@_BI\YDPE.=Q@&?1&41.;*=BOHMIZ#CIP:.^>]2L4'O^.#FQ M#Y239?-DOH?Q#7H*TQ)73\)$*9/J,B5?:CX/>'8MER02%PH>"#6#^B;(F[N+ MXU\:1F3TS$<$X"DP#!#;7)H!ETEXGZ2)D@-BN2$+>')V>#"V[(`)0B<:7!#H MMFR`CSN8%9Z001+/,1WDCYY+B+$*AQ(BNTN28K_=I^0K]JMR`_-SM-WE<(/# MA@=!G[((;>$E*@I<[E^M[L+',56F:'<$,M.>3RL3?Z9D*\=;4XP8-\&_@H?& M%H.>$D!$"T1]-0##/$NR]?*LG00M9"7>(X:;&&)X;]Z&P^/J!3!*Z+Z_1'X7$T:8?UO$?;BL*UU8K1]UO4FYK6)QF(*M&%Z:H/ M`S0U4`PGE;H#&FIZ6I!X_[TO2OIF]`[=0/*H$SJ[W.6(.W0>%IOK'#TD,8S? M/_U20/Q+KG9D"T!4SITT9+;A8O9Z[(/M8HL8\"%O[/RZ=W1PR!QT.J6P&M>]M MF'-=_9KELG2:HJ]D%\^/*+]`^_MRM4_'[P0%TVE3=)N\:J8[-V&:>+,_.S#! MNS3/&=L+;II7YBN4XRPT>K>^<#::!"1D(;Y,_C`Q,T@,YOX/C6A[\P!3/%N% M,YD#:'0HH!NM]A4>N.FM&O'CO>7!(2X:^1\,XXN.^B6-Y:]YUE;0Z,!LK6Q6 MNK!:M.MZF\KEP9)E!7]_K8277B&I#PI-IBJ7(BMU=2GIQX+C7@-OPQ3B1%'N M<]%G!UK"'/KQA"U2;VS>%>V$GG0I)S#`T(U*@5K,0ZI)@B^@F3Q$8HJ-]43T M$GE8CEI;L@O6/^B2\JO5IZS$^$AP!WQ6%+!D/Z_4$VZHI1">2RVI>1>K)W4< M2AFF-A#T9G7L'J80%,BQS!.JC=@ MG(8'Y_`S&BFI!_]:_N;![V2(OY>'*]%8QB*PQJ,5^\@ZU4*6[(P+4VR=SL;6 MZ4O'UJE[;)T>`%OOK!6D6J[F@>K=N,/LQ$`E]_*0]LX]TMXM69%R*T]NA6FI MDIQ4,9;CT[P8`FC7A;WZCQ[>!4(?D"M&J*I.&P/.8MTUK;Z29BK]$FI0*CV3 M((F*'DF4%IURI:VHYW]%"S9D,H/D,)*Q`C_&JM5Y'(D#-31Y>NTY/U5667K% M@#1T(P!+GC0/SHSX&-U<>PMC70IR*;HMPWHJGG4F3W@.U'AFEL]XDW'5P-5% MK!BJ4HS.#[#EZ0FN?;,`>]6GFD58VL?JA=C"Q,'(IMY$@7:OQ)HV"^]I$UY_ M=BZ9$&G1,-\@TN-A_$+5E:RJDE53=JLH1P,O@W50(_EZ&!8-"BQSG*P=XEDV"G';U_BRKL^2P[RWN^+)(-%<1;]MD\* M^@'"V6/"3OHHI.H?+I2:"5^!79N#/;D+&:!EFD%S$_3NXDX7WU^XPU4%%!D] M_2'P!0I]"DAM^L2%2WSA4PFW&H08B8I9T1.U3XW6N&-^L'X,23)4%S"%"`$J MY1]?QO&6DX8;%R5S6BT%?1CKBW/H'&WODXR^V#A'="]`W-GAOXHDIE].8,+W M=MH\WY`_/V5G6[+4[6HE4&FV9'@Z$=#Q0%X99COW:BE).&ZGBWQSF";KI*Y# MM"2HU,ANAZLPR<%#F.XA>9<:M>KDST[?CZ1X*-9Q\NL!(AWG^E&3KOY+9<:U>3*`C[;Y& M.DYXSG@Q[;!V-'`?,NE'A2:>S0G.L],1F^V:0%@"B*^3#ZIIVWUDLP@N2AI+ MHJE#7T9=S5NNOT/AU*@CJH)]6X9Y:06JTSHCKB$Y6._A.LG(;I#?#F2-NAP; MF)W_AEO;E=$Z;(W9*"/'5@![*@'L2T>F8,FW.V3._\Y;VY6US[V-/%J!Y#MI M)8^3:*,!J,I+1ZG@JW!W*%WR&W&R/7E2-L;^_2:]Z*WF M-&43VMM[RVGFSL';SDD-F)T`F+>?T@SP#&@O?9?F^=`FLB^8"#@CV1:>@N\-WKL/\*K\MR0YNM/"^AOGM)LQ' M$]#Z&KTN3:EA@>\*'[:K5CUW*E[K6`DJ05`0R2.P"YN%\Z^2#,0H3<.\(%-W MH"`J2[\_,L`'FAS`,5L5RBQ%M7SY0$ON2R#![3'A++W:80PZHI+V>QJ>"D.2 M/[Q]_?:DH\J/X&Q?;E">_`/&%4T*<`S^Y>W1V[?T?^!349!3@DE/B?9E4>(_ MR'Q.*WKR;TM^%:\8$LE+M%%4LQ9WA28^H,I>PQJ&_7$9$X+C3Y--)D:%7S(:G80OJ? MZHH_G0XWN'P*B"(A9$)?04"(L4U_>-&E0!4WQI(B?O0E;7.DL^V4)R,W1EQA MM!F^A*->QU_.<((NXPT_.@KN]'IA&7]8V_YPZ*HK#E0DXHB*6#00M4VCGG&G M/!K[,2(2J\[O>?K%F;]4XH5>QB5!B!1DZFE)V32ROB2=V).WV=/#.S:I)#LR MB27G*(.,C*,Q8HU(B2&-W+9;)-FO(((=TWGJ6/1'P+HK)'15Q&1P\UZ&+43)ZM@M-T:L4FR MXJ4G69":[3R'<5+2%R!7Y0;FE'"+CP\,4"+CG>%"%[6VE)/N%K7H.;(XF-!W M:`.7)]RD[^E:%;?0%(XMWJ]%&<8==%I_1X,8US,D_PK5XL?4\,Z)N1MN, M;79K.G9:QYFUP2@'F)@.+N`.9C$DYT'CM/`7^`1N][M=FL#P^NSJBHD0Q$+6=#'K&G1)^[,>(U*PZTY_G6.2( M+%6KA>@KG,T^BW'Q66Z6?XVC$7P9205!4A"QIR4EV\BZ8XS9/;9)Q]LX=]L4S=R=S9B! M/;N)F&=:3HBQ1D`NDM'\FEP&!;Z^--#Y\4%:#Y5%\T!P"&".C84A>P.3[?T^ M+\@$W8='7+Z.=R13R0U@S)6S`FB.9?O0%CM1@URDB^&>8L^HKBY@=6OQ22M5 M5$?@5P2`1P..RI@00KN+4H-\%U.W1K3YLDJL1PR^F`5>\`S;IH7$AXH50M7@ M.D?Q/B('*13UMU]H1S?!S]8M118^FE<97V06BS%#>!HL0<16O>&'@A<*/ECG M@8-%3UP')N"O0%_5_CL-Z/N%?!W$ZR-=AG!+8\:Q48NO&_C&3=%P4M7!%0`^ M/.NP"P=V9G%?<@!W`5GZ<2BE9\)=8=]F M.:#G2D8%'0M!(P3*\)',D&1PX25YN@%'DZ(RI(U"L<\B+1^+<^H&/L!L]'FH MX"[#F?:N)8[4]HQ+!-7$(=^^#A'Z&L$O6;A%>4D_/4F3B`Z85G#AO;I$D>*` MG?-X^>"N!7E@'MBP'W9KA8#`MF',3WK9KK[\'*,M*`',PNU#`5`WAW\BO%R( MG[ILG1'/-^M@F9?4D0&Z!P?(-P=P[TAV0QF9_8T;V.<>PEYR\K@Z$%(.<(XB MEUETAAI7>=#@%'J9YB@K>G(PO0VGDSW'SRX;. MLOLT.O)E0`Q&-[A$V?H8EZ3;40ZE0R5Z5.TPWWK%&4[@Q;3AQTA*G$Y%PAW6 MKDMDN4JU8R^30<5-N)W(2\&/7N:=`"`?\B\>_]-S\(K/L)37KQ)))@=S)2UQ MA6/;Q5R5V(T.6T3:THJV#!]!2+7\((XLWASJ*`+#YPY'B<<>H6U_Z(/_J+XS MH5M\KU#^-MHBFJFT;5-/[L\I';5<&U%4PV+0_(N^=HEQ M*D_1CNR#>41)&U%USTBKB2@9D?7#K""WW)"4\#IM\"<)X/2D',C(A24]J8,A M#=^\Z_YTTJA&8F#PYJ?N0OT>TR@PH.A=348W?#U5'ZL8YRS"L,LDO$_2I$S( M5QEJCDG%QRP3B-OC&=>!(Z;)?&ER36R"-Y%`>)=V&MZ03`X"/LV4@1(2C:LI MH)K$RX)DV^4P2NB*TQ&QQK=:$O5OS29,9\PN.49VY41@Q(/^E:7AS0D%4C]" M%K:=U!"BK/9BU79?,&+HPX49?4\R.N))Z%OQ@@RUA"";>2AC*R&&^@LED8:,&IY\H?1AM8)1 M>;7Z\!AM<.3A35C"JXQ_E"O+EPFJ#8>,5.?RRL"9-M=^J+B6P34Y;$BVO&6" M>RD-32ZGZJM[;[<=^$C:6UUF.,> M=\I7U5>E*.-W<2:*@PY.3]$*ZW5<62TD3;VJ^:YM+&CE05)M6$_>Q=`^S:MM M@2:@9\1OT[CRR*UC8TQM?<^>\?H&DI@D:36A?U9^A#%N;TJ.A=SCACP-A+4( M/\FB-!,86G22(HS:8/T[0'MM,L\LYEZ"6@04COCZ>AIR\0J,]M'8$PA(T/&TMLDI'H-X-[W>" M:H#M.3!TT9'%=I>B)X@;G=)YH&Z%"_^[`FWYIGI0R\]-3RH/5D<-FLZDB47+ M1G`613DYUQ6#A>STX,$B%OW8HXGA8=BJ4AUP4<_/1$+X_->D*^:+:+.2&ZA/X$EH0U;#4'GV9I+WCG>75"5JV MW]?[Q!!Z5N>2'M\3.S[E#"M010X0P^2:.68'>6A^^Y;FE+U*W49+G-+II.43 M*:_?]_E$[=1\ZELZ`JTMT!G[G64"#/E*LT6+[L!9%M^2;>'OR,YGXQY> M)-'UVV.)^9F#M6FU>!::5W"$8<59NC`M[48QC\F65+"%`^.XT]9B8.;W*>P^E;I+/IMG^0P9@\[,5&I MGXZ>RDQ:Z#BQ/KULX%3&'FTS0?-/L*(JQU0')*U2]8W>$0BW:+_TY),14M#T M2`XYJ*/=)Z6^MP,!U%IA9^+0!CIQF?:QC\I.&%32H!%_V;@45%6N@+EDC52U M\9+3QE\*N-JGE\F*I8.)RJ#_4*E8H:?(S(J1\^'C?EVF-NZG@[$"HM=QIZ#FU`LNLT+KF=QA&HY`%1 M>-G0E/8;]K'I9[]!]DC0[C'ZPLJ^HA)VQD=BWK1_J!+P;1GFY;1>HN=T&AE; M`\%[N$XR\NT`N`^QHLSJ/#C'EU&FKP#V(9.^3M'S M.0]?9`HWBU\TNHS3MSF\;,V2R'RI443T41^#STF=5N,#:J7NL MG?I9'MSE85:DU:*=^+_W1;GE?#,V65]=1(CTW?&2[]'!:_6I;9A(88G-X"/* M8;+.ZBW&HB=0=L(@[*2]9;8"9GID5T=>F_Y\4YH90=:.)7!_@,&NPKMUR*N& MP;@CZRF#L]\I8%YN.>+`HN/H*D^>DY<]^=//<'L/<[8OE(@TW1U79"ZS.49M MOJ>6V)>R4Z06?,IA2K[?)&M,SO;E!N5)^01^K406WEA`&D2D_]`9KG"D!W00 M6EL<\'5=0%D91H25/X5)=HF*XCU<81D<1`$/##09>FAI6F*-AB\79-)WJ\,Q M76MMN=?N'+#&$K:J.ER&*EFS]_!2R,ZDJM>Y@>*;C3\9*M7Y`1,A>!C$5"%.ZF\=O^X3N MR+XL$?7BCB:$9T@VJ5J?7AKV70/,VCA(R],L;)W4X'I%I+XG&.L)$IA=Y^30 M;5QP76,G)=T_HSX'X,-CE.[IU/%5DM(=-GX*BTZ>EFP)+5V::R\-J8*ACCVH M+CF$:1I7?Q)TARYQ\]9TH'4+2_Q[M^/OVXQTF,Y`H6.)LU(O#CL'';\Z1%;; M";H[?O!-#PP/.].`W0J+QVC MBC["/D@7[3-@1C[6/LOBLWB;9`G9XY!\X5T?M\[V%GK233^ADI[+3;E]FZ-Z M/5=2-FI8"&HA6HF%`[&%2:<9=S0I.`S/Y(H#ANGX6(Y:",5?DS1E.<1<;LC2 M7I[+BMJ0*?PU#GYE3$OAWA<-FG\MC&+VR2/Y4V-P64L,`#C0LABX"4N3E&O? M6/NZX3OQ;D6;;B!%/;DBDO/7!O6M&:T"TEIEQEK7#>2I7RO'=*,H6*&CBN)X MU&Q<4[$OKBZ2(4E3LQ2?\3%-F>G]= M94O(UG/GL)(P:H`.50P,MGRBY?95N8'Y>+&('UPSQ!2'D>:1YM-6SPZ/W"8M M.#B\[3')M%]DG#+3'7X]VBN!7H@JH[L(K,Y8`NZ)"/`3:%YW]J5NKM118 M3YCIT!PM\I6;=_%60,>A#HV?_UI=31QP>&FZ"E>NQZ.=P_6U:A?6.Y'I*V=U M++2=A*<+8EW@3)'O;0#-AWQ^@]+T8W4,O2")/`7_"4^9#O"?-P/K*U.+:EE97@I+A)NB9#SARW#(^ETQN/><=(,4J:#%?51=D9FC$`*\2 MJY^<6&PF>46&;?)4X4-&2:EJT-MVO_?-1B6Q,->4<45F,1@R2*31)XO:H$V&]]1N[Z"MI7R[/-[[ED`S]]B\EERRK_]"#;=8<5HE*4\8D#A:")63GA@`:_JLPX7WK3'#FRD@X.IN)G_E8[$N+6M>Q4^ M)F+F=-#?-E]&OGK_@C`C^.IG'F:6W(F74Q*+/B71$14/U>Q])B(S[N"C$`UW MAH,VYH./_JC-$XYHKFS7C81RL,9=M*ZV[AA(EF=#Y8[F8.ADD'B]_(S"-K14 MG?=,;'DQ=P:+ZS!AE\H*[K*)M[EKBR*5/2?C_8%I+1KT-(+SL-B`'?XG/>;* MF[=[XP#QP#U^J@(X5X)]!DH$6FC??"#3%U8P3;"Y!T^&743C+RR MCVCEG1&S]N!F$*KE6SXM6C'B9`NY6I5/;X-_!P";P?H M!1AOLZ&FD?^O7S8$C=/^5`QZE_#S/:Z&D_`^29,R@9P7W=HJLK0_4G'!1,:) MY2&RKC]C-O+,!/7UYGU/0;]YP^-,\B\/=@(VPH6*C)*X:="1T58RDNO-(TY> MP!7,8[=5%F$!>R,:1O'4J,A[<\I#OS(R$/!O#\]O1"L2U4/\`]XJ6 MB'Z*VM[/*RN^$52$$RD[):%449-1E?.2Z\;A+RC`5+Z$T5!32 M5*QHG:\B5VZ)J_!JQF"IL>"<'G54D((6-8(@K+X7)P1.N^[@1]]HJP20E+\Z MH541661#SFBY9X^H3=9J9]B;3O'+D142>"!KG;,]ZP>9`A_[,R,HJQ_T+OA& M.5Z4I2P3!$-%K)Z:G$LC^Z[AY'`.@^-I%I+$;7-,5U#LE[ M9?Z9$[KBPD3-BELGU]#!0=(UUZ49SS@F@OK:<%:"#G]\8Y@``U*2B>.DHME0 M4\XTGI<#0,YA2N<[FXLV<6)O4/C!DX7S3J"GG>+G86_91#_<5NHS+-L3"-O= MIT0#;7/5M@,P49W-3'UG=H?;QG[E?#4T%YQ%O^T3,AO6J?KT(>0$]*#Y466I MK&]E2&M3[UXS?`*S)S#Z($P^-(,M,;<9D+=;*5938T<@@PL?YF<$!D."SB.F M*2&7)R+=M4`TA.+>[>@UO#N?27U[3L9#/`\*FHPT@N:B+U]H\H.$M)[L".%] M00;,8QOV(VYQ.,*U;1CLDUZT/1E63(FV<-!@$NZ%AP2T.=S/+<:WF`QEZ4.+ MSICE#IVUJP-2T?<527W?#YB*OZ_@/TP^/L=?5K#:"P*SFA]]PIW[")CC6RTP M^[=F`[,SYF1AZ\B\')^,N$]O=#@!0>H'R8*RDQJ"DM6V'%>S30G4>T^.K9O$ M]:0+[-,1N"/NGE=TA7VB7GAM;",PM&AQ[X"Q89/0G@Y"^WGYP9Y98(4[`.@% M=MEO_>NV?"2G4F]@3(:)9-QXM;J!!F80O:8A]V2RA==UHT M4%@)FOM@300\(8=&_'F629CJL4ZIP)). MHF"+%I>:[I;&>C M%F7YY68[&[%QEP.NJ=O9*-0]')!I;SFB%P@!@90[CJBL.\:1Q;E/M:,Y$.J/ M_7S=S,8NLE2#Q9G06G9J==0VX>(*I:0X'5M<.B&T[:3`F;@1M%R[GX,]6OZ@ MCJ^<,SJ+&X1*"L)XLW2A;MG?4/Z%K)Q"$2ST!@MJ#98^,@U;-!+[<$(GI3LM M6BFL!.3^<9(=[RH)3WBE`0`>O_0B)."96)G+-Y6OQ7C7^S3WG!YSSO9.8H'Z MR?`$9I)H;-*4,\IY>J$+&4\$2@&=IJ^/B2_[G[;-H8`K^-Z-(U#?>KXP$!3H4W"P9#'>:]%9%M^6>'RP06D,\Z(Z M1D:<\Z3BXPPH$+?'`*X#E]E1YE"3(&(3=>;L94SZB4NQ"7-82_\10"KO#8?D MB.`S2ADU(;VXF@*R2;P<`(`N$K+4V5ST#9,U!=Z'%PPU=2JW@C5/TOQG_(!5 M]>Q89IS0^S+V2-19=9FZ1UXT&OC$N9;+PM<3BSY_.`_>B$G.G$! M$5A[KD#B(KV./4Q""%OU=G>?.SS4.=,0'YYDQ[HL%TQ(JP6%0W]KT]%BTS:G MSY1>S(:`S#8XX_F`A;>[T0BL=$2HGH<6Z\@'B)[,0JL*'#5AM-0TQXTNR"1U MY(A:.C[G%/-#VK$U_?,;3&J24CN49@6_@K`:7A>D;YFLZ0Z"M[#$OYF<"'RV M)7O"C@BK$FPI*A:<34J1:;LT5'B1$T^J'-SAT4!!-FLLVMOD7VFKMC3/E%%& MIO%@N232&;)';GDYOJ`PPP5J"8N[/(PAIO85V5RFVS._4*\FFV6C8=DT&W,) M.,6K@X5I<]HA9>]DN\%Y#N.D!#=)\87VH6=IBKZ&F&CT6[@+M+\O5_NTW:Y\ M89K/0B"R"`@F.4PQ-\@;T]NS%#7LS5+,:8$35I!9#J)+YC=*,LU!]2D]J(7> MF2V%GZOWEB>*:#YE,:8L.A^#BN(<96335IA%N+2^XYP"(Q=J^T^^T.PLP#-K MM3J5>9"S6*@8D'M@G'[24"*3!\_RAR<_)(C8HB<$>+H(M^$:%K=H MO]Z4?PW3T6;\VO)<6G#EK3*$X\$=6<3.]'DCLA'@>@^N80SBZCX@``:[',7[ MJ*0[[T>V1KB^S;;+S_1K(T/(,D7P9(3CJ(JY)_3C"0UQ;KA,,OBIA%MV MQ:U:4-0?]01M]TFM::?]$NO%J&\:*G/[)R("J(QOG=0XQK*.BAL-16?5ZD@[ M+,:R/VQY__0Y+'%=>;7JD?SL,5&R1ZDH8I-$T3:[A*Z-O$#;,,GD]2A/DE^) M#B7MUJ!]VPZK3XX;@[ISI,W2D&R04E'PUTK**];Q0RTN+44QD1:5?25).3FV MO1AS/L.R.IR=-)%!*_=>_?N9>S/Y,+!F?7D=S[H,^&/Y@&R4`\,\PP%<>.:< M'Q2D\2R'R!V(];'*T;<=76LSSES+1J$]>=ZQ%4S.Z@=WR-UCAZ2 M&,;OGWXI8/PI^YAD(:XVLO595"8/U0(&_AJ>Z0:Z+&9L8#X9#%W:K`@F>U>0 M:HK1H!4`82NQ.`&G`@K9"O&(R8:V&+I/:HEO*8%\DUN4,U*"A@%Y2I`:<),2 M)"X/D!+4WB>D!)71H!7P/27H`$J=$C1#K)42)+8T4H*R)<\@)4Q.!9-3P`&I M[V)49.;:#M^[\51$-NO>8SER8%7RC(D_C_`VB#Z-X+8&=P;N;([\#-W:@V\] M9J2;S3S[2G/4VM7#0/RCDMJP`W] M)2X/4+NJO4](!BJCP55W;KK?I-69K M\HS6`6>R#E6[BEW;F;YB:M==K^]?/>.YK'ES6#;FKJ;-6;FL7P7N7->O$K?V M(*RN7[N96<_K5R=H-JM?K<+Y>=2OD^O6R?7J`>O40W568M=VBE-)9X6><:4Z MKT*U49E.JTA==E8"=ZX[*XE;>Q!6=U;=N,OSSLH)FLTZ*ZMP7K2S0EF;Q:H5 M#?7QG**Y%5WYIFM2R\_ELLJ#U8D236=2WFK9"*H/*YL%->!5?3)P\?W"&^GH M(P!-#!+#0)7J@'AZ?A:CV]6P<9S%@A*)^KEP)6:2B&/3>OTF]B%CBTBK-TWH MQZ(S6>"0]I,>8I\CW$>[T)8;-%BK@R3V)T#AI(^%ZA9X16Y^_YP!(:A'IB%B MR0KC*E^'6?(/N@?,.["X M,M\D6^OFYW+3-.S1Q24'0,WL$!H;IKC5]TX3@K7'06?=S(YOGF@!$]X M@\PA\Z.1$L3JP3GVFD2XZB$U40[7^Y1$>>$MHK6B/*:K,AI<'G*U.`236%^: M.2/N\WA/7E#3PH>;!>BIC#@57*..N/?4[N*COL_=&#@\/R/NX(Y!!NO?W']Z2DNA'H%M! M>9%F#\Q@C3++.3'T"C(GS=`IW1S^_L6ZJNOPB4(>_[8;N,/9C[19E M]$P%)GOJ*]31U%&8F-33Z3)(Y[< MRP'`9SW_JYS-Q5T_]^,'6@N"3O((4-F7B3Q%UK<%/:\R_G5.EFF63]<8-W1F M#5_=;B1 M<5^(`38GNN4&(O;\L\3`+(28>0^N81J&\_=WR(,NED@"R; M'U$$85S05^$1'E[?H+[2J,Z-JL@TXW'5(F^16VTEF;U'`@B MBXA@D\($<\.D,;D]2W'#8J\THP5.:$%[M4JW&D=4)"$+^-[W24(MU"0Y_YTD M8VCXPA(?NE[2PD]%L2<'4E_EMV$*KU9D_%0^"?I9M0+3JT MO>FP7V&D8SJE-![9X+$.S*.DFARC_2!`.X*D*AD4V$)[IUU!U(R/_*"^!G0X M/-<++I_38ET>@56>O"!KU2SM^6YS30Y]E9H6>:SPY8K0>FYUF:UCC4/QAL2^ M3'=/`(^`P`91%3-9841$:2W?2W*;G`3\,]S>PWS,WO&]CI_]>_,9V%FSS+&1 M806+&/G@KV&>'%^2UT*_5I<7_F*2'Q6D\3!'T.[$&/"R^DO#\U.V0OF65JZ7 M@A.--22'T.5+V@$RS[8#6$O<:(!A\[@B-6R:/RH^"/7+UH'OMNB,RPR4$='"T.('4 M`4?F@1E12*C%<$AA?4D2/20%9O5'E%^@_7VYVJ=G483V60,H+"^#G(8P>2!?`8"PC1%7\E`>7$FJ:..S*,S M8I)0BV&2POIB3+J!$5IG2;4]Q051;*.:/U\Y*(SF20S;KR9 M(,SE+\$TG,GHI%0/SK;D8ZI_M#O$U(N?P0HN3"&M<"/SL`PI)-/J4TAMW3&J MK+U`TG$T!U(GY/.J5H1`JA$"M=3+PI7@]8TM8"WY,N8&%A`_T0TNOBYPBU)$ MRZ]ZK<8H.VO(MNE9*CN;21+K-DL='4=R)JGT@T:$#A7B3FAI"NG$&DT("$-4*,3(/!DD>D,R2-W/+29&$GK=C+ M0R+,GXQJ#!D/EU5[[S.&-7!=SRK=$O&[^19!E`XR>.6E%[;3:6$[ M]2#-RRLAT3'1X]N6\.>PUC$YP)FK0D\1J]/)PB<1"@E M.Q3E,$ZJ5]?5KH'4BC\5OQ8,T(1H,2R2J0THI;:_&+_("L2BYOQ/",7%>`V( M3*1^(GR1F23B&;7)'8E]&66$:NW2*"\J4&G4D/Y3'F*>)]V'NMC:<@B/-C#> MDW6VG[(2!S6Y3^%94<"24)*T\6N2IG=T`TG!N4LS+#3\F&)A+GW,?5I_=3V] M#5(&3K0:-/=HUQ56.S20`V$;(R"D5A8F[@RT(6OA9VAO;FR0%::V91D*6'O/ M/L._`_R??!',8T+*T$,S3+,.+)=<#])N,>WER MA$*]8X-V%ZJCQNDWY6H6,X7,D=7ZT\RG;D90F@H:F<4//3=&A8#(NA$3DU=F M0<18M5KN'G/?EPYVI%O_PN-"D[P<:(OT8VK)'9P*L; M9ILW0(_FIG:#1@&$E<9PQW.`]F6!>Z`XR=:^I(0IJ./FAXD@$"4+`W/\S&'< M'@_22+/)ZEFW37+Q_JGW+]IN808Q4Q\E#UUU:WE#SZ&;E&'D6R];&)@<#!$: M/=!7/`+W3_T+]4C!F^&!(=:X*<,\_J)LH6>)GRA,6N%!COB0X8?P]+U ME&2Q50ZG^>RW4B_#V?;;S.7CU)?%H+GO6ZISP09N/G0$/E'2M.B.GUFM_QY? M:>Y@*M-!"Q?A^$FW;I7N!Z\3.=W?/#96HVF0FS[-)I MAG;T7ME!Z_PMV::]HW;B?&[IYN-[[>>>+@Y5S1T\7RQ:U<$U^8[Y!N[('AW9 M6K#T6276U%1"L;D946#8ZA2YW(:ZONS@#ZR\+&2!*THZ&1Q2>A-,>@4DJ("S0DF/2B: M?H)HG8>[31*%Z07:A@E[0)-2;M@+\.3L$&]LV4'A)'2B03&!;L.K(]`7`+]6 M(GZ021+=,87D@>#R9JS"88O([H(425-2RF7QSV'^!1(B\S?U4@NV)!$+SF:) MR+1=FBB\R'DB50[HAU&T^-DV]Y=FAS*NR#0"+#]$.D."R"TOQQ"R'N^]XH@_ MN5###('07%9PS5IEA,R#E`UBQ>#6RX/R%(%$)H^=H0%7?D`!B<7EX%^&)21= M%UGJCN,$,4-)\W*XP2U,'F!]53`?-4V[(8RI]EPFF?FS2K%)KJ7W?UP7-GF_@U3X+]W&"Y;_W9ZIL(NJ0%2@PM#HT*V\:N)RIAN M$A5[M!,Z<40_E3]-&LK-#.GX/DS).2UXB`3)_@.>DU`-%#X9M0(I)*506T!. MA;<%28J'_1N4QC`OJI-KA=14";:$%`O.IJ'(M%WR*;S(*2=5#NBD0GW_C_2( ML?)IX4T,-2*+3&/`\D:D,V2+W+)''%%R0\D)!UPP7J:LVK)9Z,*,`!7PJUV` M"P[\?4._'NI-T"Y'N9VE`ERS]E8&",V;8^&DGFQN85`_I+.RS)/[?=E\%G(= MD@T\GB\Z1._U)\!CT;?V^]TNI55,F#9#C-X:3E&Y8*;5Y$E=K;ELT?-CM:HP MDW.*TBI3$,DOLQ<_O"L M6J6-Q(&4+4*]@-PBY5OO)EW`]AEEQV'OVAW^L\"5"#T>P(=WD?(P(X.H,$SA MB0\((K:W&"]^R?+JR+%_0-P%/KZ'&5PE95$M(<`7KF$6IN1``O[RSZGJ]9,S M5Y])-%.'-CDXT;>,GI-,TNXMA_1`1K!K)`"L1);EYF0\(3LQ'C+:U%*?[--: MX5\>*"&F5'F5M0TW3@5J"ZIL(+/@*B&(?1XD)RC=3TH+"JN#S)#4TIXG!@UT MZ>0&O7!KI@>Q,:T,H6J+;TE"+Q'HD=T5H0]`VNG$K,C7OXG91V(/2DQ(>NJ( ME^PS8)@QBS28LC`;_AJF^VJN-4W15[)2Y0*N8)[3-M)S&LXWI-+_E)UMT3YC MWTQ,5:^?GKGZ3&*9.K3)N(F^952<9#(XBV.Z:B9,^PSUHH>-4R#5?<3&`8;E$:T###SP':_CU(`$V^(GM% MW<`"Y@^PX&XM8*(B[/!Y*M8[^;$3MQV[T)]99RXPTZ-R)TI9W0A[LCN!$4"D M/;@\@*I>>ZPM[ZE%WCPE9[W$W(B=C(X6/5L=I_RLO1R.H$.'TQG:MQ.T3%RA M'(1-#XM'@#!Y(-G^"&1+CX?-`*)-3T[\3/C9?"^A3="!/P\8*N_J+P4+(2;K M&];1E]:62QA[7**>9IW;J*F'-@WKZDM?%E],!]R$`IN+@6E%]B5OU<;$=GB0 M+7@9C;QBYZSL,%/2ZM$[):==>N/F<'TZXW%ZISXPI%%XTP4E/BP0,42+=O?. MBZ5)_][HZW?P0X^+<59ZI.%5=[;D^[!((H8FDW3KIVJH.Y/(1MYL\GF*8QFM MS>V-SP\='QP*CL$]40"ODN9^7Y?DT:"$+$1^RWLA,G_P3_/N6`RZ2=(^O MCIJLEP54VO(\(-9VDPE$_@Z0"Q2N)V0#J47-?!!7-KS/"$J8J7."3NRULH+( MD$9>D+=A9F8H8/1ZC1[>T'%#_D02P[OF'R0GO.OEA/KRWPG4ADM';IEG02Y, M)&/GQ`:_1M9XE&&$@E^RI-U6I@"__@Q)'!8N;GN/&(D>$K-`XY9@BY6<`)>' ML(AH]_#VAW=O*1#(E;]?H&A/5T-G<74ZA_JK3A.5^L?HJ4S$FO;OL/(QM+$W M'E8-C02-*!VS5<*@)^W-CBQ&T$!30S=DB(XZX9"I+WLPQ/6FFEZCNL'R-M+5^9`R`*N?'#6'AR'5)@!2./Y>N'/6T2Q1!K/G_FBA9%L,MS$J$T3'[:WF^XV4MXO_X1G/MS@#DR M9SUUB3P(P*)31QPI!.C(;9'HBVT M!4:L8\=.3A.:-D,-SFCU]2.`[_RG)QEM8L@%^-^RRF<3TW@7,*QDR,!Y3T[W MQ/"N-X*&Q"IN"/T(..DM*@B+`F$/9!$-+>WBZ@O$+1UA%""&N`V5-X0;B`?? M6UHG/E;D(;5CU0;?$H\^`<3YQPB1JBRD-"9)1IH-68"/KNI$;>>VF2BJ&OO* M9*JJ5S-Z]-W4@CS0KB:=$\'QG(BH#05O]Y&IZL;=TV[A'D,95600@2$C1!HM\N4F7<'%3N96>9@$E!,I4EX`4`2Y MLXV4RSDY:H!$9@(5`*P4JL1>$)$%_;05*,_MME7F+?;>.J\F`.FT!U>8L M-E.]($`).G`K@++:D7_&0_`-#(OR-DI(#[%*(OZR7I5:&C359FK),=<6%72(*S%01R6 M2\\2:<8=&4=GR`NY7DL.'?-NP64GL^KYF0$KG&-K(=!(@4H,8#E/4JUU;`F2 MKC5PS2Q@$Q2N/GTZN/`R_E"#<\&A1I]>048?@BJKO7I=-:P8M]PSC[1DNR4;,MF9;U?%IETLWE!ZD[UH52@'_2WX[I_: M#RA7X]X=7]O".(E(1P\?DFCIKEX/#L@T:J/7L&*U_KM8E7&GB+.V_D/M9CK6 MJI4@-;I&O;T?IV99QI1X;8@-4-G=J@CFVZO56?,I-`-#P=UFDR+V[JSM9X;& MK"=4OGWQ]C,<<3H(ZC(E_?(\!.3$!)P5N\_)05+@2*9)O/1V1(+@(?439W:C M&0IV6]'P#%C&@*7]A_B&3:)/=A["5TG@VT@_N_B*MAO2#[#5Y/-^7R09+(HS MLK*EH`N&KS$V-F$!KW/,*7(V2409?2+8T'F&A?H13+(P!^03'-HCP@SG0K), MMADTFJ"G>@0:94"U04_=F\VBY\`.6<+!D,(3K+4TG]Z2!7A@<>YA1@MLDX&\ M>VA@OZ.P#UO!WU$OG-Q8`/6'F`;AG$2G(2F?`IEUYIRJL8>:_E"<+Z>E^O*F M/MA3Y4RBI35";0Z/TS/L$&-.)SSZ3J:B2S'9X<$AA18Q9#;-80(BN]N9UL<8 M75?[<)Z')5RC/!GM]J>4:]8_BN5FK7\4F;6>7%6>Q*L@I8K!];/H?)Q*:`V^^3>O94NI&"&^)5M#*;%"59,D6C_R> M\#^P&?+=1%.`8MD(QGMR&"+YL()\[A4GX3I#!>Y6R84^=KIE4@!6G' M=<@8OGQ+%YDY-_"SDUKE]B<`[X2'/#\60\Q&AB"93H;&S+DML6&CZ:L'F-\C MR026W,T$B)SV('+]PB`BF$*:#!&K$T%WJ`S3VD>]BPK_X!B57/-J5BPWZP6= MR*S]U[4*3^)7=U+%:LMP(@+R>J,@&.9D+TC>!YF M9G:R4MM6^UFEIVG8.6VPTTR#9$!-WQ9(A8[8C_ M"I.L<7&6Q;?5TEI^?ZPE6_](A>P,PTIS#(@-'U@L/<]]"BIF::K?T%\[4YS`-:2U2#?J+A"PJ MH^L[*?EI"][\.B@&7QNCY2@#0BS'-\LSY9M#[9JK)+7LH3VVFR M34HZ1W'4[.!:N02Y12G9VJ^H[\CP*.C.S7S?' ML!:THAMX;XV1,_]J`PL7>5,R`)I'S6%"-3#2IE=CQP=,0'9*Q0E.;:6>$W*" M77522%ZI4(Q'?27/7O@<$,2"BO,`*)Y9C1IZLUB;3O!L"\NG+9:/P$T/S`.M M;P_$@MKV`"!V<=IJ=SC`^8;4(`SZ%5+#X]G&4A8.IF*-6J]3Y7Y4ATUQU9K/ M_IO#*2)ZBRS7;%*_8.T(_3?=4;"ZZL>):L+H(_U0<<^+8A788Z'X!AV!RNJA M9B('4^#4.Z)LA*EGCP_Y@6)3`&+G2'6>9?NGIXN\3(%)NS8D%X'%KS-Q+(!' M?O3Y%/`X/M#\EJP)O(%X+)[A_Q0EBK[@;@"[ST4]KZ&R\+Q4N;+=`R1EOEQU MWV;N#8Z05%H+NJN$9_@R"`LR+3,XG(JL!O6C-S=%E/BX2-TXJ\Z*E-F1G!2I M=G]86+LZ%57'KT5`BTY$I7J@5L0CP@[UE>XW!F[MDU`=H=M.F6/@T'[U8^C< M(L9/>5G;Q^KH<'B6UU+N\6RU\OH)/<`\HW4#60\<5:LX^:N"M&3KAZ*0G4-( MJ6GK59..-R'?U,K!'?Z]I.PA"VKQ/?*NAR"B7'I9CEZPD6E,AIR1JK44T3#N M%$]VRA4M-].1A(N1O@SH"7DR\VP948*RPA*DK'[K_Q=LN]WID9];92+U#^2+ MS$$^SZ+U!"IQ(D2[4,?;="F-'])\WD,D\Z1;`(M-N0"$G0PHLVX,!9SOR"W0 MW?,DSUD$2Y$L^Z8P7.4[\C;-WB):]8U)3\WKQGK-5O'ZNO- MVBA3UXWUM&CJ6;PKII&AX)JN@0))MB+OU:H]B2.TW:5A@O]:)6FU6\K/X1/` M*'BW<%HUAP^:$UEF!TQ=$]V^EV9.#X9<2QLC M,>M()[4#ZYV'OD_QZ4Z:)H)*$(0]25*`Q[5L\Q)UZ4/J#("!ID6..?M)K=P= M`*7KZ``XM'1ZG;ZSN0@\T8;@BT6@Z%`[^Q"<>[R=GA>;9]SI>YP+Q%-M()(W MVN"W?9CCMK]84(K.Q+,/2JLO/(:C9<'1)W(A[GR]E_<"0"M*2U_>6<'X@KCSE^X:(->2U_R MTL43&NB&7O'B18,8"DW5RQ=G5/F4X7XXH_U+F/X00Q@T$OV3TXTRR\]3B6SYJ1!L9Q67(!K%. M2P2567=0LI-AU3XF@NB$G"33$P`-IOR8X;.&'$$BG0T=N\>8XKO%!J7Q1Y3? MP!TIUK/U^;XHT18/S7[*45':,/HL8`.;2D*.HM`Z@)LGE^M><$BT=_22'+)[[H.T(?7\\M1Z5:RN5:?RU-UEC[&W`]>EP@9, M3!<">QI9HGY#\WS*3PG0]+*`//@FY!];TB2]J`F'1OPARDJQ9ZM8URHC>6#_ M!K$^J5JT#':GU2'?Y<&J0K%[JY#7J@)YD'].Q9\C"DPJ]BQ3P/&.$1=)$:6H MV.?P#CZ6[[&Q+PR3C'2$^T-P=>Q^8,QQ<8#=(,1>#;XG%AD)NAMDQ4P816A/ MO^`!.Y0FT5--Z&I]2-[9&VX/ZMV^$#(`B;\P5L17]5TQ1UWR.;'0V4$PZVJK M!XF[^6CE;^P`>A#^E<@#JK#PNRC'F-3>O,$***UOU2#P8_6(%".O\\%YR@7G MBP:A]HX+5D!HM4XYQS5G4MXDQ9>S+#Y+4_0UQ$\15TT7:']?KO;I6=43BA9N M3=9O#@[-2;#K6 MD)7P,X<'F]KJSA6>V`J+K">GXV'#'QY+LG$]RJ[I)J4LM^52#8-%4K-XRC=J M?90A]R-FGD0MN(!%E">[P>B@D6OVB"77DRT>:N#.&WS=)-$&,Q&$S;)[+!+"RP=/5%;$B/38+E$S'^-7PJP"M"9_@8 M;GE+AHF@I)\!$ZME M^RHQ>NZDTK\]XY;L>)8 M"C6D#0QVH3%/OK?(6&S.#7YMK4N7V9^`7+H>O<)I!T4?,O%L7`A7H$\$QLS. M6FS88E\M=S(!'J92&[%`HMC31F2RGVP-6WQ&@^O= MR37OGYJ6B-ZTV;+7S=O/M3=SVFN>>ZM3J'::(IM%L^$A&,B#G+S`(T^ZP/0' MT>!>[\R:^Z;9[L\/6FGEXLRS.S5MISUNZ7=:[214 M@.M-F&_#".YQ!Q*F'KT>]Y-3XIETGSAEM>O7.@V6H::13OTH-76P0X^580UL>^AK@.W^!^ M=A?F9;5FF!C)D_6&XG5/3F"^WY=TRQGT-3L"$8-(),^[>'DN=Y6.^33;2B=!_7/IJM;=)D2S>U*=%1U9*B;@HY MVH[NMHV;@79/]-X1*&&TR5"*UD]'8!MF^Q5F2/4\=F0OI*(X`@5:E5^)>?+[ M\C"&VS#_\AJ[3'CN]$)U^*9'RUULT.MY\\":;NQ4^T;N9N?7$[:L]<[ MRF+D1H.CU[W8(-8Q(@6UM2-(SJR1M?U8K(.-?,X'YFD+S*-O')F""M41,JU6 MFA<0=VPQQ$_N*OL+;"O;0O2)F;9\_2@TY.?03&G>>F6IZU'(+ST#[$H2,E73 M[CB8X+X@KJ!#*I8'E.ZW]*NS^STN[W"%18JJK,!U%Z[:OB9DG0Y?B$6E,BB7JI)%Y#>ZPA[C7F&*#]FE,%J'@NNVW/7G_A=N1 MD)4J6[!*,FR-O"YR'OE,I^EXDX`0%D&7`M85/_QE>XK_PQ>82_K_[L(#XRO\' M4$L#!!0````(`+F$545N,A\)G"@``'6.`@`5`!P`=F%S8RTR,#$T,#DS,%]P M&UL550)``,>Q$94'L1&5'5X"P`!!"4.```$.0$``.U=6W?;.))^WW/V M/W@SSXZ3SDSWI,_TSO$UZ]..Y;7=W3M/?6@*DC"A"#5(.E;_^@4H4A)!7`H@ M)0**7W(1"P54X0-0*!0*__CGRSPY>D8TPR3]Z'*$T)F.<3G]Z4V3' M419C_.:?__V?__&/_SH^_H121*,ED<7.(L3DA44'3V0I,@9A^SH[GYT M=7US>?3A[;NWW[U]=W1.%DN*I[/\Z/W'CW\[.C[Z[MW[OQX]SL@\(^G1/2IR M5O?1:1RCI,C>'ITFR5%)GAU1E"'ZC,9OCX]Y[0E.O_S(_WB*,G3$6IUF/[YD M^*)?VTL^37;FNKFNZ-ONU+M;HFW_:I939.T1ZTO%5-]T;? M(8K)^#(=[[[A8E5]-?XAC^@>H-*NK+L`NV^U15.?V4KV-B;S%=L[2L9%G&>G MZ?B!K3(X1MD%RB.<9.;VRFNF14Q1X_12R?-RKC8MX6).V0;C:M_4"+5`Z9FS0*/T9+1^*Q2+!;%+LT%`C2Q>-,FYI3E?0 M&4W.*1KCG*EAE,\0O$7I#B*9\4";-& M2<%ZM8L$UG78R_&)D/%7G"2U7JY39N]-\5."RG'[JD;*QFG6R$B"Q]Q%\L#8H'*>9,,\RF97;.!D MOZ11P083&CM.'F#N/;:=S!<4S5":X6=4=]FZICO6;RD;9#F.(X#+R4(HFVKW M)>W^!.Q3IIV*T7O+SZ*$KR\/,\2FZMW@#%3%+J383<.=["X2%[P'V1IYR4RX M?'F=3@B=.T^@>G[;[5MLS;$W[(=&9>@EYR;<6E&\K2X2E/75-28D;E22\#-( M0DTB\5]^U]5R^I0Q2R[.:T8)=XK_],:F"/O,!805.;&7JM)`G!>4Z_@*9VP1_1>*Z&4ZOF!+EX`1$UFE0C59 M,$@!2NH&%C7S"B_?^8Z7E7B_H23Y.25?TP<4921%X^LL*Q"53BP&VL8$HZ0- M!CXV,G>9<)0U5$#Z$`:0?B5)P31`EU>:;V4+.4[TI$U#1D$:&&I`$G"Q?=AP.*N>$IP?)602/0(*+\W(-'X M'A@@U+)U@4.#:P6&'\(``S\F)>E#3N(OY=E&-BIR'A;.X_OEJPV@0'/-T18( M##\6TG=:?[355`C[N^\(JV7>;/NNV"^B$6.@$CR/+:I@``23TPTU2MX55#Z& M!955K+D9+!(Z*5P:=($"1BUK'Y!I<*]]>-Y[>6L9'AE;!5"V/PG86'T*#@X2 MB;HA8,6P[G3O/;>GK,WC$KE)))HHTF^5DH1OP?2[3B:WCAAH7/@XL0N4IU$JBH&D(U*(93"X>I<"F/M'HWQ MC.@3$>Y1#S&&JHCL>Q0C)N53@FY17NE#'$H`TGI$:4G]!92%B$`O75D7J(#0O93!#1LPK7$*^OL`JH M$'^NM+3YV5K39U+.;8L&;V>+]8W[U]25."AYUH.AHFR+K71BDB(<`<9#5 M!!X8RZ%#F_LUSF])&H/M\S:QQD3?)O80/U;RF9!C8A:Z=2XURZ7VN)=]+6TO MS(X,WMBV.JTBAN.>ILX@K#>:[,,4]V1IOL'1$TZ8G*A,3L0#`V6S,4,+`*2,=)NY2$7G.82@$EK.2"J>0]^.[@R9>[*,$B-@5%1-N+2I MP@"+03H'J+0YAN\BJ)*^Z8_NY$2"2T`D\APE(-EL0*)BZ.X2\,3",:X_QFDY MP!6GUZ5&L\:$ZFVPWN)*=0KR/D"KDFOZ$`X&A:G%Z,I5TLFG;"\[["D_F]2U?]I9*(.<$6O+V28&"/$BH`:7OCCAU1>'N3B`P@VCW$`"U M6Q3IH>.P7U$;'7N]PP-TP(-=[EXZV;?2$$AO?2@^UQ<\6I\'/)*"C`2#/.)1 ME`[V;5;A&GVGXW%YP!8E=Q$>7Z?GT0*S,;@EHNC5`1>H'3R``IYCQUIF&S1! MF`?M72[F1>DV+Y]!:"0<7STJ3G`"B]Y^]AI6A+T:9;/`A8^;N\P[6N0G>&5];3_\"E%3/.AG==\,8,'A;_FBT%* MFN'DTKRTN,D[H8C_<2E;Z\&NK,>W=3LH`7J;UZX*=U^E>JONT;6,$&[[>FR` M>'U?PPM?T>MMC6_^O(S9CB-:PG]<'@")3]"VC]!,)=JG:NH2GKM][*5V/'M3 M$XC\WNYXVN%24;5"U*<,!DT%*1Q"UN89[UM82JWP^RPB< M)I4*-#55:("12M<)+#7'<".D+-X%L7@3P].W0!QQ`WW[PQ(\LK<^^CK0\MRK M[,?9Q3>PAWMU(O?O1-:_-C]<4A\>BK%NFV+?9:!:I^Y14`T8E5&&PZL\PZK/ MZX@+\?-P.^0H05G5'I[Y)VNG6M.1U+MB*ZNK"YY"F]2<(J(;04JFIYRPUD46;M`P*5 M\1()+O*:H0'DZK[B>.%IK"57S'N*^[K3<$.088^Q`*8EF%B7-*: MRE+PV];9(5Q+/"=9SDW+*KFURAHPD:TWJ2JR004<3-].N6.(VO M@Z';J']BDJ6);A6_U:Y:X!,VND>3>X3G3P7-^$%M);`4!AJZ!B"D=`%`PRR? M+4BD',-U\=XSZ9G"^?LQ%VR.3TB99U@.&1#MVGC0TGH-'1LYX?`Q<`W7^5M= MZ,CRC>"C!>*6<\OY"R&M%*LG]1H_%E+"X:-G&O!-!I0PGE,FU>>(?D%<'/GL M8R:LW1H:0J]Q`Y80CAH=RW!C[S^AE"$_85*=CN'#\K+!T@=9UUWD3M M-83L9(7CR,C7/:Q^<#!%..5W#ZM5,3_-V)*I5F1I8L#)^ MP\M!;@N0P;A74/O>`FH?5U!+T;1,MSET[M67&&>('VYQA_1C]-+RR&DHZORJ M,@JOL6.6"8X4*:\*%S^$-P6=S@G-\9^EX*.)^,R#@`T8\?H9$(CQ- M5Q?=XN4CC=*,"1DCVUIE]EYS(ZAU3S7[/&2&ZP+PX-MK$W>1.VKO8YGI MH)J?SE"*)JTL=0:JQAB14/F/9Y-HEMB3L',X*/'+TKM%N7(G+/U6[VF:WWS& M@DX,^-+?9.)P:N'3_%!?4:GO1)]%&8Z%WM?2U.<6HG*ZO`LA*UM1!@_+DJO;?:V<244_XO6?7_ M^-_%:E-5)P._X\>U[$.>4_Q4Y#SP^I&LLBW*PTOW6W\5*(CQ6,,`,I-)A`U98A#`2YZ9^!JJ^KS'-9WR]*[!+VO9J:U%5&Z M824SKCC'MB>;'CD:5GPKCB%.7OVKKLU63>C*Z/9@'HVQVE9"O?NVJUZTR MSVU*TO9$)B$=5&YBV.Y$-FGJB6JS5T%TL&`%:64_(%4U)=R\ M'1=58V&A7T#J]4)OH#Y8R-KI:5_F@*%-X<8@7[[$*.,W@"M9>(RF?*A*="0& MJ?3!:W,_NPNO@QT>?>IX/X.G8XL=XH+]BO<\*S*<,@TP29]P6@JZ"J6>,E5S M#R33):V@29GEMG)"GL_X/Z]39ML5I9M.7J1.]KU\+XS%/==:(6IOM1[L^!ZF MW_8S$^Q-MO"3Z8S2"YPMJNS^HXETOPZB%9+G*&@/=CC9Z&@_@\#0HN"3\Y3J MR)A,DL+'PM-+0?].H;%&X4/E,+1

O4"KO[<4<1XM>6O)^0=>HQ^'TW5&TB/!8E;L%1J[$ MG$@>/.RT\O>+/+$JAW,%W\%7S^AWT=)JX17HC:ONFCYX_.DUL)OU=EV7^Z&` M)WD0I3+2@@FQ>6(0`D)%$1T.6T4.`8IZ/?2.QE9UX28L;\M7'\G)'W4#TRLQ MV*(/'H!Z#?2+OE9=/7MD#\C%X^Q`V(_#QZ9Y/=VP#RX2>0_1KWT$-.^FF>%> MM(1KT?F6@?/M@F#'@K-N>@K9!U<>^-N5H,L^5OT!FGETU=KUP"&\A*F0=I77 MKL-])0`#_8RB93#!UI4'OS90TO8.IX%99]H^P8>E%P%U1;YH0!4 MKX>=P+)59?!'$TPC,4+C,JVNH.SG=SA=,HC3OLO``, M]#.*EL'@INL5H?=H4=!X%F6HS/9.^>*9XI;0D^'B;R<>@F%KR2-4//>@L5X@[M8.]T7+ MD["*;2/_.LL*IB,THBMS?_4\AF;'IB\@V:BI"@0.7K`N^D2JKM*#VXU)=.)L M0SG;3L'BU%DW?>#5IO)O>S<&M_=[V8UIJPMW!N&B\AR3["\^'3ZSB9$'0B** M^2-/S0`280YQ*5HG-;8JZCU".VC"#IMV%>UB?MAG?HO)!,5,$\S"+.\1WS/= MC%*Y"@1HNA2MLU=8%?4>FATT80=-NXJ"3PTA%^R4+1V4+MDJ\6N4M$);K]QZ")['W-CJP;W<-9%.)D. M/OL]%(M%4JHB2FI57*<30N>K/E=DN;8K56?^@Y8:_%GXNPB+C[_)/@D/PJ\^ M#3>`+#N%:(42!@R,]_:S\"N>X<85KO/,H4P*!^E7\?'8^FM8H-")U@$7`MMP M'V.'+E5NTZ3=4@6NHZ>\(/M[&(*_*IKQX)L-N\%>@*CNE;*E_XXD.-8D83<2 MUKF;-83#O5A#IU%:)3'>O,N!RV?`MOMA-*F<:%&R>;+C`F=Q0K*"HD?6RV=) M^T![5^SKMVQZ9S_FN%L.LB/&_4U;MR@7G[\= M;-H2&Z*8M$QDBI>-/9BPQ":I9AXCG4)$'^8"8^](WF^D59]D3SKV,S($L MB>H&-+]N.4WQH(9$NRF*,6DFK+I41^@P+KGFRL:_^_CA7=ET_HNDW>;EWJJ, M4AJ_%F9`MQ`WR9M#4UT/'YQ`_J$NH=L)K(;;_J_:L-QH5IE]T$BY=@MH*`=T M=+1:I1K1$%*UK#Z,7TAG$2M!Q:0=2OXK)XB.;ZCC]1,AXZ\X29BM7[YAV7K] M9K!,SIN&B6TR#FNGLG6F9[NRPV6ZAK13-1FX%;;1D`\3AAL,2$?U-"<5JS:4 M^:TMZPYUXCEGS<3Y/47UD2:1SC57,D#T=9[=3WM<#$U MVWW!&VF>96R*U!,QJ,APC@I01Q(GT057A:ZF,IH&5$.H(_\"+3@IOXV2_HR6 MY7DL1G2XX=Y2=_;(JF1S<>/#':+\/]%4M?_IRD8U3,!L^G->JKI(-1N`Z3'8#XXMJ!Z`]I49('FH8?V@5CRDTU/3)J._ MQ*GL>I*P*CN@90%HI]K&<"ELHR$_YAL7&)".ZA%G'(LVK"P4N[I#G7.V8O`& M/%BIV@`X6#%2BO&67LT6DE:I#U;,I&I9?1CWD,XB5H*VLJ&K^#>B2P]JO$H> MZ^035.G)+;/JK5XN'&XP2QLH'\T04O4+MC[X%23-,H]LNT)J!?@UVD&=*7]) MUW;@ZZI2/&A[4'/`'27C(BX-DP=$GW$\X-K]@*;<2+I'"T++?&:*ZT$&LOH^ MD))LN.M00I/,X]NBA$)LOT:VL>^(B\S"G09%'>5]!@CO4,>R)#;XL3P+>8T0 MWMF(CF=H7/`D0;\A/)WE:'S*,!!-T6TQ?T)T-"D;FI7=H!SC77C4H]Z-A]=1 MQWWH!1Z1[%A;<-'*6]&/`T\.WTX,Y`9;Z_:=%Y2/#>#$`"O6F@M,Q7R/DW14 M@%7,)+R.X(:Z*7!RX/'_&CX)GS6:S60MKX4`3R"6'"1S"9A#>-&4W175,:32 MJ0'N$U*.J$\>AX$GHL/W.ZS1=9FR5BY_PV.T=8N_NN_#4Y]>LGZD:92<%UE. MY@PE9TM9?QGGFQW5TYJ5>J_';\_(GO1KX4_978O"G-TD/I@+E$77"[$Q` M[89]5.096U''K,T\Y46&@-)76PU)=.D1@`G71&9KJ>GI*,#5DGH*A5Z;#25?`'PK([E%>T)3]E?'' M6_CSZ0PU4S&_IEMAI7SZPL%E,K#01;>4!OJ*^C0^=X.XTSFWQO^LTA[=,.,Y MS=`5JC;3YO$#*JX>58;B@RV\//A[-#FEE.>6YMN6TQ;8`\0HI)!'S:X>/C>V^0]A=^L!\`DE.@"T/CZ2K;=14MK0RKE+K2GI>@H?= M^<'V&@1FF1NW?=K:RFE.7HM'5@]T$):];=1]]_1RQJ1)' M27:+\M'DGO4J?6XMJ_`"HMR:`KZ'(%L+[9:P5<,]W$/PM72_$?KE.BV?V,Y@ M$#.7$#&F*Q$,R,!BNZ%,QWX(EU_/,+O"*N3")SR4S`(:0OB!H623Y_O2_MS>V9H2_7U^@Q,/_JAY M?<6''P4DJ[X9_[O(5EG#%!VN)Q9@H"+V'1P@(:T@H^+H8`'[]=:\87YHO5H= MS@QA>'`;.D@ZB44'(7HNFT/Q&STN<%#SJ>ZT;E4O0 MONCFE6^+HH,IAV_M,"MDT.G$DOIQ=T5O$H^`DU5 M'82)U#SU:#T"U80>C+B.;S40!P<]*^F[0<]45?!&E69L@8QUY_+F>=$[DWX' M4Z6#^=_C[&G8*MC8D\&@VG8=;]GFW]A*;MB;[&@M=W"FAK^5Z6!?=]SCV-4< M7``&^`TN=Z?WZX-WG2?M7Z.D6(W/=/R_193@R9*GXZB[9I/*5'(#T*ELI2/+ MLA[HI^Y''FM=GSWRJ%_)94"[0BV-Z`MYJHH+,H]P:J6(9A&0&NHBP^T8-<-9 M?DT27*#>.0(*#+;,6G4H<9"^N:9"JBMWC(!JPO4>;DNW?<7G9^"[NAV8G.3T7;UF]US>!7U.- M]0G,'C.0.2'3,3&9P_PQ9%;72-=,VN]C*ZCC!F*WT[)\TDY]]$E%_%#_1\NW8?!5@9?UR`BY3LO<[;SA4?(YHE^0PH%N)MR$ M.RH)_>Y6L(@6W:WC&>Z&P3R]$OC\)&A3Q7KKC4<9RW"WR(:5F,!7,\%HE?(M MU:CF%Z[+L"6NRC=H)E19/]V\?>HLB"B;D63,MA/KASC63VE4FXCL;%G_)$CC M6GR30=&RN#_C1.K(ZZ@/PQ!J.._LJ_(M][1>@D^49$R,&.'G\A4G1PR:V8"P MJ&,3-";!^ND/F[HJ^W1#^+`,W"'*?XBFZ+UI(9"0JI:"!JGG\+.0TP9B>K8] M9X/PRAX#6Q!0@TS',-Q=`LR7)M,G(+&:CK=4I?T>`.S/P7J!%IR423-*?T;+ MAV*Q2#";:8?VJK847`8>9+>D\6$S)ZBB?#NR44W08#;]65-MR&F;<+;N2ZAJ M7/DIO;G6_/IT/.$RZ^78 MJNQ@+J<;DF6-ULGB+?1$E<0J(G]$.UO>1CE3^VBR^7DI"<"P+ZA2@::@)VJI M&B@-T@!02@47*/LS<C5T[$>2`T)%4RI&3^-[]`,&L>EW.+]R3%@`J: MU]>J=_1:=3]:8FORN(ASJ0ZDWVHG8?-;B&^8ZL1K3A$.[Y<*S,.=A_5#__7M MT@$6/LAL#%WC%+S"?8FG)>J-(KK63*AR]-SL(KI6L5%2/IX!HM9O3CWP2%87 M#\R:%[*,UP#]9L*E+3`CG.T M)`!#H)#)4"-OA1WS131G8F4/I)C.]BBQ)U]GM("8^A8"\Q%!X@SH&;M^KL_;]D M:%(D-WC2@IA%$>,+"]M%?`:9O&@7.7I=CX8OVG=`@TPR,,M M`EBF7T`&29NZI"H/]9;H=";6N;>(5#QFN-4PWIU]U#!HN8'K/=4FAEN3,3E9(+BG&U'UWJXCW(D4Y"L!"LHV]02[JF87$J^T65&;8)7O9Y?(29?E/#L?P5KR+)!#(*H M$TV6U>_"`S+HEFUB>T>2.LDWXRTI:`6`FLDVZ"`69[X`!"F@% M##7/"@!_"W2V^B6E*W?TGR7&JYVN:#`:J.K$Z2HJWQ$#$\\*,$J6%5Z^#\_( M4XA4[[A&Z=9VK'*43IDI' M>KE41U*'&$E)AI_V5-U!0%(IYC6!:1E&)&46[LU&PV`E8,2;5%C?&E6S"U>) M@$E=JDCC'5$U8[DJ@\][()/W1G%9%$:L6TYO/'B`6?119=*6\AY08A MK9,E:DF'2R<0S]"X2-!H4C=PNRO.EEO_DVV878O7:0BLBP^F*$D#);MK`Y6` MA1:55]+Q?U(DSWT*IM=(+-#W=UIW2V@^0U&6;U)M2C?41KJJ\1JZP98E>`<0 MN*#-ME,D]]F"B&OO MK8%XL&$+ZP=B*6YSJ&KK*'V[!M[>75N7M??Q*X'CI$6LP\D6<:`X48G;!TZV M>._BKOKP.A;M$YNI$Z3@VCXQ,/XV;1/X*MO=/M'6%>Z-"XD"5$<+$%+UOK/; ML8+JZ8UV/7<%C6=1ANXHCA$/>HW+3G]O<"4Y<%#+:N;0XX/CB,Y'D_5-+O,]>UBJQV(I6]A>^[$%;E56;AY M8T#'IJ3SZ:)\),@J+9.`6U<67":9ZHD-?NK^@.@S&]Z#'[8_H"FW8N_1@B<8 M3*>*W9&)K#Y/5I)Y<,!^F;)6+G_#8W2=3@B=E]U9)293/$,-=C32I='JB^ID# M!5&(#S:!!&XNDPXO-ZEJ<5\?GQ%](CLXD_D?-"<9DU2+$CU1I30548@H`0G< M&26J6MP]#[M"R:\(IY(52PH6$&V=0$)/&R)T;,3OC"!#98-E!U8YQ,GJ&0#> MWLH\DD+(2%=;&FJZ$*$#%;LS;#05N>?#V=7<<\,0G6;HGBRC)%^6F4X3AA-" MMZUL*8P<2JZ?2;$H&2+4W%73&7Q65;MGO/'"K_;Z\.5@CLQ=[/N=WLW<29/, MSVX&>)NR$G9+.2U'G:RJK8_L_-"44(['A1KHZ MP%Y--UR<%4#I!"ZB$&.E9EX&U:N9AHOW:NB+&!%_7K]J4?_L.P(4`EAU^(:' M?[OAJFV;-&VK/'WR;E11-7NU315()QO$<^GS-LO`3[IW;I3`E\,]F2;:!H5[ M\]EXYD;V<_(D]**B5X@_JPM_K"_WB*,L1^^7]02P,$%`````@` MN81517%UGC4W"P``V'```!$`'`!V87-C+3(P,30P.3,P+GAS9%54"0`#'L1& M5![$1E1U>`L``00E#@``!#D!``#M75]SXC@2?[^J^PXZGN8>"#"9F9ND)KM% MDDDVM9DD1=C[\[0E[`948R16DA.X3W\MV08;&]DFR:ZWSD\Q5G>KNW\MJ=4" MYGO=X3ZGKDB47/=-$_.3:F!+``KJ^$7%S"E(:! M/NO\%M*`31GX'8*V@E;N5.J)E9JTF)9NOU!]WB0,`6,?\\HLIK((%'EN&>:)U3!1NLR9]S30PJ0S-LP"%Z!1_#N#I\/K%@U;$@C@/%%B(DPRKG0U$2R M?16_7"X9GXKX#;XSOCU-\!C!E%AOGQHMSCJ*+9:!<:5]-Y

N80.DF0?+K M4L(1ZI>02!&``QS3W%N:P<`CS6ZW'2 M#>J:A2Q>:*A^F=:U"%L99DXT*Z*2N4<@"P=O:8^2,T0)B'GX9W>3G6:O) MI?!",ZD/N?^5:Z;7-S@XY<)&48N'/L[Y_3XN4HF$]"/E M/HG$D92\+[U=(;OR0P7^/?_!/N^.XY@[)G%Q[@R5ZHS9:"SFB]\F`!R&RP4N M_R)@ODD/SFE@%I3'.8!6OW`:^DR;!=>@4X'.B1$B9#%Z1#="#%):)HF%DD@J M>1@E4=K`BN;B"E)I+?#NPZ$%V*!9L^! M*_8$-?$LX76">UP/W$Q7+=1O`'7)['ZHH,HS?EV\2]:!X[)UH&Y_[>I0.]ZH MFE\%XKGR=)*G=T+\H>84@N*)E=].&T4PGE/%$(6'E(D17D4-3F`^)7NF;3FP M2ZP4@T-:3NO]Q/MWH)-9YP'DXQSGFLC[10TEWG^?]SY*V>?'0DA*2NOYQ/,W')VCA62@(I>G7Y3X^D/> MURGNUL>)CZ^%\)]9$`RY?X\)C+Q!._F,30(8*H6[X,CQI50E:'S,HY&(M*4R M*Y1LI9)(;`O3)I&2@$G)B*GO",$PP%3%5"JNA+P4X41/PV#H>2+D"5[5R4N` M^Y0'+I)-C'"+W48\F0I)D@Y(TD.+82H9]M`V:74T2:UU9#*DC#_5)@LN)2S! M[1\%N&6DVK0W0G([`*WH%K#-X0$L@?N`;KOG/\/Z,5PN`P8R1FEO:PDTG_/0 M;$41P0D*(QMI+1K;X;-8,&WW;#@4,)HU9JSHLTUVX"(HP>2D:+ALI-D1DI'7 MHK+-T?`1QG2US=&V+]Q>'_2+K^%3%DM8@0J4Y?`4[13CT63M.PH"S#225I\"U\"WX,4?NC96>D1Y!/SDK%2 MU%`"2L$&/I%B<4CDM-YWE$_&%/<8:F\1)6YVU:>+BR8EA>?/U/\Z6<]):=;3@E0W[?^[2!\X5RK%NMXQ50MOK0.KG5%>2N<>W8Z#JE*8ZYY\M4`[S\!VLO3<>W>6 MOCW[*L.M[.RLA>GP4[0,AG697`#7.3TK#8`7GLZU`5*I@IF)!4?[:]0OE1A1NDR\_!B!0HN7ZBB0XHM?NYN11RF MB=T[RG5M5=)\R8>7*Q-*',;>NC8X&<;-IQ?#!"MO7EN7#9-]>K$.G#+/7D@R MJ*/$EBMZ[&X%'*:&8EYM)1(>\W"(`KN7'9Q$JP:'&;4_8-JC0X8MD#+#U35R MNH/WW<&GE^NA:^N@#^D_ZU2]E/612)CLTVM@D;Z7IHH/+(OYU$WXC">.C2=> MH,6'GC277514P%*;;G%`?NX.^O4`R-VQ4['7A,%T_/$P2XMOT:G2?YKS+F)\ M\0C(WP-43Y/#U7!?U'1X4F%E'3)3YV>&^,855-7375@M`XK;`B'75_BY^FR1 MEO)U*\3AL_@N+:OC_AK6&%;Z/!#>]RB_-MGXKQ5HHYMKHGN>3G7R_D;#PJ2, M:%8X49II>\G8M13A\JQC;[4Z94C2(9P%@3GV/^MH&2(Y16J)EIUUIC2P=V99 MXB6&A?#'MB\_E/&O'O>9>(NY.%1,07'W>FS*Q('YD:*;00 M.&%3N?Y]#(W:)M&5&&<=SU9U]]N?J0.;BJ^1I^Y$YOT#2/.!SN!\`^PP5BKE MFU>0E?8;OF-\]@I>BSX?$AT/EOI^^B_)M`9^)S3"/Q:)WBG;2RG3EB4=_[&A M?V/V=#08SB38UY$)*9OV$33/%%/JE':2T^;W_C;*LK;LI6B@,54/&(N&8'W> MA@VY@J^W;&HI1>M.1?HFKCWCN00U%X&/^(S`Y`;H_(M0:8&IC8H-4^?KY%7* MZOJLL0/0^F4T`S?9=M1"H14>L"?[1;\#?.`2T3!?W'`-,BK[TN`;E=]!JV^P MF&2L=1%E@ML7"\I>8PH[?`Q?BR?4U;R@P8,4'H"Y:K9HOBJE;-CL]#,JL%D/ MBPS:1]`P.ZY"C?/C<&$&S7\M[?WT$J8@^YP'F`/WH,7[$I M\RZ$7)K\'6YQ^9A9F;G15X.G:8,Q&Y$YRXJ;FV;$GGDB9TT)7=/,RB./X!X/.^VY6M;FY#MN9];@9&[;BQ>IO]X*H)R\R,$_1,$LJU0-R85J+ MJVE!^T]@O.!(-6=D"5W3S/H)%CC)4YVHG+-G'T'3#!F+:/(S2NX+0`=-T\RY MH.:"/I![<=E'T#1#[D*CE[EUS>J):L,L=4F2M<5!D\ZO&&X&9B#?#*OE&3NJ;-P^A M].94P8/$27[9*B-LFF%WN&.>`U5ZNW/,V>2@:9HY MPX6I'3]09DIN7U=>$)J[=4?V7_FD+'*3_=YU@LU"ME,F\&'BJA)L=Q[VGE1- M5]'W=+/3QQZ2AFU2\KO%;"TGWHY<0?S;;N=&LXSUL$5]OC:>"B?P=HMZ=5-N MJB#')'B;MBBGK?A/T"E&HO8%$BAZ33=Q=:\=.".>2*@['HQF>=GWWQ; MTV;=\5R:[X4_X!)1L)$K:&RL`?Y^]?V&*W\-P3[E4TU-4][U3Y(*-B[5R/_` M2``#HRP0`$0`8```` M```!````I($`````=F%S8RTR,#$T,#DS,"YX;6Q55`4``Q[$1E1U>`L``00E M#@``!#D!``!02P$"'@,4````"`"YA%5%0"<#F2D-``"OJ@``%0`8```````! M````I(&H7@``=F%S8RTR,#$T,#DS,%]C86PN>&UL550%``,>Q$94=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`N8151=Y57+[.#P``%M4``!4`&``````` M`0```*2!(&P``'9A`Q0````(`+F$544]I<)9LU(``#YR!``5`!@````` M``$```"D@3U\``!V87-C+3(P,30P.3,P7VQA8BYX;6Q55`4``Q[$1E1U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"YA%5%;C(?"9PH``!UC@(`%0`8```` M```!````I($_SP``=F%S8RTR,#$T,#DS,%]P&UL550%``,>Q$94=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`N81517%UGC4W"P``V'```!$`&``` M`````0```*2!*O@``'9A'-D550%``,>Q$94=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``*P#`0`````` ` end XML 41 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Credit Risk and Allowance for Doubtful Accounts
9 Months Ended

Sep. 30, 2014

Credit Risk and Allowance for Doubtful Accounts [Abstract]

Credit Risk and Allowance for Doubtful Accounts
(6)
Credit Risk and Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. The Company does not accrue interest on past due accounts receivable. Receivables are written off only after all collection attempts have failed and are based on an individual credit evaluation and the specific circumstances of the customer. At September 30, 2014 and December 31, 2013, the allowance for doubtful accounts was $220,000 and $150,000, respectively.

All product returns must be pre-approved, and if approved, customers are subject to a 20% restocking charge. The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on our balance sheet. At September 30, 2014 and December 31, 2013, the sales and return allowance was $65,000 and $50,000, respectively.

Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $285,000 and $200,000 at September 30, 2014 and December 31, 2013, respectively.

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

XML 42 R14.htm IDEA: XBRL DOCUMENT

Concentrations of Credit and Other Risks

Concentrations of Credit and Other Risks [Abstract]

Concentrations of Credit and Other Risks

(7)	Concentrations of Credit and Other Risks

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

XML 43 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

Commitments and Contingencies [Abstract]

Commitments and Contingencies

(9)	Commitments and Contingencies

Boston Scientific Corporation Litigation

Governmental Proceedings

King Agreements

The entire disclosure for commitments and contingencies.

XML 44 R34.htm IDEA: XBRL DOCUMENT

Products and Services (Details) (USD $)	3 Months Ended		9 Months Ended
Products and Services (Details) (USD $)	Sep. 30, 2014 Category	Sep. 30, 2013	Sep. 30, 2014 Category	Sep. 30, 2013
Product Information [Line Items]
Number of product categories	3		3
Total revenue	$ 31,929,000	$ 28,009,000	$ 92,513,000	$ 81,427,000
Total revenue percentage change (in hundredths)	14.00%	14.00%	14.00%	11.00%
Catheter Products [Member]
Product Information [Line Items]
Total revenue	21,116,000	17,965,000	60,675,000	52,031,000
Total revenue percentage change (in hundredths)	18.00%	17.00%	17.00%	14.00%
Hemostat Products [Member]
Product Information [Line Items]
Total revenue	6,108,000	5,962,000	18,305,000	17,768,000
Total revenue percentage change (in hundredths)	2.00%	7.00%	3.00%	3.00%
Vein Products and Services [Member]
Product Information [Line Items]
Total revenue	4,542,000	3,999,000	13,236,000	11,398,000
Total revenue percentage change (in hundredths)	14.00%	11.00%	16.00%	14.00%
Total Product Revenue [Member]
Product Information [Line Items]
Total revenue	31,766,000	27,926,000	92,216,000	81,197,000
Total revenue percentage change (in hundredths)	14.00%	14.00%	14.00%	12.00%
License, Royalty and Collaboration [Member]
Product Information [Line Items]
Total revenue	$ 163,000	$ 83,000	$ 297,000	$ 230,000
Total revenue percentage change (in hundredths)	96.00%	(5.00%)	29.00%	(12.00%)

XML 45 R21.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

Inventories are comprised of the following:

Inventories [Abstract]

Inventories

	September 30, 2014		December 31, 2013
	(unaudited)

Raw materials	$	7,533,000	$	6,386,000
Work-in-process		1,548,000		926,000
Finished goods		6,651,000		6,690,000
	$	15,732,000	$	14,002,000

XML 46 R26.htm IDEA: XBRL DOCUMENT

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 7,533,000	$ 6,386,000
Work-in-process	1,548,000	926,000
Finished goods	6,651,000	6,690,000
Inventory, Total	$ 15,732,000	$ 14,002,000

Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

XML 47 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statements of Comprehensive Earnings (unaudited) [Abstract]
Net earnings	$ 2,570,000	$ 2,672,000	$ 8,574,000	$ 7,605,000
Other comprehensive earnings (losses), net of $0 tax: Foreign currency translation adjustments	(346,000)	192,000	(547,000)	61,000
Comprehensive earnings	$ 2,224,000	$ 2,864,000	$ 8,027,000	$ 7,666,000

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

XML 48 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition

XML 49 R27.htm IDEA: XBRL DOCUMENT

Revenue Recognition [Abstract]

Revenue Recognition

(3)	Revenue Recognition

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended		9 Months Ended
Goodwill and Other Intangible Assets (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill [Abstract]
Beginning balance			$ 10,532,000
Foreign currency translation adjustments			(186,000)
Ending balance	10,346,000		10,346,000
Acquired Intangibles [Abstract]
Beginning balance			11,943,000
Amortization	(410,000)	(404,000)	(1,234,000)	(1,162,000)
Foreign currency translation adjustments			(95,000)
Ending balance	$ 10,614,000		$ 10,614,000

Net Earnings per Share (Tables)